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Riassunto 
 
La fenilalanina idrossilasi (PAH) è un enzima contenente ferro, che catalizza la 
conversione dell’aminoacido essenziale L-Phe in L-Tyr, utilizzando il cofattore 6R-L-
eritro-tetraidrobiopterina (BH4) e ossigeno molecolare (Hufton et al. , 1995; Kaufman, 
1993). Difetti nell'attività enzimatica, causati da mutazioni nel gene umano, portano ad 
una malattia ereditaria autosomica recessiva del metabolismo degli aminoacidi, nota 
come fenilchetonuria (PKU). 
La funzione di una proteina è determinata dalla sua struttura 3D. Le mutazioni nel gene 
umano della PAH possono modificare la sequenza e la struttura di una proteina, 
alterando la sua funzione e causando quindi la malattia. Molti studi, infatti, hanno 
confermato una relazione diretta tra l'alterazione strutturale dell’enzima ed i fenotipi 
osservati. Ad oggi, più di 560 mutazioni del gene PAH sono stati identificati (vedi 
database Mutaztions PAH Analysis Consortium: http://www.pahdb.mcgill.ca/) e tali 
mutazioni sono localizzate in tutta la struttura 3D.  
È stato dimostrato che PAH è un enzima tetramerico assemblato come dimero di dimeri. 
Ogni monomero adotta una struttura α/β ed è costituito da un dominio regolatorio N-
terminale (RD) (residui 1-117), un dominio catalitico (residui 118-410), che comprende 
i siti di legame per il ferro, il substrato ed il cofattore, e un dominio di tetramerizzazione 
(residui 411-452) (Fusetti et al., 1998). 
L'N-terminale RD di PAH contiene un dominio ACT (residui 33-111), che è costituito 
da un motivo strutturale composto da quattro β-strand e due α-eliche disposte in un 
βαββαβ fold. Il dominio ACT è stato identificato in alcune proteine che sono coinvolte 
nel metabolismo degli amminoacidi e delle purine, e che sono regolate da specifici 
aminoacidi (Aravind e Koonin, 1999). Generalmente, questi domini si associano in 
oligomeri di 2, 3 o 4 unità. Diversamente, nella struttura tetramerica della PAH i quattro 
domini ACT non si associano tra loro. Nelle proteine che contengono il domino ACT, i 
ligandi di solito si legano alle interfacce tra domini ACT e in prossimità di una specifica 
Gly (Gly46 in hPAH) (Grant, 2006). 
La funzione regolatoria del dominio ACT di PAH è poco conosciuta e pertanto merita 
ulteriori studi. Perciò, in questo contesto si inserisce il mio lavoro di tesi.  
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I principali meccanismi regolatori della PAH includono l'attivazione da fenilalanina, 
inibizione da BH4, e un'ulteriore attivazione per fosforilazione (Hufton et al., 1995). In 
alcuni studi è stato proposto che la L-Phe si lega ad un sito allosterico sull’RD della 
PAH, diverso dal sito attivo, inducendo grandi cambiamenti conformazionali 
(Fitzpatrick, 2000; Kaufman, 1993;. Shiman et al, 1979). 
Tuttavia, il putativo sito di legame allosterico per la L-Phe non è stato ancora 
identificato e il ruolo del dominio come modulo allosterico non è ancora chiaro.  
Per investigare sulle basi strutturali dei difetti della proteina alla base della malattia, ho 
usato un approccio computazionale. L'approccio computazionale è molto efficace per 
capire come le variazioni genetiche possono modificare la struttura delle macromolecole 
biologiche e per far luce sulle relazioni struttura-funzione. 
I risultati di questo lavoro di tesi contribuiscono a chiarire aspetti specifici sulla PHA e 
sulla PKU relativi a: (i) la stabilità conformazionale di alcuni mutanti di PAH che 
causano la malattia, (ii) le caratteristiche strutturali e dinamiche del dominio ACT 
isolato dell’enzima wild-type e di sei mutanti, (iii) le basi strutturali per la regolazione 
della PAH, attraverso l'identificazione in silico del putativo sito di legame allosterico 
per L-Phe. 
Studi strutturali, effettuati tramite homology modelling, su selezionati mutanti patogeni 
di PAH hanno rivelato una diminuita stabilità conformazionale che può essere associata 
a possibili difetti di fold ed ad una ridotta attività dell'enzima, che causa la malattia. 
Studi di dinamica molecolare sul dominio regolatore ACT isolato hanno evidenziato un 
comportamento dinamico specifico dell’enzima wild-type e dei sei mutanti. L’RD ha 
mostrato una transizione da una struttura iniziale aperta ad una struttura finale più 
chiusa, che porta alla riduzione dell'esposizione al solvente di una superficie idrofobica 
in cui il ligando L-Phe può legarsi al dominio. Inoltre, la correlazione, trovata tra 
l'accessibilità al solvente della superficie idrofobica e i moti globali intrinseci della 
proteina, suggerisce una relazione tra il legame con la L-Phe ed il comportamento 
dinamico globale dell'enzima. Nei mutanti, diversamente che nell’enzima wild-type, le 
simulazioni hanno rivelato cambiamenti nelle interazioni all'interno del core idrofobico 
dell’RD che possono influenzare significativamente la sua stabilità e, quindi, il suo 
ruolo regolativo. 
Al fine di indagare sul sito di legame allosterico per la L-Phe, ho generato dei modelli 
per le interazioni L-Phe-PAH, attraverso studi di docking molecolare in combinazione a 
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simulazioni di dinamica molecolare sulla PAH dimerica. I modelli hanno confermato la 
mia ipotesi iniziale riguardo la posizione del sito di legame allosterico all'interfaccia 
dimerica RD/CD. Per la PAH umana, il legame con la L-Phe ha mostrato una riduzione 
della mobilità del dominio RD. L'analisi di questi modelli ha chiarito gli effetti 
strutturali del mutante G46S, che influenzano il corretto legame con la L-Phe. 
In conclusione, questa tesi aggiunge ulteriori informazioni utili per una più profonda 
comprensione sia dei meccanismi di regolazione dell'enzima e sia dell’interconnessione 
tra le mutazioni e la malattia. 
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Summary 
 
The phenylalanine hydroxylase (PAH) is an iron-containing enzyme, that catalyzes the 
conversion of the essential amino acid L-Phe into L-Tyr, utilizing the cofactor 6R-L-
erythro-tetrahydrobiopterin (BH4) and dioxygen (Hufton et al., 1995; Kaufman, 1993). 
Defects in the PAH enzymatic activity, caused by mutations in the human gene, result 
in an autosomal recessively inherited disorder of amino acid metabolism, known as 
phenylketonuria (PKU).  
Many studies have confirmed a straightforward relation between 3D-structural 
alteration and the observed phenotypes. To date, more than 560 mutations in the PAH 
gene have been identified (see PAH Mutation Analysis Consortium database: 
http://www.pahdb.mcgill.ca/) and they are spread throughout the 3D-structure. 
It has been shown that PAH is a tetrameric enzyme assembled as dimer of dimers.  Each 
monomer adopts an α/β structure and is built up from an N-terminal regulatory domain 
(RD) (residues 1-117), a catalytic domain (residues 118-410), which includes binding 
sites for iron, substrate and cofactor, and a tetramerization domain (residues 411-452) 
(Fusetti et al., 1998).  
The N-terminal RD of PAH contains an ACT domain (residues 33-111), which consists 
of a structural motif composed of four β-strands and two α-helices arranged in a βαββαβ 
fold. The ACT domain was identified in some proteins involved in amino acid and 
purine metabolism and regulated by specific amino acids (Aravind and Koonin, 1999). 
In these proteins, the ligands usually bind at the interfaces between ACT domains and in 
proximity of a specific Gly (Gly46 in hPAH) located in the loop between the first β-
strand and the first α helix (Grant, 2006).  
The regulatory function of the N-terminal ACT domain of PAH is poorly understood 
and hence deserves further investigation. The major regulatory mechanisms of the PAH 
include activation by phenylalanine, inhibition by BH4, and additional activation by 
phosphorylation (Hufton et al., 1995). In some studies it was proposed that L-Phe binds 
to an allosteric site on RD of PAH, different from the active site, inducing large 
conformational changes (Fitzpatrick, 2000; Kaufman, 1993; Shiman et al., 1979).  
However, the putative allosteric L-Phe-binding site in PAH has not been identified yet 
and the role of the domain as an allosteric module is still unclear. 
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To get insight into the structural basis of the protein defects underlying the disease, I 
used a computational approach. The computational approach has been proven to be very 
powerful to understand how genetic variations modify the structure of biological 
macromolecules and to shed light on the structure-function relationships. 
Here, my current results contribute to elucidate specific aspects of PAH and PKU 
related to: (i) the conformational stability of disease-causing PAH mutants, (ii) the 
structural and dynamical features of the isolated ACT domain of the wild-type enzyme 
and of six mutants, (iii) the structural basis for the regulation of PAH, through the 
identification in silico of the putative allosteric L-Phe-binding site. 
Structural studies, by homology modelling, on selected disease-causing PAH mutants 
revealed a decreased conformational stability that can be associated to possible defects 
in the folding and to a reduced activity of the enzyme, leading to the disease. 
MD studies on the isolated ACT regulatory domain highlighted a specific dynamic 
behaviour of the wild-type enzymes and of the six mutants. The RD showed a transition 
from an initial open to a final more closed structure, leading to the decrease of the 
solvent exposure of a hydrophobic surface where the L-Phe ligand can bind to the 
domain. Moreover, the correlation, found between the solvent accessibility of the 
hydrophobic surface and the global intrinsic motions of the protein, suggested a 
relationship between the L-Phe-binding and the overall dynamic behaviour of the 
enzyme. In the mutants, the simulations revealed changes in the interactions within the 
hydrophobic core of the RD that may significantly affect its stability and hence its 
regulatory role.  
In order to investigate the allosteric regulatory binding site for L-Phe, I generated 
models for the L-Phe-PAH interactions, performing molecular docking studies 
combined with MD simulations on the dimeric PAH. The allosteric L-Phe-binding site 
was localized at the dimeric RD/CD interface, confirming my initial hypothesis on the 
site position. For the hPAH, the L-Phe-binding showed also to reduce the mobility of 
RD domain. The analysis of these models elucidated the structural effects of the 
disease-causing G46S mutant, which showed to significantly affect the correct binding 
of L-Phe. 
In conclusion, this thesis adds further evidences toward a deeper understanding of the 
regulatory mechanisms of the enzyme and of the relationship between the mutations and 
the disease.  
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Abbreviations 
 
3D Three Dimensional  
3PGDH  3-PhosphoGlycerate DeHydrogenase 
AAAH Aromatic Amino Acid Hydroxylase 
ACT from Aspartokinase, Chorismate mutase and prephenate 
dehydrogenase (TyrA), three proteins from the ACT family 
ATP Adenosine TriPhosphate 
BH2 Dihydropterin 
BH4 (6R)-L-erythro-5,6,7,8-tetrahydrobiopterin  
CD Catalytic Domain 
DHPLC Denaturant High Performance Liquid Chromatography 
DSSP Dictionary of Secondary Structure Protein 
ED  Essential Dynamics 
FMA Functional Mode Analysis 
GCK GluCoKinase 
H-bond Hydrogen Bond 
HPA HyperPhenylAlaninemia 
HPC High Performance Computing 
IARS Intrinsic AutoRegulatory Sequence 
MCM Maximally Correlated Motion 
MD Molecular Dynamics 
MHP Mild HyperPhenylalaninemia 
MODY2 Maturity Onset Diabetes of Young 
MPKU Mild PhenylKetonUria 
MSA Multiple Sequence Alignment 
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NMR Nuclear magnetic resonance 
PAH PhenylAlanine Hydroxylase 
hPAH human PhenylAlanine Hydroxylase 
rPAH rat PhenylAlanine Hydroxylase 
PDB  Protein Data Bank 
PC Principal Component 
PCA Principal Component Analysis 
PDT Prephenate DehydraTase 
PKA  cAMP dependent protein kinase 
PKU classical PhenylKetonUria 
RD Regulatory Domain 
RMSD Root Mean Square Deviation 
RMSF Root Mean Square Fluctuation 
SASA Solvent Accessible Surface Area 
SPC Simple Point Charge 
TH  Tyrosine Hydroxylase 
THA THienylAlanine 
TPH Tryptophan Hydroxylase 
VDW Van Der Waals 
wt-hPAH wild-type hPAH 
wt-rPAH wild-type rPAH 
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CHAPTER 1. General introduction 
 
1.1 The aromatic amino acid hydroxylases family 
The aromatic amino acid hydroxylases family consists of the non-heme iron-containing 
enzymes: phenylalanine hydroxylase (PAH, EC 1.14.16.1), tyrosine hydroxylase (TH, 
EC 1.14.16.2) and tryptophan hydroxylase (TPH, EC 1.14.16.4). These enzymes play an 
important role in the mammalian metabolism. The enzymes catalyze the hydroxylation 
of the respective aromatic amino acid L-phenylalanine (L-Phe), L-tyrosine (L-Tyr) and 
L-tryptophan (L-Trp) (Figure 1.1). They present a common catalytic mechanism 
involving the non-heme iron, the (6R)-L-erythro-5,6,7,8-tetrahydrobiopterin cofactor 
(BH4) and molecular oxygen (Flatmark and Stevens, 1999; Kappock and Caradonna, 
1996). Dioxygen is used by the active site, containing a single reduced iron ion, to 
hydroxylate an unactivated aromatic substrate, concomitant with a two-electron 
oxidation of the cofactor to its quinonoid dihydropterin form. This form can also 
isomerize to L-erythro-7,8-dihydrobiopterin (BH2) which is converted back to BH4 by 
dihydrofolate reductase (DHFR) (Kappock and Caradonna, 1996) (Figure 1.1).  
PAH, which is mainly found in liver, catalyzes the first and rate-limiting step in the 
catabolic pathway of L-Phe, by hydroxylating L-Phe into L-Tyr and resulting in the 
complete degradation of the amino acid (Flatmark and Stevens, 1999).  
TH, which is found in the central nervous system and in the adrenal gland, catalyzes the 
first step in the formation of catecholamines by converting L-Tyr into L-3,4-
dihydroxyphenylalanine (L-Dopa) (Fitzpatrick, 1999; Flatmark and Stevens, 1999). L-
Dopa is decarboxylated by the aromatic L-amino acid decarboxylase and dopamine is 
the product. Dopamine can further be converted into norepinephrine and epinephrine, 
and these are all important hormones and/or neurotransmitters.  
There are two isoforms of TPH: TPH1, mainly expressed in the pineal gland and the 
periphery, and TPH2, abundant in the brain (Walther and Bader, 2003). The reaction 
catalyzed by TPH is the first and rate-limiting step in the biosynthesis of serotonin and 
the initial and uncommitted step in the synthesis of melatonin, by hydroxylating L-Trp 
into 5-hydroxytrypthophan (5-HTP).  
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Figure 1.1: Scheme of the hydroxylation reactions catalyzed by the aromatic amino acid 
hydroxylases, using the (6R)-L-erythro-5,6,7,8-tetrahydrobiopterin cofactor (BH4) and 
molecular oxygen. The de novo BH4 biosynthetic pathway from guanosine triphosphate 
involves the enzymes GTP cyclohydrolase (GTP-CH), 6-pyruvoyl-tetrahydropterin synthase (6-
PTPS) and sepiapterin reductase (SR). 
 
The three enzymes share a high degree of sequence identity (65%) (Figure 1.2) and 
domain organization. In solution, as well as in vivo, all three hydroxylases form 
tetramers in which each monomer is composed of three structural and functional 
domains: an N-terminal domain with regulatory properties, a central catalytic domain 
where is located the active site, and a C-terminal tetramerization domain (Erlandsen and 
Stevens, 1999; Fusetti et al., 1998; Kobe et al., 1999). The latter domain, consisting of 
the last 20-23 amino acids, is responsible for the oligomeric state of the enzymes 
forming a domain-swapped tetrameric coiled-coil.  
The active site, with the non-heme iron coordinated to a 2-His-1-carboxylate facial 
triad, is very similar in the three enzymes, that present 80% sequence similarity in the 
catalytic domains (Kappock and Caradonna, 1996). In contrast to the high degree of 
similarity found in the catalytic and oligomerization domains, the regulatory N-terminal 
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Figure 1.2: Multiple sequence alignment of human AAAHs. The sequences were aligned using 
T-Coffee (Notredame et al., 2000). The residue color scheme reflects the primary library 
support for the alignment of the considered residue on a scale between 0 (blue, poorly 
supported) and 9 (dark red, strongly supported). The asterisks below the sequences indicate 
identity, and two dots or one dot denote homolog properties, depending on the degree of 
similarity of the residues.  
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domain is highly variable in length and topology, reflecting different regulatory specific 
function of the three enzymes (Hufton et al., 1995). 
 
1.2 Human phenylalanine hydroxylase 
Human PAH (hPAH) is a catabolic enzyme that degrades the L-Phe from food and 
provides an endogenous source of L-Tyr to the organism by converting L-Phe, an 
essential amino acid that has to be included in the diet (Kalhan and Bier, 2008), into L-
Tyr which therefore is a non-essential amino acid (Figure 1.1). Human PAH is present 
mainly in the liver, but is also expressed to some extent in the kidney and epidermis. 
The human PAH gene, mapped on chromosome 12q23.2 (Scriver, 2007; Woo et al., 
1987), is composed of 171 kb organized into 13 exons. The full-lenght PAH cDNA 
(GenBank cDNA Reference Sequence U 49897) encodes a protein of 452 amino acids 
(about 52 kDa for each subunit).  
 
1.2.1 Human PAH three-dimensional structure 
Crystal structure information is available for several truncated forms of hPAH, with or 
without cofactor and substrate analogues, but the full-length structure has not been 
solved yet. In particular, the structure of the regulatory domain (RD) of hPAH is not 
available. Its closest homolog with known structural data (PDB code 1PHZ) is the RD 
from rat dimeric PAH (rPAH) (Kobe et al., 1999), which shares a 86% sequence 
identity of the RD with hPAH. A full-length composite model of human PAH can be 
constructed by superimposing the structure of rat PAH which includes the 
regulatory/catalytic domains and the structures of human dimeric and tetrameric PAH 
that include the catalytic/tetramerization domains (Figure 1.3 A,B).  
It has been shown that hPAH is a tetrameric enzyme (Figure 1.3A) in equilibrium with a 
dimeric form (Bjorgo et al., 2001; Martínez et al., 1995). The hPAH tetramer  dimer 
equilibrium is dependent on pH (Kappock et al., 1995) and L-Phe concentration (Bjorgo 
et al., 2001; Martínez et al., 1995). A decrease of pH (to pH=6) and L-Phe concentration 
shifts the equilibrium towards the tetrameric form.  
Each monomer adopts an α/β structure and is built up from an N-terminal RD (residues 
1-117), a catalytic domain (residues 118-410), which includes binding sites for iron, 
substrate and cofactor, and a C-terminal oligomerization domain (residues 411-452) 
(Figure 1.3B).  
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Figure 1.3: Composite model of the full-lenght (A) tetrameric and (B) monomeric PAH 
structures created by superimposing the regulatory/catalytic domain from rat crystal structure 
(1PHZ) and the catalytic/tetramerization domain from human crystal structure (2PAH). In (A) 
each monomer is colored separately, the iron is shown as a red sphere. In (B) RD is drawn in 
blue, the catalytic domain in yellow and the tetramerization domain in green. 
 
The N-terminal RD of PAH contains an ACT domain (residues 33-111), consistng of a 
four-stranded antiparallel β-sheet flanked on one side by two short α-helices and on the 
other side by the catalytic domain (Kobe et al., 1999) (see section 1.3).  
The catalytic domain has a basket-like arrangement of 14 α-helices and 8 β-strands. In 
this domain the active-site iron resides in an open and solvent accessible region 
(Erlandsen et al., 1997). There is also a narrow tunnel connected to the active-site 
pocket and this may be where the substrate is directed into the active site. The iron is 
located at the entrance of the pocket thus leaving space for binding of both the pterin 
and the substrate (Flatmark and Stevens, 1999). The iron is ligated in an octahedral 
manner by two histidine residues (His285 and His290), one glutamic acid residue 
(Glu330) and three water molecules (Figure 1.4).  
The cofactor BH4 binds at the active site, in the vicinity of the iron ion, where it makes 
stacking interactions with Phe254 (Teigen et al., 1999; Teigen et al., 2004).  
In the ternary crystal structures of substrate analogs (THA or NLE) the substrate was 
found to bind in the second coordination sphere of the iron with the aromatic ring 
stacking against the imidazole group of the iron-bound His285 (Andersen et al., 2002; 
Andersen et al., 2003).  
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Figure 1.4: Close-up view of the iron binding site in hPAH. The iron ion is shown as a yellow 
sphere hexa-coordinated in an octahedral geometry to His285, His290, Glu330 (in stick) and 
three water molecules (Wat1, Wat2 and Wat3) represented as red spheres. The figure was 
prepared using the crystal structure of the binary cofactor complex (ΔN102/ΔC24-hPAH-
Fe(II)·BH4) (PDB code: 1J8U) (Andersen et al., 2001) and the program Pymol (Schrödinger, 
2009). 
 
 
 
Figure 1.5: Close-up view of the BH4 and THA (analog of Phe) binding sites in hPAH. The 
iron ion is shown as a orange sphere, the BH4 in yellow stick and the THA in cyan stick. All 
residues involved in the binding of Fe, BH4 and THA (see text) are highlighted in green stick. 
The figure was prepared using the crystal structure of the ternary complex (PDB code: 1KW0) 
(Andersen et al., 2002) and the program Pymol (Schrödinger, 2009). 
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The substrate was found to interact through hydrogen bonds and hydrophobic 
interactions with some residue in the site (Andersen et al., 2002).  
The short oligomerization domain includes a dimerization motif (411-427), consisting 
of two antiparallel β-strands, and a tetramerization motif (428-452), a single 40 Å long 
C-terminal α-helix responsible for forming the core of tetramer. The helix has a 
conserved heptad repeat of hydrophobic Leu-rich residues forming a leucine zipper that 
plays an important role in the tetramerization domain swapping mechanism. The 
tetramer core is formed by four α-helices, one from each subunit, tightly packed in an 
antiparallel coiled-coil motif (Fusetti et al., 1998).  
The hPAH tetramer is not completely symmetrical, and is considered a dimer of two 
conformationally dimers (Fusetti et al., 1998). The two dimers within the tetramer adopt 
a different relative orientation, due to rotation around the hinge region Asp425-Gln429 
(at Thr427) that connects the dimerization and tetramerization motifs, followed by an 
another rotation around Gly442 in the C-terminal tetramerization helix (Fusetti et al., 
1998). 
 
1.3 Structure of N-terminal regulatory domain  
The RD has a flexible and quite instable structure, consistent with thermal denaturation 
studies that have shown that the RD unfolds at a lower temperature than the more 
compact catalytic domain (Thorolfsson et al., 2002). Structural information on this 
domain is just provided from the rat dimeric crystal PAH structures (PDB code 1PHZ, 
2PHM) (Kobe et al., 1999). The rat dimeric crystal structure shows that the N-terminus 
of the RD extends across the active site opening. This first sequence stretch in the N-
terminus (residues 1-33), different among the AAAHs, is called the intrinsic 
autoregulatory sequence (IARS) (Teigen and Martinez, 2003). The IARS partly controls 
the access of the solvent and substrates to the active site (Horne et al., 2002; Kobe et al., 
1999) and includes the phosphorylation site (Ser16), which is involved in the activation 
of the enzyme (see section 1.4).  
The structured part of RD (residues 34-110) is classified as an ACT domain, a structural 
motif composed of four β-strands and two α-helices arranged in a βαββαβ fold (Figure 
1.5A). The ACT (from Aspartokinase, Chorismate mutase and prephenate 
dehydrogenase (TyrA), three proteins from the ACT family) domain is a small 
molecule-binding domain (SMBD) with a high sequence divergence and evolutionary 
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mobility (Anantharaman et al., 2001). The ACT domain was identified by sequence 
analysis of a set of proteins involved in amino acid and purine metabolism and 
regulated by specific amino acid (Aravind and Koonin, 1999).  
In the available 3D structures, this domain was found either isolated or associated into 
oligomers of 2, 3 or 4 units (Figure 1.5B). Differently, in the tetrameric PAH structure 
the four ACT domains do not associate with each other. In many cases, the proteins 
containing the ACT domain are allosteric enzymes regulated via transmission of 
conformational changes upon ligand binding (Aravind and Koonin, 1999). In the ACT 
domain-containing proteins, the ligands usually bind at the interfaces between ACT 
domains (Figure 1.5B) and in proximity of a specific Gly (Gly46 in hPAH) located in 
the loop between the first β-strand and the first α helix (Grant, 2006).  
The regulatory ACT domain is connected to the catalytic domain by a hinge bending 
region (residues 111-117), which is involved in domain movements occurring upon 
activation by the substrate (Li et al., 2010; Stokka et al., 2004). The regulatory ACT 
domain is also in contact with the catalytic domain of the adjacent chain in the dimer 
and with the oligomerization domain of its own chain.  
 
 
 
Figure 1.5: (A) A single ACT domain from E. coli D-3-phosphoglycerate dehydrogenase 
displaying the βαββαβ motif. In the schematic representation at the bottom, the triangles 
pointing up or down indicate the direction of the strand in the β sheet, with numbers starting 
from the N-terminus. ( B) The E. coli D-3-phosphoglycerate dehydrogenase tetramer (PDB code 
1PSD), with the subunits in green and gray and ACT domains colored blue and red. The arrows 
indicate the location of the ACT domains in the structure, with the ligand (L-Ser), in CPK 
format, bound at the dimer interface. Figure from Grant 2006. 
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1.4 Regulatory function of PAH 
Human PAH is highly regulated in order to maintain the correct levels of L-Phe in the 
blood. The three main regulatory mechanisms of hPAH are i) activation by 
phenylalanine (Shiman and Gray, 1980; Shiman et al., 1990), ii) inhibition by BH4 
(Døskeland et al., 1996), and iii) additional activation by phosphorylation (Shiman and 
Gray, 1980). Studies on truncated forms of hPAH partially or fully lacking the N-
terminal domain have shown that the enzyme is already in an activated state 
(Knappskog et al., 1996a) and is not inhibited by the cofactor BH4 (Jennings et al., 
2001), properties that are not exhibited by the full-length enzyme. Removal of a N-
terminal fragment activates the enzyme, and a regulatory effect by this domain was then 
proposed (Iwaki et al., 1986). 
 
1.4.1 Activation by substrate  
The substrate L-Phe is an allosteric activator of the hPAH enzyme, inducing 
conformational changes (Kaufman, 1993). Preincubation with L-Phe results in a 5- to 6- 
fold activation of full-length hPAH (Bjorgo et al., 2001), a process caused by 
conformational changes in the tetrameric/dimeric enzyme (Flatmark and Stevens, 1999; 
Li et al., 2010; Stokka and Flatmark, 2003; Stokka et al., 2004). Movements of the RD 
with displacement of the IARS seem to be involved, resulting in an increased 
accessibility to the active site, as N-terminal truncated mutants are already in an 
activated state (Knappskog et al., 1996a; Stokka and Flatmark, 2003). This L-Phe 
activation results in a transition of the enzyme from a low activity, low affinity “T”-
state to a high activity “R”-state (Shiman and Gray, 1980; Shiman et al., 1990). 
Furthermore, the full-length tetrameric form of hPAH binds the substrate L-Phe with 
positive cooperativity, that involves all four monomers (Bjorgo et al., 2001; Shiman and 
Gray, 1980; Shiman et al., 1990). Human PAH shows a non-hyperbolic (sigmoidal) 
dependence on substrate concentration for its equilibrium binding (Parniak and 
Kaufman, 1981) and steady-state kinetics (Kaufman, 1993). The substrate L-Phe binds 
with an affinity (S0.5) of ~150 μM for eukaryotic PAH and a Hill coefficient (nH) of ~2 
(Kaufman, 1993; Teigen et al., 2007). The positive cooperative binding of L-Phe is 
physiologically important as a protection mechanism when the serum L-Phe 
concentration increases above normal levels, allowing L-Phe homeostasis in the blood 
by preventing HPA (Kappock and Caradonna, 1996). The activation and positive 
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cooperativity mechanism of the full-length hPAH enzyme is a complex process that is 
still not completely understood. 
 
1.4.2 Activation by phosphorylation 
Phosphorylation at Ser16 by the cyclic AMP dependent protein kinase A (PKA) is a 
post-translational modification that acts synergistically with L-Phe activation. The 
phosphorylated enzyme requires a lower L-Phe concentration for full catalytic 
activation, while L-Phe levels increase the rate of phosphorylation by PKA (Døskeland 
et al., 1996; Kaufman, 1993). In contrast, BH4 reduces the rate of phosphorylation, but 
this inhibition is prevented in the presence of L-Phe (Døskeland et al., 1996). 
Phosphorylation seems to induce a local conformational change at Ser16 in the IARS, 
which facilitates the access of L-Phe to the active site (Miranda et al., 2004; Miranda et 
al., 2002). 
 
1.4.3 Inhibition by cofactor 
The cofactor BH4 plays a role as co-substrate in the catalytic reaction, but has also a 
regulatory role. BH4 inhibits the enzyme by inducing a low-activity conformational 
state, inhibits L-Phe activation and reduces the rate of phosphorylation at Ser16 
(Døskeland et al., 1996; Pey et al., 2004a; Pey et al., 2004b; Solstad et al., 2003; Teigen 
and Martinez, 2003). The cofactor BH4 inhibits hPAH in the absence of L-Phe by 
protecting the enzyme from unfolding and degradation (Mitnaul and Shiman, 1995), a 
stabilization process that plays a major role in the BH4-responsive PKU (Martínez et 
al., 2008). On the other side, recent studies demonstrate that the binding of BH4 to an 
activated form of PAH (in the presence of the substrate) results in a positive 
cooperativity indicated by a sigmoidal behaviour of data originating from continuous 
PAH activity assay (whereas the BH4-dependent kinetics of the non-activated enzyme 
followed the non-cooperative Michaelis-Menten model) (Gersting et al., 2010). 
 
1.5 Hyperphenylalaninemias 
Mutations in the human gene encoding the PAH enzyme result in the autosomal 
recessively inherited disease hyperphenylalaninemia (HPA). The resulting HPA 
phenotypes can range in severity as follow: mild hyperphenylalaninemia (MHP or HPA 
III) when plasma Phe levels of untreated subjects are between 120 and 600 μM/L; mild 
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phenylketonuria (MPKU or HPA II) when untreated plasma Phe levels are between 600 
and 1200 μM/L; and classical phenylketonuria (PKU or HPA I) when untreated plasma 
Phe levels are > 1200 µM/L. The normal range of blood phenylalanine concentrations is 
50-110 μM/L (Blau et al., 2010).  
Impaired function of PAH results in the accumulation of high levels of blood plasma 
Phe and toxic concentrations in the brain (Erlandsen and Stevens, 1999). L-Tyr is the 
substrate for the biosynthesis of the thyroid hormone thyroxine, the neurotransmitter 
dopamine, the adrenal hormones and the pigment molecule melanin. Lack of L-Tyr and 
excess of L-Phe leads to various clinical manifestations such as mental retardation and 
decreased pigmentation. Additional symptoms include eczematous rash, autism, 
seizures, and motor deficits. Developmental problems, aberrant behaviour, and 
psychiatric symptoms often become apparent as the child grows (Blau et al., 2010).  
Early diagnosis and prompt intervention has allowed most individuals with PKU to 
avoid severe mental disability (Blau et al., 2010). Nowadays, many countries include a 
test for HPA in neonatal screening programmes. To prevent mental retardation due to 
the build up of neurotoxic metabolites of L-Phe, patients with severe PKU must be 
treated with a low-L-Phe diet starting early in the life (Erlandsen and Stevens, 2001). 
This low-protein diet, supplemented with L-Phe-free mixture of amino acids, vitamins, 
minerals and other nutrients remains the most effective treatment for PKU (Blau et al., 
2010; Giovannini et al., 2007). However, the diet is difficult to maintain and compliance 
if often poor, expecially in adolescents and pregnant women. About 1-2% of cases of 
HPA are due to mutations in the genes coding for enzymes involved in the biosynthesis 
or regeneration of the PAH cofactor BH4 (Thöny and Blau, 2006). BH4 stimulates PAH 
activity in about 20% of patients, and in those patients serves as a useful adjunct to the 
low-L-Phe diet, because it increases Phe tolerance and allows some dietary freedom 
(Blau et al., 2010). About 75% of PAH mutations, characterized by high residual 
enzyme activity, have been found to be associated with BH4-responsiveness, both in 
vitro (Erlandsen et al., 2004) and in vivo (Giovannini et al., 2007). The BH4-
responsiveness in HPA has been the subject of numerous studies. Various mechanisms 
have been proposed to explain BH4-responsiveness, in particular: increased enzyme 
activity (Erlandsen et al., 2004; Muntau et al., 2002; Scriver, 2007), correction or 
compensation of the BH4 decreased affinity, protection toward catalytic inactivation 
and chaperone-like activity that, by stabilizing the protein, protects it from proteolytic 
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degradation (Erlandsen et al., 2004; Scriver, 2007). In addition, BH4 supplementation 
may restore the optimal concentration of BH4 cofactor in hepatocytes (Aguado et al., 
2006). In some cases the addiction of BH4 influences the oligomerization equilibrium 
by shifting it toward a tetrameric quaternary structure (Cerreto et al., 2011). 
Restoration of the function of the affected enzyme could be accomplished by a gene 
therapy approach (Blau et al., 2010; Cerreto et al., 2011). Enzyme substitution therapy 
with the plant derived phenylalanine ammonia lyase (PAL, E. C. 4.3.1.5) is an 
additional approach to treat PKU, that is currently in phase II clinical trials 
(ClinicalTrials.gov, 2010). 
More than 560 disease-causing mutations in the PAH gene have been identified and 
registered in the Human PAH Mutation Knowledgebase (hPAHdb; 
www.pahdb.mcgill.ca/). The current set of PKU mutations consists of ~60% missense 
mutations; ~13% deletions; ~11% splice mutations; ~6% silent mutations; ~5% 
nonsense mutations and ~2% insertions. Mutations have been identified in all 13 exons 
and, due to the large number of mutations, most of the patients (approximately 75%) are 
heteroallelic for PAH mutations, being classified as compound heterozygous (Scriver 
and Waters, 1999).  
Characterization analyses in vitro of several PAH missense mutations have identified at 
least three main groups of enzymatic phenotypes which differ in their kinetic behaviour 
and/or stability: (i) structurally stable mutations with altered kinetic properties, e.g. 
mutations at residues involved in substrate (L-Phe) or the pterin cofactor (BH4) 
binding; (ii) mutations with normal or almost normal kinetic properties, but reduced 
stability both in vitro and in vivo; and (iii) mutations affecting both kinetic and stability 
properties of the enzyme (Bjorgo et al., 1998; Gersting et al., 2008; Knappskog et al., 
1996b; Waters, 2003; Waters et al., 2000). 
Mutations are spread throughout the 3D structure, even though most of them fall in the 
catalytic domain. The mutated residues were classified on the basis of 3D-structural 
criteria into 5 diverse categories: 1) active site residues, 2) structural residues, 3) 
residues involving interdomain interactions within a monomer, 4) residues that interact 
with the N-terminal IARS, and 5) residues at the dimer or tetramer interface regions 
(Erlandsen, 2003). 
Many studies have confirmed a straightforward relation between structural alteration 
and the observed phenotypes. The decrease in protein stability is the main molecular 
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pathogenic mechanism, so PKU is also considered a protein misfolded disease 
(Gregersen et al., 2001; Martínez et al., 2008). 
 
1.6 Aims of the thesis 
PKU is mainly caused by missense mutations in the phenylalanine hydroxylase gene. 
The effects of a specific mutation on protein function have been studied through a 
number of different approaches including in vivo, in vitro and in silico studies. All 
together these investigations have demonstrated that, in the majority of PKU cases, the 
loss of PAH function is due to decreased stability (Gersting et al., 2008; Knappskog et 
al., 1996a), increased susceptibility toward aggregation and degradation of PAH mutant 
proteins (Eiken et al., 1996; Gersting et al., 2008; Gjetting et al., 2001a), 
thermodynamic instability (Waters et al., 2000) and/or low folding efficiency (Pey et 
al., 2007). Structural analysis of wild-type enzyme and its mutants can contribute to a 
better understanding of the function of the enzyme and can provide a molecular 
explanation for the structural/functional effects induced by PAH mutations.  
The computational approach has been proven to be very powerful to understand how 
genetic variations modify the structure of biological macromolecules and to shed light 
on the structure-function relationships. Therefore, in the framework of this doctorate, I 
used computational methods aimed to get insight into the structural basis of the protein 
defect underlying the disease.  
PKU has been the subject of extensive research along many years, but there are still 
diverse aspects that demand a further study. In this perspective, the main goal of this 
thesis was to thoroughly elucidate some structural aspects. First, I carried out the 
mapping of some mutations to search for structural alterations (Chapter 2); then I 
studied the structural effects of the most frequent mutants falling in the ACT regulatory 
domain of PAH by molecular dynamics (MD) simulations in solution (Chapter 3). 
Finally, I investigated the open questions on the regulation function of the enzyme, 
through the identification of the putative allosteric Phe-binding site in the dimeric PAH 
model by molecular docking and subsequently by the analysis of the best scoring 
docking poses by MD simulations in solution (Chapter 4).  
The study of the structure and the correlation between structure and function of proteins 
is important to understand how the different amino acid sequence will specify the 
folding and to understand how the structure assumed by the protein will determine the 
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biological function. In this context, to investigate the structural effects of the amino 
acidic replacements in the missense disease-causing PAH mutants, I examined in silico 
the alterations in the three-dimensional structure of two groups of mutations. First, a 
group of seven natural PAH variants (p.I65M, p.N223Y, p.R297L, p.F382L, p.K398N, 
p.A403V, and p.Q419R), that were, at the same time, biophysically-biochemically 
characterized in vitro (Cerreto et al., 2011). Then, a group of four novel natural PAH 
mutants (p.L321I, p.I406M, p.T418I, p.N426H), found in young HPA patients from 
Southern Italy (Chapter 2). 
Phenylketonuria is considered a protein misfolding disease with loss of function 
(Gregersen et al., 2001). The misfolding of hPAH mutants does not directly affect the 
catalytic function, but impairs molecular motions involved in regulatory processes, 
substrate and cofactor binding and oligomerization assembly (Leandro et al., 2011). 
Particularly the N-terminal RD seems to play a crucial role in the instability and 
misfolding of the protein (Gersting et al., 2008). Therefore, I aimed to comprehensively 
study in silico the isolated ACT regulatory domain of the wild-type enzyme and of six 
selected disease-causing missense mutants (p.G46S, p.F39C, p.F39L, p.I65S, p.I65T 
and p.I65V) falling in such domain, by MD simulation in solution (Chapter 3). MD 
simulations are powerful tools for understanding internal motions in biological 
macromolecules. They are used to investigate motions that have particular functional 
implications and to reveal conformational changes as a function of time.  
The N-terminal RD has a regulatory function, that is poorly understood and deserves 
further clarification. In particular the regulatory mechanism of the activation by the 
substrate phenylalanine is controversial. There is a debate regarding the ability of hPAH 
to bind L-Phe to an allosteric binding site, different from the active site, at the 
regulatory ACT domain (Fitzpatrick, 2000; Kaufman, 1993; Shiman and Gray, 1980). 
In order to investigate the allosteric regulatory binding site for L-Phe, I also aimed to 
extend the structural and dynamical studies on the dimeric hPAH and to perform a Phe-
docking simulation of the dimer (Chapter 4). In this way, through the computational 
approach, I directly investigated the unclear regulation of the domain, by studing the 
motions and the flexibility of the enzyme upon ligand-binding.  
Furthermore, this thesis contributes to clarify the relationship between the genetic 
mutations and the disease. All the performed simulations can inspire new experiments 
in the light of possible treatments of the disease. 
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CHAPTER 2. Structural analysis of selected natural hPAH 
variants 
 
2.1 Introduction  
HPAs represent the most common inherited disorder of amino acid metabolism, mostly 
caused by mutations in the PAH gene. About two-thirds of  PKU mutations are caused 
by point mutations in which a single nucleotide is changed, resulting in a codon that 
codes for a different amino acid. A large proportion of all missense mutations, including 
many of the most common mutations found in patients, display stability and folding 
defects when they are expressed in vitro (Waters, 2003). These mutants are found to 
aggregate when expressed in prokaryote systems, where they appear as both soluble and 
insoluble aggregates (Leandro et al., 2010). The current understanding of PKU is related 
to a loss-of-function mechanism associated with increased degradation (Waters, 2006) 
and in some cases aggregation of the mutants. 
Recombinant variant proteins containing prevalently missense mutations have been 
thoroughly characterized and analyzed in vitro and in silico. Each mutation exerts a 
distinct effect on the behavior of the enzyme and results in a specific biochemical 
phenotype. The effects of a specific mutation on protein structure and function have 
been studied by various approaches. 
Several novel natural disease-causing mutants of hPAH were found (Daniele et al., 
2008) in young patients of the “Dipartimento Clinico di Pediatria (DCP)” of the 
University of Naples “Federico II” and of the “Centro Screening Fenilchetonuria” of the 
hospital “S.S. Annunziata”, Napoli. The resulting phenotypes of these mutations 
correspond to the mild form of HPA. Verification of clinical suspicion of HPA in these 
patients was carried out by the non-invasive molecular analysis of the PAH gene at the 
research institute CEINGE, Napoli. In our group, seven of these mutants have been 
deeply characterized, while for other four mutants found more recently we conducted a 
preliminary structural study.   
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2.1.1 Study of seven selected natural disease-causing hPAH mutants 
A combined in vitro-in silico approach was used to analyzed the wild-type hPAH 
enzyme and seven selected natural disease-causing PAH mutants, in order to obtain 
further information about the molecular basis of HPAs and the mechanism of BH4 
responsiveness (Paper I). The full-length wild-type and seven natural variants, namely 
p.I65M, p.N223Y, p.R297L, p.F382L, p.K398N, p.A403V, and p.Q419R were 
reproduced by in vitro mutagenesis. The activity, the oligomeric structure and the 
stability of the produced enzymes were determined to understand the impact of each 
mutation. In addition, the mechanism underlying BH4 responsiveness was investigated 
using p.A403V, which is one of the most frequent mutations in our geographic area, and 
is associated with a BH4-responsive mild phenotype. To complete this study, I 
performed the mapping of these mutations on the 3D hPAH structure to search for 
structural alterations caused by the amino-acidic replacement. 
 
2.1.2 Study of four novel natural disease-causing hPAH mutants 
Recently, four novel natural disease-causing mutants of hPAH, namely p.L321I, 
p.I406M, p.T418I and p.N426H, have been studied. Starting from wild-type human 
tetrameric phenylalanine hydroxylase structure (PDB code 2PAH), 3D structural 
models of the four novel mutants were generated, using template-based protein structure 
modelling to investigate the effects of the mutations on the structure.  
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2.2 Experimental methods 
2.2.1 PAH tetrameric structure 
No full-length structure, including all three domains, is available for PAH or any 
AAAHs in the PDB. There are various structures of catalytic domains with different 
combinations of pterin cofactors, Fe in diverse oxidation state and substrate analogs, 
mostly from human PAH. There are two structures (phosphorylated and 
dephosphorylated) of the regulatory domain in conjunction with the catalytic domain 
from rat PAH (Kobe et al., 1999). Only one structure of tetrameric hPAH with the 
catalytic domain and the entire oligomerization domain is available (Fusetti et al., 
1998). Nevertheless, the available truncated structures have allowed the build up of 
composite full-length models, as e.g. in (Flatmark and Stevens, 1999; Thorolfsson et al., 
2002). Our model (see Paper I) was constructed by combining various structures: 
tetrameric human PAH lacking residues 1-117 (PDB code 2PAH); dimeric truncated 
human PAH lacking residues 1-117 and 425-452 (PDB code 1KW0); and the dimeric 
rat PAH, from residue 19 to 427 (PDB code 1PHZ), which encompasses the regulatory 
domain. The composite monomeric model that included the three domains was built by 
superimposing the secondary structure elements of the respective catalytic domains of 
the above-mentioned structures. The structural superposition was performed using the 
program O.  
 
2.2.2 Homology modelling 
Evolution has produced diverse families of protein whose share similar 3D structure and 
similar sequences. In the post-genomic era, the structural genomics project aims to a 
systematic and large-scale effort towards structural characterization of all proteins 
encoded in the genomes. This aim will be achieved by a focused determination of 
selected protein structures by X-ray crystallography and NMR spectroscopy (one 
determined structure per sequence family), combined with accurate protein structure 
modelling techniques.  
The homology modelling predicts the 3D structure of a given protein of unknown 
structure (target) on the basis of sequence similarity to one or more proteins of known 
structures (templates) (Bajorath et al., 1994; Blundell et al., 1987). This technique is 
based on the assumption that homologous proteins with similar sequences have similar 
3D structures. The 3D structures of proteins in a family are more conserved than their 
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sequences (Lesk and Chothia, 1980). Moreover, even proteins that do not have sequence 
similarity can have similar structures.  
The homology modelling is increasingly used because the number of unique structural 
folds that proteins adopt is limited (Zhang, 1997) and the number of experimentally 
determined new structures is increasing exponentially (Holm and Sander, 1996). 
The structure-based modelling methods consist of four sequential steps (Sanchez and 
Sali, 1997) (Figure 2.1): template selection, target-template alignment, model building 
and model evaluation. If the model is not satisfactory, the steps can be repeated until a 
satisfactory model is obtained. 
 
2.2.2.1 Template selection 
The first step in homology modelling is to identify all protein structures related to the 
target sequence, and then to select those that will be used as templates. Templates can 
be found using the target sequence as a query for searching structure databases. The 
target sequence is compared with each of the database sequences independently, using 
programs as FASTA (Pearson, 1998) and BLAST (Altschul et al., 1990). To improve 
the sensitivity of the search, a multiple sequence comparisons can be performed. A 
widely used program for multiple sequences comparisons is PSI-BLAST (Altschul et 
al., 1997), which iteratively expands the set of homologs of the target sequence. For a 
given sequence, an initial set of homologs from a sequence database is collected, a 
weighted multiple alignment is made from the query sequence and its homologs. 
Generally, a higher overall sequence similarity between the target and the template 
sequence provides a better template. However, several other criteria should be 
considered when selecting the templates: the quality of the experimental template 
structure (the resolution and the R-factor of a crystallographic structure and the number 
of restraints per residue for an NMR structure), the choice of the template that contains 
the entire sequence to be modeled and similar conditions (e.g., solvent, pH, ligands and 
quaternary interactions). The use of several templates usually increases the model 
accuracy. 
 
2.2.2.2 Target-Template Alignment  
The alignment is very important in homology modelling. If the alignment is wrong, it 
will result in an inaccurate model. Therefore, it is sometimes important to use more 
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Figure 2.1: Scheme of the steps in the protein structure homology modelling. Figure from 
Martí-Renom 2000. 
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sequences and to build a multiple sequence alignment that provides more information. 
There is a great variety of protein sequence alignment methods. The frequently used 
programs for multiple sequence alignment are ClustalW, Blast, T-coffee, ect. The target 
and the template should be aligned taking structural information into account as much 
as possible. In principle, most sequence alignment and structure comparison methods 
can be coordinately used to obtain the best alignment.  
 
2.2.2.3 Model building 
The built alignment is used by software that, using the structure of the template as a 
reference, generate one or more 3D-models of the target protein.  
The methods (Martì-Renom et al., 2000) for the construction of a model are: 
 Rigid -bodies assembly: this method assembles a model from a small number of 
rigid bodies, obtained from the template. The frame-work is calculated by 
averaging the coordinates of the Cα atoms of structurally conserved regions in 
the template structure. The main chain atoms of each core region in the target 
model are generated by superposing the core segment from the template with the 
highest sequence similarity to the target on the framework. The loops are 
generated by scanning a database of all known protein structures to identify the 
structurally variable regions that fit the regions and have a compatible sequence. 
The side chains are modeled based on their intrinsic conformational preferences 
and on the conformation of the equivalent side chains in the template structures. 
 Segment matching: this method is based on the finding that most hexapeptide 
segments of protein structure can be clustered into approximately 100 structural 
classes. Thus, comparative models can be constructed by using a subset of 
atomic positions from template structures as guiding positions, and by 
identifying in a representative database of all known protein structures and 
assembling hexapeptide segments that fit these guiding positions. This method 
can construct both main chain and side chain atoms and can also model 
insertions and deletions.  
 Spatial restraints: this method generates many constraints or restraints on the 
structure of the target sequence, using the target as a guide. The restraints are 
generally obtained by assuming that the corresponding distances and angles 
between aligned residues in the template and the target structures are similar. In 
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addition, stereochemical restraints on bond lengths, bond angles, dihedral 
angles, and nonbonded atom-atom contacts are considered. The model is then 
derived by minimizing the violations of all the restraints.  
Loop modelling is a mini-protein folding problem. The correct conformation of a given 
unstructured segment of a polypeptide chain is difficult to calculate. Structural 
variability, that results from substitutions, insertions and deletions of residues between 
members of the family, frequently occurs in the exposed loop regions. Thus, loops often 
determine the functional specificity of a given protein. Loop modelling methods 
include: ab initio methods (Bruccoleri and Karplus, 1987), based on a conformational 
search or enumeration of conformations in a given environment guided by a scoring or 
energy function; database search techniques (Chothia and Lesk, 1987), consisting in the 
finding of a main chain segment that fits the two stem regions of a loop;  procedures 
that combine the first two basic methods (Martin et al., 1989).  
As the loops, side chain conformations are predicted from similar structures and from 
steric or energetic considerations. Disulphide bridges are modeled using structural 
information from proteins in general and from equivalent disulfide bridges in related 
structures. 
 
2.2.2.4 Model evaluation 
The accuracy of 3D protein models is essential. The model can be evaluated as a whole 
as well as in individual regions. The first step in model evaluation is to assess if the 
model has the correct fold (Sanchez and Sali, 1998). Then, a basic requirement for a 
model is to have good stereochemistry (Martì-Renom et al., 2000). There are many 
model evaluation programs and servers. Some useful programs for evaluating 
stereochemistry are PROCHECK (Laskowski et al., 1993), AQUA (Laskowski et al., 
1996), SQUID (Oldfield, 1992) and WHATCHECK (Hooft et al., 1996). The features 
of a model that are checked by these programs include bond lengths, bond angles, 
peptide bond and side-chain ring planarities, chirality, main-chain and side-chain 
torsion angles, and clashes between non-bonded pairs of atoms. In addition, many 
spatial features including packing, formation of a hydrophobic core, residue and atomic 
solvent accessibilities, spatial distribution of charged groups, distribution of atom-atom 
distances, atomic volumes and main-chain hydrogen bonds, are evaluated. Distributions 
Chapter 2 
 
30 
 
of these features have been compiled from high resolution protein structures, and large 
deviations from the most likely values have been interpreted as errors in the model.   
 
2.2.3 Building of the four novel hPAH mutants structural models 
The homology modelling was used to generate the 3D model structures of the four 
novel hPAH mutants p.L321I, p.I406M, p.T418I and p.N426H. The structure of the 
tetrameric hPAH (PDB code 2PAH) was selected as template. The template contains 
both the catalytic and the tetramerization domain, where the mutated residues under 
study are located. The sequences of the mutants and the sequence of the tetrameric wild-
type template were aligned using Bodil software, a multi-platform package for 
biomolecular visualization and modelling (Lehtonen et al., 2004). Bodil aims to provide 
easy three-dimensional molecular graphics closely integrated with sequence viewing 
and sequence alignment editing. In particular, for each mutant, the mutated residue was 
replaced in the alignment file. The output file originating form Bodil is in a format 
readable by Modeller (Sali and Blundell, 1993), the program used to build mutant 
structural models. Modeller implements homology protein structure modelling by 
satisfaction of spatial restraints, that consists in extracting information about spatial 
relationships between residues of the template, and using this information as constraints 
for the construction phase of the model. It is assumed that the spatial restraints existing 
in the template are similar to those existing in the structure to predict; these restraints 
are used to create a mathematical function that describes the free energy of the protein. 
The optimal structure of the template will be obtained by varying its starting 
conformation so that the free energy becomes as low as possible. To create the models 
of the above-mentioned mutants, the input file of alignment originating from Bodil and 
the template structure were provided to Modeller. For each studied mutants, 200 models 
were generated. The program selects the most abundant conformers of the replaced 
residue and performs a simulated annealing procedure to optimize side chain 
conformations. The model that presented the best Modeller DOPE score was selected 
for further analysis. Structure analysis of the generated models was carried out by 
PDBSum server (Laskowski et al., 1997). For each models, the interatomic contacts, the 
Phi and Psi angles, and the hydrogen bonds were calculated using What If (Vriend, 
1990), a molecular modelling package, used for the validation, that is specialized on 
working with proteins and the molecules in their environment like water, ligands, etc. 
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2.3 Results 
2.3.1 Mapping the seven natural disease-causing hPAH mutants  
A composite model of the full-length human enzyme was built and used as a template 
for structural analysis of the wild-type and the seven mutants. In Figure 2.2, the position 
of the seven mutations is drawn on the monomer structure. Mutations p.I65M and 
p.Q419R fall in the regulatory and tetramerization domain, respectively; mutations 
p.N223Y, p.R297L, p.F382L, p.K398N and p.A403V fall in the large catalytic domain 
(Figure 2.3). All mutations are far from the active and cofactor binding sites. All 
mutations, except for positions 65 and 403, are located on the surface of the molecule in 
hydrated regions. 
Structural alterations were related to the residual enzyme activity, to the oligomeric 
equilibrium and to the thermal stability (it should be noted that in the denaturation 
process of hPAH upon heating, two transitions occur with melting temperatures Tm1 and 
Tm2). 
 
 
 
Figure 2.2: Full-length composite model of the PAH monomer structure and distribution of the 
seven selected HPA-related missense mutations studied. The N-terminal regulatory domain is 
shown in blue, the catalytic domain in red and the tetramerization domain in green. The Fe ion 
is shown as a cyan sphere at the center of the catalytic domain; the mutation sites are marked as 
yellow balls. 
Chapter 2 
 
32 
 
 
 
Figure 2.4: Primary and secondary structures of full-lengt hPAH model. Letters R, C and D are 
associated to the secondary structure nomenclature refer to Regulatory domain, Catalytic 
domain and Tetramerization. Figure from PDBsum server. 
 
Ile65 is located in the Rβ2 strand in a hydrophobic environment of the regulatory 
domain. In the mutant enzyme p.I65M, the Ile change to a somewhat larger but 
differently shaped Met may distort the hydrophobic packing of the region. As a result, 
both the tertiary structure and the quaternary structure are perturbed. These data are in 
line with the dimer abundance (see Paper I).  
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Asn223 is located in the solvent exposed Cα4-Cα5 loop (Figure 2.4A). In mutant 
p.N223Y the structural perturbation is mainly due to tyrosine solvent exposure that may 
affect the function. It has been proposed that this residue is embodied in an intra-domain 
hinge bending region, that is involved in the conformational transition induced by 
substrate binding. Overall, its properties are similar to those of the wild-type enzyme, 
except that the dimeric form is favored over the tetramer.  
Mutant p.R297L exhibits properties very similar to those of the wild-type enzyme. 
Interestingly, two other mutants reported in the database, e.g. p.R297C and p.R297H, 
which are also associated with a mild phenotype, indicate that mutations at this site are 
not critical.  
Mutant p.F382L is the one that differs most from the wild-type enzyme. It occurs 
prevalently as a dimer (88.3%) (see Paper I). Moreover, the mutation (in the Cα11-Cβ6 
loop) falls in a region rich in aromatic residues (Figure 2.4B). Phe forms various 
stacking aromatic interactions with the aromatic residues Tyr356 and Tyr277 in the 
wild-type enzyme. The replacement by Leu, despite the hydrophobic nature of this 
residue, breaks the aromatic network and results in marked destabilization. This is in 
line with larger ΔTm1 (19.6 °C) and ΔTm2 (14.0 °C) and with a lower inactivation 
temperature compared to the wild-type protein (see Paper I). This is the largest 
difference observed so far for a PAH mutant. This highlights that Phe in position 382 is 
crucial for the stability of this aromatic amino acid-rich region. 
Lys398 is located in the Cα12 helix at the tetramer interface, although it is not directly 
engaged in inter-subunit interactions. The positively charged Lys is embedded in a 
negatively charged environment because of the presence of Asp394 and Glu390 (Figure 
2.4C). The high dimer/tetramer ratio observed for mutant pK398N (75.0/17.2)  is in line 
with tetramer destabilization. Also the structural stability was decreased. In fact, Tm1 
and Tm2 were lower than that of the wild-type enzyme being 5.6 and 4.0 °C, respectively 
(see Paper I).  
Q419 lies in the Tβ1-Tβ2 loop in a hydrated region at the dimer/tetramer interface. The 
substitution of Gln by an Arg generates unfavorable ionic interactions with a nearby 
Arg241 that destabilize the tetramer (Figure 2.4D). The thermal stability of p.Q419R is 
not significantly affected by the mutation. 
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Figure 2.3: (A) Asn223 site. Segment 217–224 is drawn in ball-and-stick form. The stabilizing 
H-bonds displayed by Asn223 (magenta) in the β-turn 220–223 are represented by dotted lines. 
(B) Phe382 site. Phe382 (magenta) and nearby residues (Tyr356, Tyr277, His146) are 
highlighted in the substrate-bound structure (PDB code 1kw0). The substrate analogue, 
thienylalanine (cyan), and the BH4 cofactor (yellow) are also shown. (C) Lys398 site. The 
negatively-charged side-chains close to Lys398 (magenta) are shown. In the dimer, the H-bond 
between Glu397 and Ser439 is also drawn. (D) Gln419 site. Two Gln419 (magenta) residues at 
the dimer interface are shown with the positively-charged Arg241 residues nearby. 
 
2.3.2 Structural analysis of four novel hPAH mutants 
The structure models of four mutants, namely p.L321I, p.I406M, p.T418I and p.N426H, 
were generated in silico using the tetrameric hPAH structure (PDB code 2PAH) as 
template. Leu321 and Ile406 are located in the catalytic domain, in Cα9 helix and in the 
loop connecting Cα12 helix to Tβ1 strand, respectively; while Thr418 and Asn426 are 
located in the tetramerization domain, in the Tβ1-Tβ2 β-hairpin and in Tα1 helix 
respectively (Figure 2.3, 2.5).  
A comparative analysis of the overall structure of each mutant model with the wild-type 
shows no significant changes. In particular, all mutated residues conserve secondary 
structure assignment of respective residues in the wild-type structure. Table 2.1 shows 
the main structural features of the four studied mutations.  
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Table 2.1: Features of the four studied PAH mutations. 
Exon Mutation Other mutations 
described on the 
same position 
Enzyme domain / Secondary 
structure position 
Structural contacts in WT / 
Consequent alterations in 
mutated enzyme 
9 p.L321I None Catalytic / α-helix H9 (315-
326) 
L321 is situated in a hydrophobic 
core involving helices  H6,  H8, 
H9 and  H12 / Loss of a favorable 
interaction. 
12 p.I406M I406T Catalytic / Loop preceding 
tetramerization domain (406-
410) 
I406 is situated in a hydrophobic 
core involving helices  H6,  H8, 
H9 and  H12 / Mild structural 
alteration 
12 p.T418I T418P Tetramerization / Loop (416-
419) connecting two β-strands  
T418 is situated in the loop 
connecting  strands of β-sheet C 
in the dimerization motif / two 
hydrogen bonds are lost, one 
hydrogen bond weakens 
12 p.N426H 
 
None Tetramerization / α-helix H13 
(426-450) 
N426 is situated in the α-helix 
H13 responsible for the formation 
of the tetramer / one hydrogen 
bond is lost 
 
 
 
Figure 2.5: Dimeric model of the hPAH structure generated in silico and distribution of the four 
HPA-related missense mutations studied. The chain A in the dimer is shown in green and the 
chain B in cyan. The mutation sites are marked as balls in diverse color. Color code: Leu321 
yellow, Ile406 red, Thr418 magenta, Asn426 blue. 
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Leu321 is located in Cα9 helix of the catalytic domain, in the hydrophobic core 
involving residues of Cα6, Cα8, Cα9 and Cα12 helices. In the mutant p.L321I some 
hydrophobic interactions are lost, others are formed; but in general there are no 
substantial changes in the hydrophobic asset of the core, where the mutated residue is 
located (Figure 2.6). In particular the number of interactions of residue 321 with Leu255 
and Phe402 increases, while the number of interactions between residue 321 and Ile306 
decreases. Leu is a γ-branched residue and has a major steric hindrance in the final part 
of the side chain, while Ile is a β-branched residue and has an increased steric hindrance 
in the first part of the side chain. Thus the Ile side chain, compared to Leu side chain, is 
located closer to residues Leu255, Ile306 and Phe402. Furthermore, in the mutant the 
interaction between Leu321 and Ile406, that occur in the wild-type enzyme, is lost. This 
result may be significant if we consider that Ile406 is located in the loop between 
catalytic and tetramerization domains. The interaction between Leu321 and Ile406 can 
contribute to the stability of the loop and can keep it in the proper orientation. So 
disrupting this interaction can destabilize the loop in the mutant structure.  
 
 
 
Figure 2.6: Hydrophobic interactions that involve atoms of residue 321 (A) in the wild-type 
structure (PDB code 2PAH) and (B) in the mutant p.L321I model structure. The residue 321 (in 
yellow) and the residues with which it interacts (including residue 406 in red) are shown as 
stick.  
 
In p.I406M mutation, the substitution of an apolar residue into another apolar residue 
occurs. Ile406 is situated in the hydrophobic core of the catalytic domain, in the loop 
preceding the tetramerization domain. In the mutant I406M, some hydrophobic 
interactions of the residue 406 (with Tyr317, Leu321 and Phe402) change, others 
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interactions (with Ala309) are preserved. Moreover, three weak interactions with 
Ala313, Pro314 and Ala403 are lost in the mutant (Figure 2.7). Analyzing all these 
hydrophobic interactions, a rearrangement of the hydrophobic region is observed. 
Overall the number of favorable hydrophobic interactions decreases in the mutant; 
while the pattern of hydrogen bonds is conserved. The mutation causes a change of 
orientation of some close residues and leads to a reorganization of the region where is 
located.  
 
 
 
Figure 2.7: Hydrophobic interactions that involve atoms of residue 406 (A) in the wild-type 
structure (PDB code 2PAH) and (B) in the mutant p.I406M model structure. The residue 406 (in 
red) and the residues with which it interacts (including residue 321 in yellow) are shown as 
stick. 
 
 
 
Figure 2.8: Hydrogen bonds in the loop of the dimerization motif (A) in the wild-type structure 
and (B) in the mutant p.T418I model structure. The loop residues are shown as stick, with the 
mutated residue 418 in magenta. 
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In the p.T418I mutant there is the substitution of a polar residue into an apolar residue. 
Thr418 is located in the tetramerization domain, in the loop (416-419) connecting the 
two β-strands forming the dimerization motif. The hydrogen bonds of all residues of the 
whole region have been examined (Figure 2.8). Both in wild-type and in mutant 
structures, the amino group of residue 415 binds the carbonyl oxygen of Arg420, the 
carbonyl oxygen binds the amino group of Gln419 and the OD1 oxygen binds the 
amino group of Tyr417. A hydrogen bond between side chains of residue 415 and 
Thr418 is lost in the mutant; this helps to stabilize the residues involved in the bond and 
its lack may cause a destabilization of the entire loop. Furthermore, a hydrogen bond 
between Gln419 and Arg241 (in the catalytic domain) is weaker in the mutant structure 
with respect to the wild-type (Figure 2.8). This bond can help to approximate the 
catalytic domain to the tetramerization domain, and a change in distance of this bond 
can affect the relative orientation of the two dimers leading to a destabilization of the 
tertiary and quaternary structure. 
The p.N426H mutation substitutes a polar amino acid into a polar amino acid with a 
pKa≈6,5. At physiological pH, relatively small shifts in pH will change the average 
charge of His. The alterations in the structure of this mutant can result from the presence 
of His that may have a positive charge on its side chain, in a region where there is an 
uncharged residue in the wild-type. Moreover, the alterations in the structure can result 
from the greater steric hindrance of the imidazole ring in the side chain. PAH is not a 
symmetric homotetramer but a dimer of dimers, and one of the main differences 
between subunits of the two diverse dimers lies in the orientation of the long C-terminal 
α-helix of the tetramerization domain. Particularly, the differences result from a change 
in backbone conformation at the hinge region that connects the β-hairpin to the helix, 
accompanied by another rotation of the helix. Asn426 is located in the region that 
differs in the two subunits constituting the two conformationally diverse dimers; for this 
reason, the substitution in position 426 on both A and B subunits of the dimeric hPAH 
structure model was analysed. In the chain A, Asn426 is the first residue of C-terminal 
α-helix (426-450), instead, in the chain B, is located in the loop preceding this α-helix 
(Figure 2.9). In chain A, a hydrogen bond with the amino group of L430 is conserved in 
the mutant, while the H-bond formed by the oxygen in the side chain of Asn426 with 
F410 is lost in the mutant, because of the lack of the acceptor of the hydrogen bond. The 
loss of this H-bond may have some effects on the stability of the tertiary and quaternary 
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structure of the enzyme, as it contributes to hold together the dimerization motif and the 
α-helix responsible for the formation of the tetramer. Moreover, the amino group of the 
side chain of N426 can bond the OD1 oxygen of D425; also this H-bond in the mutant 
is lost, because of the lack of the donor of the hydrogen bond. In the subunit B, the 
situation is quite different. In fact, in chain B of the wild-type structure, the carbonyl 
oxygen of N426 forms a hydrogen bond (3.13Å) with the amino group of Q429 (Figure 
2.10), instead of the amino group of L430, as in chain A (Figure 2.9); moreover, in 
chain B there is no hydrogen bond involving N426 and F410, as in chain A. Also in 
chain B of the mutant structure, the carbonyl oxygen of H426 makes a hydrogen bond 
with the amino group of Q429 (Figure 2.10). 
 
 
 
Figure 2.9: Hydrogen bonds of residue 426 in the chain A of (A) the wild-type structure and 
(B) the mutant p.N426H model structure. The residues involved in the H-bond are shown as 
stick with the mutated residue 426 in blue. In the figure are also drawn the other two mutated 
residues 418 (stick magenta), 406 (stick red) and part of the C-terminal helix of the adjacent 
subunits (chain B) in cyan. 
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Figure 2.10: Hydrogen bonds of residue 426 in the chain B of (A) the wild-type structure and 
(B) the mutant p.N426H model structure. The residues involved in the H-bond are shown as 
stick with the mutated residue 426 in blue. In the figure are also drawn the other two mutated 
residues 418 (stick magenta), 406 (stick red) and part of the C-terminal helix of the adjacent 
subunits (chain A) in green. 
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2.4 Discussion 
The aim of this structural analysis is to provide an explanation of the structural effects 
of the disease-causing studied hPAH missense mutations, aided by a three-dimensional 
visualization. 
Previous studies on structure/function correlations showed that the disease-causing 
mutations are spread throughout the protein structure, with a certain number localised at 
dimer/tetramer interfaces. This finding highlights the relevance of interactions among 
subunits for the correct functioning of PAH (Andersen et al., 2002; Erlandsen et al., 
1997). The structural examination of the two groups of hPAH mutants, here studied, 
revealed that the substituted residues are neither directly involved in the active site nor 
in the cofactor binding site. Overall, the analysis of the mutant models showed no 
dramatic changes in the structure. Accordingly all these mutations generate a mild 
phenotype. In details, the analysis showed structural differences in the regions where the 
mutated residues are located. 
Mutations at positions 65, 321, 406 perturbs the hydrophobic packing of the regulatory 
and the catalytic domains; the mutations at positions 223 and 382 perturb the local 
structure of regions that are involved in substrate-induced molecular motions; whereas 
mutations at position 297, 398, 418, 419 and 426 disturb the dimer/tetramer interfaces. 
All the substitutions of the first group of seven mutants, that were also characterized in 
vitro, result in enzymes with decreased residual catalytic activity (to 38-69%) compared 
to the wild-type enzyme and affect the oligomerization state, the thermal stability and 
the folding of PAH protein. 
In conclusion, the structural alterations do not directly affect the binding site of either 
the substrate or the coenzyme, rather they interfere with favorable interactions at the 
hydrophobic core, at the molecular surface and/or at its quaternary structure, and hence 
may destabilize structural integrity. The decreased conformational stability of the 
studied hPAH mutants can be associated to possible defects in the folding and to a 
reduced activity of the enzyme, leading to the disease.  
 
 
 
 
 
 
 
Chapter 2 
 
42 
 
 
 
Chapter 3 
 
43 
 
CHAPTER 3. Structural features of the regulatory ACT domain 
in the wild-type and in six hPAH mutants 
 
3.1 Introduction 
The aim of this part of my thesis was to get further insights into the structural properties 
of the isolated human wild-type PAH RD and into the structural effects of the most 
frequent natural missense mutations on this domain. In PAH the RD has some unique 
biological, structural and physicochemical properties, that may explain why mutations 
in this domain affect the stability of the enzyme. First, the 3D structure of the rPAH RD 
has an overall high crystallographic B-factor and the 3D structure of the hPAH is not 
determined yet, consistent with the low stability of this domain. Then, the regulatory 
function of the RD is poorly understood and deserves further clarification.  
The RD has been classified as an ACT domain homolog. The ACT domains are 
frequently found regulating metabolic enzymes in an allosteric manner. The allosteric 
effector is often an amino acid that binds to an interface formed by two ACT domains 
and in proximity of a specific Gly (Gly46 in hPAH) located in the loop between the first 
β-strand and the first α helix (Grant, 2006). Instead, no contacts are formed between the 
four ACT domains in the hPAH tetramer.  
The major regulatory mechanisms of the PAH include activation by L-Phe (hereafter 
referred as to Phe) pre-incubation (Hufton et al., 1995). Tetrameric wild-type PAH 
displayed substrate activation and positive cooperativity for Phe binding, involving all 
three functional domains and all four subunits in the holoenzyme (Kaufman, 1993).  
The literature contains conflicting models to explain these data. A possible explanation 
is that the activation mechanism results from the homotropic binding of Phe at the 
active site and the RD is involved in cooperativity, through its interactions with the 
catalytic and oligomerization domains (Liberles and Martinez, 2009; Liberles et al., 
2005; Thorolfsson et al., 2003; Thorolfsson et al., 2002). In a number of studies it was 
instead proposed that Phe binds to an allosteric site on RD of PAH, different from the 
active site, inducing large conformational changes (Fitzpatrick, 2000; Kaufman, 1993; 
Shiman et al., 1979). In support of the latter model, it has been shown that when the RD 
is removed, the hPAH is no longer activated by preincubation with the substrate 
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(Knappskog et al., 1996a). Recently, NMR spectroscopy provided strong evidence for 
Phe-binding site in the isolated RD (Li et al., 2011). Moreover, it has been proved that 
the GAL (46-48) and IESRP (65-68) sequence motifs, conserved in the ACT domain 
family, are involved in Phe binding at the PAH RD (Gjetting et al., 2001b). A Phe 
bound structure of the protein prephenate dehydratase (PDT) from Chlorobium tepidum 
TLS is available (PDB code 2QMX), where the ligand-binding region in the ACT 
domain contains the GAL-IESRP motif (Tan et al., 2008). While Phe binds PDT at the 
dimer interface of two ACT domains, the GAL-IESRP motif in PAH lies at the interface 
between the RD and the catalytic domain of the adjacent subunit. Together with the 
structural similarities to the ACT regulatory domains of the above-mentioned allosteric 
enzymes, it was proposed that Phe binds PAH between the RD and the interacting 
catalytic domain, near the sequence binding motif (Hufton et al., 1995; Kobe et al., 
1999).  
In spite of all these evidences, the putative allosteric Phe-binding site in PAH has not 
been identified yet and the role of the domain as an allosteric module is still unclear. In 
this study, I analysed for the first time the intrinsic structural and dynamical properties 
of the isolated RD of the hPAH by molecular dynamics (MD) simulations in solution, in 
the light of the presence of a putative allosteric Phe-binding site. Moreover, I 
investigated the structural and dynamical effects induced by six selected missense 
disease-causing mutations found in young patients (p.G46S, p.F39C, p.F39L, p.I65S, 
p.I65T and p.I65V) (see PAH Mutation Analysis Consortium database: 
http://www.pahdb.mcgill.ca/) and located in the RD of the hPAH enzyme. 
Most of the this work has been performed in a joint collaboration with Dr. Fraternali 
and Dr. Fornili at King’s College, London. 
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3.2 Experimental methods 
3.2.1 Molecular Modelling of the hPAH ACT domain and its mutants  
Models of the ACT domain (residues 33-111) of the wt-hPAH enzyme and hPAH 
mutants were generated in silico with the program Modeller 9v8 (Sali and Blundell, 
1993), using the rat wt-rPAH crystal structure as template (PDB code 1PHZ) (Kobe et 
al., 1999). The sequence identity percentage between the RD domain of wt-hPAH 
enzyme and the RD domain of wt-rPAH is 86%. The template and the target sequences 
were aligned using Bodil (Lehtonen et al., 2004). Subsequently, the alignment files 
were used as input in Modeller and 200 models of each studied forms were generated. 
For the mutants, the mutated residues were replaced in the alignment file. The program 
selects the most abundant conformers of the replaced residue and performs a simulated 
annealing procedure to optimize side chain conformations. The model that presented the 
best Modeller DOPE score was selected for the MD simulations.  
The same procedure was used to generate the model of the rat PAH enzyme used to test 
the stability in wt-rPAH of an alternate conformation of the L2 region (Figure 3. 1B). In 
this case, two templates were used: the rat crystallographic structure of PAH for 
residues 33-57 and 67-111, and the ACT domain (fragment 339-408) of D-3-
phosphoglycerate dehydrogenase from Escherichia coli (PDB code 1PSD) for residues 
58-66. 
Furthermore, a tetrameric model of wt-hPAH was built with Modeller 9v8, using as 
template the regulatory domain from rat crystal structure (PDB code 1PHZ) and the 
catalytic/tetramerization domain from human crystal structure (PDB code 2PAH). 
 
3.2.2 Molecular Dynamics Simulations 
The aim of computer simulations of molecular systems is to compute macroscopic 
behavior from microscopic interactions. MD simulations solve Newton’ s equations of 
motion for a system of N interacting atoms: 
                 
Where Fi is the total force acting on the i-th atom, mi is its mass, ∂
2
ri/∂t
2
 is its 
acceleration, ri is its position. The forces are the negative derivatives of a potential 
function V (r1, r2, . . . ,rN): 
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The equations are solved simultaneously in small time steps. In order to solve 
numerically the equations of motion, we need to be able to calculate the forces acting on 
the atoms, and these are usually derived from a potential energy that represents the 
complete set of 3N atomic coordinates. The potential energy function, also called force 
field, used in most of the standard molecular simulation programs for biological systems 
consist of: 
 
Vtot = Vbonds + Vangles + Vdihedrals + Vvdw + Velect 
 
It takes form of the summation of different additive terms that correspond to bond 
distances stretching (Vbonds), bond angles bending (Vangles), bond dihedral or torsion 
angle (Vdihedrals), van der Waals potential (Vvdw) and electrostatic potential (Velect). The 
first three terms are considered to be the intramolecular bonding interactions, each term 
involves a multiplet of atoms connected by chemical bonds. The other two terms 
represent the non-bonded interactions between atoms.  
Molecular dynamics is a very useful and powerful tool. It can provide a wealth of 
detailed information on the structure and dynamics of peptides and proteins. However, 
it suffers certain limitations. First, the method is computationally very demanding and 
depending on the size of the system simulation; times are currently limited to hundreds 
of nanoseconds or a few microseconds at most. The possibility to observe certain 
properties is directly related to the quality of the force field and, whether or not it has 
been parameterized for the system simulated. The quality of the force field is especially 
critical in the simulation of proteins. Proteins are in general only marginally stable. The 
difference in free energy between the folded and unfolded form is in the order of 10-20 
kbT, which corresponds to the energy associated with the formation of a couple of 
hydrogen bonds in vacuum. The force field thus needs to be very accurate to 
discriminate between different conformations. However, it is questionable whether an 
empirical force-field can achieve the required accuracy especially when important 
effects such as polarization of the atoms by their environment is not taken into account 
by the electrostatic potential. The most used force fields in molecular dynamics are 
CHARMM, AMBER and GROMOS. 
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MD simulations are usually performed under periodic boundary conditions (PBC), to 
minimize boundary effects and to mimic the presence of the “bulk" environment. In this 
approach, the system is surrounded with replicas of itself in all directions, to yield an 
infinite periodic lattice of identical cells. When a particle moves in the central cell, its 
periodic image in every another cell moves accordingly. As one molecule leaves the 
central cell, its image enters from the opposite side without “filling" the cell boundary. 
When Newton’s equations of motion are integrated the total energy is conserved 
(adiabatic system) and if the volume is held constant the simulation will generate a 
microcanonical ensemble (NVE). However, this is not always very convenient. Other 
statistical ensembles, such as canonical (NVT) and isothermal-isobaric (NPT) 
ensembles, better represent the conditions under which experiments are performed than 
the standard microcanonical ensemble. Moreover, with the automatic control of 
temperature and/or pressure, slow temperature drifts that are an unavoidable result of 
force truncation errors are corrected and also rapid transitions to new desired conditions 
of temperature and pressure are more easily accomplished. 
 
3.2.3 MD Simulations of the PAH models and the template 
MD simulations were performed with the GROMACS (Van Der Spoel et al., 2005) 
package using the GROMOS 43a1 force field (van Gunsteren et al., 1996). Each of the 
initial models generated in silico and the wt-rPAH crystal structure were solvated in 
boxes containing simple point charge (SPC) water molecules (Berendsen et al., 1981). 
Simulations were carried out with periodic boundary conditions and a 2-fs time step. All 
the bonds in the protein were frozen with the LINCS method (Hess et al., 1997), while 
SETTLE (Miyamoto and Kollman, 1992) was used for water molecules. The Berendsen 
algorithm (Berendsen et al., 1984) was applied for temperature and pressure coupling. 
The particle mesh Ewald method (Essmann et al., 1995) was used for the calculation of 
the electrostatic contribution to non-bonded interactions with a direct sums cut-off of 14 
Å. The same cut-off was used for van der Waals interactions. The systems were energy 
minimized with 1000 steps of the steepest descent method and subsequently with 1000 
steps of conjugate gradient method. After the minimization, harmonic positional 
restraints (with an initial force constant of 4.8 kcal/mol/Å
2
) were imposed onto the 
protein heavy atoms and gradually turned off in 360 ps, while the temperature was 
increased from 200 to 300 K at constant volume. The system was then equilibrated for 2 
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ns without restraints in NPT conditions (T=300 K, p=1 bar). Finally, NPT MD 
simulations were performed for 50 ns. Two replicas were run for each system. MD 
trajectories were analysed using GROMACS analysis tools. Images were produced with 
the Visual Molecular Dynamics software (Humphrey et al., 1996) and PyMOL 
(Schrödinger, 2009). 
 
3.2.4 Analysis tools 
The displacement of the atoms or group of atoms along the trajectory could be 
estimated calculating the Root Mean Square Displacement (RMSD). The RMSD of a 
set of N atoms at time t, with respect to a reference conformation (e.g. initial 
conformation), is: 
 
Where is the displacement of the i
th
 atom at time t from the reference position 
ri
0
. An increase of the RMSD indicates that the protein moves to a conformation 
different from the initial structure and thus suggests an incomplete sampling or a 
conformational change. 
Similar to the previous analysis is the calculation of the fluctuations of an atom or a 
groups of atoms, this calculated according: 
 
Where  is the position vector of the i
th
 atom and the brackets stand for a temporal 
average. This analysis give clues about the most mobile regions of the protein. 
The secondary structure content was measured with DSSP (Kabsch and Sander, 1983), 
while the solvent accessible surface area was calculated with the GROMACS utility 
g_sas (Eisenhaber et al., 1995). 
Correlated motions were identified by performing Essential Dynamics (ED) (Amadei et 
al., 1993) on each MD trajectory. Principal components (PCs) were generated by 
diagonalizing the covariance matrix of C
α
 positions. Correlation webs, connecting C
α
 
atom pairs with a correlation (per atom normalized covariance) higher than 0.3 were 
generated with Dynatraj (Barrett et al., 2004). A Combined ED analysis (van Aalten et 
al., 1995) was also performed on the trajectory obtained by concatenating the 16 
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trajectories obtained from all the simulated systems (2 replicas x (wt-hPAH + wt-rPAH 
+ 6 hPAH mutants)).  
To further investigate the accessible collective motions of the RD, we sampled 
alternative ensembles of structures for all the models with the tCONCOORD method 
(Seeliger et al., 2007). tCONCOORD allows a computationally efficient sampling of 
conformational transitions of a protein based on geometrical constraints as determined 
from the initial coordinates and interaction types. Under-wrapped hydrogen bonds are 
detected and modelled as unstable. Each model was first energy-minimized using the 
OPLS-AA force field (Jorgensen and Tirado-Rives, 1988) with 250 steps of the steepest 
descent algorithm. Ensembles of 1000 structures were then generated using standard 
tCONCOORD parameters (Seeliger et al., 2007). The similarity of the MD and 
tCONCOORD correlated motions from ED confirmed that all the relevant loop 
collective motions are already sampled by MD.   
To investigate interactions with the solvent during the simulations, we generated the 
water density maps g(r) around each construct (De Simone et al., 2005; Lounnas and 
Pettitt, 1994; Lounnas et al., 1994). The maps were calculated at discrete points r 
defined by a 0.5-Å spaced rectangular grid around the solute. Each structure of the last 2 
ns of the trajectory was superimposed to a reference to remove the overall roto-
translational motion of the protein. The number density of the water oxygen atoms was 
then averaged at each grid point over the MD snapshots extracted every 0.1 ps and 
normalized by the bulk density evaluated in the 6-8 Å shell around the solute. The 
hydration sites were then identified as local maxima of the density map with g(r) > 1 
and used to define the atomic hydration score Shyd
atom  
as previously described (Fornili et 
al., 2012). Atoms with a high Shyd
atom
 score are either surrounded by many maxima or 
close to a few maxima with a high density. 
The relationship between the RD collective dynamics and the putative Phe binding site 
was investigated using the functional mode analysis (FMA) (Hub and de Groot, 2009). 
FMA aims to detect the collective motion that is maximally correlated with a particular 
protein functional property (Maximally Correlated Motion or MCM). The MCM is 
usually expressed as a linear combination of Principal Components (PCs) derived from 
ED. We selected the FMA approach where the MCM coefficients are determined by 
maximizing the Pearson correlation coefficient between the time evolution of the 
chosen functional property (solvent accessibility of the putative Phe binding site) and 
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the projection of the trajectory onto the MCM. For each MD simulation, the MCM was 
expanded in the essential space of the C
α
 atoms, composed of the first n PCs accounting 
for the 90% of the total fluctuation. The first 45 ns were used as model building set, 
while the remaining 5 ns were used as cross-validation. 
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3.3 Results 
In silico models were generated for the ACT regulatory domain (residues 33-111) of wt-
hPAH enzyme and of the six hPAH mutants, G46S, F39C, F39L, I65S, I65T and I65V. 
The model structures consist of a common α-β sandwich motif with a four-stranded 
antiparallel β-sheet flanked on one side by two short α-helices (Figure 3.1A-C). In 
particular, the loop-containing regions L42-V45 (L1), D59-H64 (L2), S70-D75 (L3) and 
H82-V90 (L4) are highlighted in Figure 3.1A and 3.1B. Two replicas of MD 
simulations were performed onto the generated models and the wt-rPAH template. 
During the 50-ns long simulations, the systems show no large deviations from the initial 
structures and at the end of the simulations all trajectories reach a plateau within 2-3 Å 
in the RMSD from the initial structure calculated over all C
α
 atoms. 
 
 
Figure 3.1: Structure representation of human PAH subunit and its RD. (A) Structural model of 
a PAH subunit created by superimposing the regulatory/catalytic domain from rat crystal 
structure (1PHZ) and the catalytic/tetramerization domain from human crystal structure 
(2PAH). RD is drawn in magenta, the catalytic domain in yellow and the tetramerization 
domain in blue. The iron is shown as a red sphere. (B) Starting models of the ACT domain (33-
111 residues) of wt-hPAH with the residues G46, F39 and I65 drawn as stick in yellow. The two 
highly conserved GAL and IERSP motifs are highlighted in light magenta. Mobile loop-
containing regions, L1 to L4, are drawn in different colours. (C) Primary and secondary 
structure of human RD represented in B. Loop-containing regions, L1 to L4, are highlighted in 
red boxes. 
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3.3.1 Mobility and conformational change of loop-containing regions 
The dynamics of wt-hPAH is mostly characterized by the large motions of the L2, L3 
and L4 regions (Figure 3.2A, B and 3.3) and a small fluctuation of L1. In particular, a 
large rearrangement is observed for the L3 loop, located near the dimerization interface 
in the dimer/tetramer structures. This motion is probably enhanced by the absence of the 
other subunits in the simulated system. In the rat dimeric PAH crystal structure, the L1 
and L3 loops of RD interact with both the catalytic domain of the opposite subunit and 
the tetramerization domain of the same subunit. Differently, in the simulated systems, 
where the RD is isolated, L1 and L3 are free to move so that we can study their intrinsic 
flexibility. 
L2 and L4 regions are located close to each other on the opposite side of the domain 
with respect to the L3 loop (Figure 3.1A, B). The L2 region corresponds to the loop/turn 
located between helix α1 and the strand β2, while the L4 region includes the β3-α2 
connecting loop and the N-terminal part of helix α2 (Figure 3.1B, C). 
As shown by Essential Dynamics (ED) analyses, the movements of the L2, L3 and L4 
regions are represented by the first principal component (PC) of the motion in the 
human wild-type enzyme (Figure 3.2B). In particular, part of the L2 region (residues 
from 61 to 64) changes its conformation from turn to β-strand, resulting in the 
elongation of the β2 strand, while the L4 region undergoes the unwinding of the N-
terminal part of the helix α2, leading the two regions closer to each other (Figure 3.2A-
C). This is also highlighted by the formation of new H-bonds between the L2 and L4 
regions observed during the dynamics (as shown in the WT panel of Figure 3.4). 
Indeed, His64 (L2) and Thr63 (L2) form H-bonds with His82 (L4), while Asn61 (L2) 
interacts with Asp84 (L4). 
The conformational change of the L2 region from turn/bend to β-strand in the wt-hPAH 
is also highlighted in the secondary structure analysis by DSSP of the simulated 
trajectories (WT in Figure 3.5). This change is paralleled by the stabilization of the C-
terminal part of the β3 strand (Figure 3.5) that interacts with the L2 region, forming a 
hydrogen-bond pattern typical of a β-sheet structure (Figure 3.6).  
Similar features were also observed for most of the mutants (Figure 3.3, 3.4, 3.5). In 
particular, the conformational change of the L2 region from turn/bend to β-strand was 
found in all systems, except in the rat structure and in the F39C mutant (Figure 3.5). 
However, the closure of L2 and L4 and the formation of new H-bonds between these  
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Figure 3.2: Mobility and conformational change of loop-containing regions. (A) Sausage 
representation of the Cα RMSF of the wt-hPAH structure, in which the thickness of the sausage 
is proportional to the fluctuation of Cα atoms from their average position. (B) Porcupine plot 
illustrating the motions represented by the first PC (accounting for 78% of the overall 
fluctuation of Cα atoms) from the simulation of the wt-hPAH. Each Cα atom has a cone 
attached pointing in the direction of motion described by PC1. Blue arrows highlight the motion 
corresponding to the transition of L2 to β-strand. (C) Initial (light green) and final (light pink) 
wt-hPAH structures with the L2 and L4 regions highlighted in green and magenta.  
 
 
 
Figure 3.3: Root Mean Square Fluctuation (RMSF) of the C
α
 atoms during the simulation. 
Color code: wt-hPAH in black, wt-rPAH in red, G46S in orange, F39C in blue, F39L in green, 
I65T in violet, I65S in magenta, I65V in cyan. 
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Figure 3.4: Variation of H-bonds number between the L2 and the L4 regions during the 
simulations. Number of H-bonds between the L2 and the L4 regions versus time in the wt-
hPAH and in the G46S, F39L, I65S mutants. Hydrogen bonds are determined using a cutoff of 
30 degrees on the Acceptor-Donor-Hydrogen angle and of 3.5 Å on the Acceptor-Donor 
distance. 
 
two regions occur in all systems in at least one replica (examples for each mutated 
position in Figure 3.4). Moreover, in the rat structure and in the G46S, F39L, I65T, 
I65V mutants, also the L1 loop, located in close proximity to L3, shows a 
rearrangement (Figure 3.3). 
In order to detect inter-simulation similarities and highlight possible differences among 
the conformational states of all the studied systems, a “combined essential dynamics” 
analysis was performed on the concatenated MD trajectories of all enzymes, for both 
replicas (see Materials and Methods). The first principal component (PC1) describes the 
transition to β strand of the L2 region (β2 elongation) and the getting closer of L2 and 
L4 regions, together with a reorientation of the α1 helix (Figure 3.7). The second 
principal component (PC2) describes the movements of all loops, with a smaller relative 
contribution from the β strands and α1 if compared to PC1, and a larger relative 
contribution from L1 and α2 (Figure 3.7B). The projection of the MD trajectories onto 
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Figure 3.5: Secondary structure analysis. Time-evolution of the DSSP secondary structure for 
the human (WT) and rat (rat X-ray) wild-type enzymes, the human mutants, and the in silico 
model of the rat enzyme using as template the ACT domain of 3PGDH (rat model). 
 
 
Figure 3.6: Number of H-bonds between the β2 strand (65-69 residues) and the β3 strand (76-
81 residues) during the simulation in the wt-hPAH. Hydrogen bonds are determined using a 
cutoff of 30 degrees on the Acceptor – Donor – Hydrogen angle and of 3.5 Å on the Acceptor - 
Donor distance. 
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the (PC1, PC2) space shows that the human and rat wild-type forms explore different 
regions (Figure 3.7C). In particular, the human wild-type samples regions in the 
conformational space where the elongation of β2 occurs (PC1>0), while in the wt-rPAH 
L2 remains in a turn conformation (PC1<0) during both simulations. The regions at 
PC1>0 are sampled by all mutants in at least one replica, except for F39C. The largest 
differences between mutants and human wild-type are observed along the second PC. 
Indeed, the G46S, F39L, I65T and I65V mutants, which have a higher flexibility of α2 
and of all loops (including L1) with respect to the β-sheet (Figure 3.3), explore large 
portions of the space with PC2>0, which seems inaccessible to the human wild-type and 
the F39C and I65S mutants (Figure 3.7C). 
  
 
Figure 3.7: Combined essential dynamics analysis. (A) Porcupine plots illustrating the motions 
represented by the first and (B) the second PCs from the combined ED analysis. Each Cα atom 
has a cone pointing in the direction of motion described by each PC. Red arrows highlight the 
motions described in the text. (C) Projections of each trajectory along PC1 and PC2 from the 
combined ED. Color code: wt-hPAH in black, wt-rPAH in red, G46S in orange, F39C in blue, 
F39L in green, I65T in violet, I65S in magenta, I65V in cyan. 
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3.3.2 L2 conformation in the RD structure from wt-rPAH 
In the rat RD crystal structure, the L2 region has a particular β-turn conformation 
(Asn61-His64 turn type IV, Leu62-Ile65 turn type I) and, unlike the human RD, does 
not undergo the conformational change of this region from turn to β-strand during the 
simulations (Figure 3.7C and 3.5). A screening of all the available structures of other 
ACT domains (PDB codes: 1PSD, 1RWU, 1TDJ, 1O8B, 1Q5Y, 1I1G, 1NH7, 1ZPV, 
1U8S, 1Y7P, 2F1F, 2F06, 2CDQ, 2QMX) shows that the L2 region preferentially 
adopts the β-strand conformation, while the turn conformation of the L2 region is 
specific to the rat RD. The B-factor values of the atoms belonging to the L2 region in 
the rat PAH crystal structure (PDB code 1PHZ) are quite high, with values higher than 
the average B factor of the protein. This suggests that the L2 region is quite disordered 
in the crystal.  
To test the stability of a hypothetical β conformation of the L2 region in wt-rPAH, we 
have generated a model of the RD of rat enzyme, using as template the ACT domain of 
D-3-phosphoglycerate dehydrogenase (3PGDH) from Escherichia coli. A superposition 
of the RD domain from rat crystal structure, rat modelled structure and 3PGDH crystal 
structure is shown in Figure 3.8. The overall fold is very similar, apart from the L2 
region. Indeed, the model has the L2 region in a β-strand conformation as the template. 
The model was then subjected to 50-ns-long MD simulations and the β-strand 
conformation of the L2 region was found to be stable during the whole simulation (rat 
model in Figure 3.5). 
 
 
Figure 3.8: Superimposition of the ACT domains. Superimposition of the ACT domains of D-
3-phosphoglycerate dehydrogenase from Escherichia coli (magenta), crystallographic wt-rPAH 
(cyan) and in silico model of wt-rPAH (green). A box encloses the L2 region discussed in the 
text. 
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3.3.3 Correlation between a hydrophobic surface and the motion in the RD  
An extended hydrophobic surface between the helix α1 and the strand β2 was identified 
by analysing the water density distribution around the solutes during the MD 
simulations. Indeed, the water density maps show the presence of a reduced number of 
hydration sites near this surface in all systems (Figure 3.9A). 
The variation of the solvent accessible surface area (SASA) of this region (residues 
Val45-Ala49, Val51, Leu52, Leu54, Phe55, Val60-Thr63, Ile65, Ser67, Tyr77 (Figure 
3.9B)) was calculated during the simulations. In the wt-hPAH a significant decrease of 
the SASA was observed, while in the mutants simulations the SASA values generally 
showed smaller variations (Figure 3.9C). 
To determine the correlation between the SASA variation of the identified hydrophobic 
surface and the protein collective motions, a functional mode analysis (FMA) was 
performed on all the simulations (see Materials and Methods). The collective motion 
that is maximally correlated with the SASA (MCM) was expanded in the space of the 
first n PCs that account for 90% of the overall fluctuation (essential space). For the 
wild-type enzyme, an overall MCM-SASA correlation coefficient of 0.82 was observed 
for the second replica (Figure 3.9E), with PC1 accounting for more than 40% of the 
variance of the SASA (% var in Figure 3.9D). This indicates that the reorganization of 
the hydrophobic patch during the simulation is mainly related with the motion described 
by PC1 (Figure 3.2C) and in particular with the restructuring of the L2 loop, which 
hosts some of the residues in the patch. The mutants showed correlation values ranging 
from 0.53 to 0.83, with only F39C and I65S having correlations as high as the human 
wild-type (Figure 3.9E). The MCM expansion of these two mutants was dominated by 
PC1 (Figure 3.9F), analogously to the human wild-type case. Although the F39C mutant 
does not show the elongation of the β2-strand, the PC1 of its trajectory describes a large 
movement of the L2 and L4 regions that approach each other, as in wt-hPAh and I65S 
mutant. This motion seems to modify the hydrophobic surface. For the rat wild-type and 
the other human mutants, no dominant contributions to the SASA variation were 
observed across the essential space (Figure 3.9F). 
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Figure 3.9: (A) Water distribution in the wt-hPAH. The protein surface atoms are coloured 
from yellow to blue according to the increasing hydration score Shyd
atom
. The local maxima of the 
water density map are represented as spheres, coloured from yellow to blue according to the 
increasing density value. Hydrophobic atoms (yellow surface) have low hydration scores and 
are poor in hydration sites. (B) The hydrophobic residues that belong to the hydrophobic surface 
between the helix α1 and the strand β2 are shown as stick in the wt-hPAH. (C) Variation of the 
SASA of the residues at the hydrophobic surface between the helix α1 and the strand β2 in the 
wt-hPAH (black) and the mutants (G46S in orange, F39C in blue, F39L in green, I65T in violet, 
I65S in magenta, I65V in cyan). (D) Relative contribution of the first 20 PCs in the MCM to the 
variance of the hydrophobic surface SASA in wt-hPAH (%var). (E) Plot of the Pearson 
correlation coefficient between the trajectory projection on the MCM and the SASA of the 
hydrophobic surface (C) for all the systems and replicas. (F) Plot of the maximum %var per PC 
for each system and replicas. In the plot, the PC that has the largest relative contribution is 
indicated for each replica. 
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3.3.4 Analysis of core interactions 
The hydrophobic contacts formed by selected residues in the hydrophobic core of wt-
hPAH (Leu37, Phe39, Leu41, Val51, Phe55, Ile65, Phe79, Leu91, Ile94, Leu98) were 
calculated on the first 5ns and on the last 5ns of the simulations by the minimum 
distance matrices (Figure 3.10). The side chains of these residues undergo a significant 
rearrangement during the simulation. In particular, the distances between the residues 
Leu37 (β1) and Phe39 (β1) on one side, and Leu91 (α2), Ile94 (α2) and Leu98 (α2) on 
the other, change due to the unwinding of the α2 N-terminal part. Moreover, the residue 
Ile65 (β2) changes its distance from Phe39 (β1), Phe55 (α1) and Leu91 (α2) due to the 
elongation of the strand β2. 
 
 
Figure 3.10:  Average distances between selected residues of the hydrophobic core in the wt-
hPAH. (A) Distance matrices calculated on selected residues (Leu37, Phe39, Leu41, Val51, 
Phe55, Ile65, Phe79, Leu91, Ile94, Leu98) of the hydrophobic core in the wt-hPAH. Average 
distances calculated over the first (0-5ns) and (B) the last (45-50ns) 5 ns of simulation are 
reported. (C) Superimposition of the structure at 0 (green) and 50 (magenta) ns of wt-hPAH 
with the hydrophobic core residues in stick. Selected residues are labelled. 
 
In the F39C and F39L mutants, the replacement of Phe39 with either a polar Cys or a 
smaller hydrophobic residue such as Leu, induces a reorganization of the interactions in 
the core with respect to the wild-type enzyme. In particular, the residue 39 looses its 
contacts with other core hydrophobic residues, namely Leu41, Val51 and Phe55 in 
F39C, and Leu37, Phe55 and Leu98 in F39L (Figure 3.11). In the latter mutant, an 
increased distance between Ile65 and Phe79 is also observed, as a result of the L2 
transition to β-strand. The perturbation of the core is particularly evident at the end of 
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the F39C simulation, where two innermost residues (Phe55 and Val60) become exposed 
to the solvent in response to the movements of the L2 loop and of the α1 helix (Figure 
3.12A). 
In the mutants in position 65, the substitution with either a polar or a smaller 
hydrophobic residue may distort the hydrophobic packing in the RD core. In I65T and 
I65V the side chains of some residues (Phe39, Val51, Phe55, Phe79, Ile94) of the 
hydrophobic core undergo a rearrangement during the simulation and the distances 
between such residues deviate with respect to the wild-type enzyme (Figure 3.11). 
Differently from I65T and I65V, in the I65S mutant the contacts of residue 65 with the 
rest of the hydrophobic core are lost (Figure 3.11). In all these mutants, the residue in 
position 65 becomes more exposed to solvent (Figure 3.12B) in response to the 
elongation of β2.  
In the G46S mutant, the Gly residue of the GAL ligand-binding motif of the ACT 
domain family is replaced by a polar residue. In this mutant some changes occur due to 
a reorganization of the core side chains (Figure 3.11), that sample different orientations 
with respect to the wild-type enzyme during the simulation. The pattern of distances 
between the hydrophobic core residues, for this mutant, result similar to that of the I65T 
and I65V mutants. 
The perturbation of the core introduced by the mutations is also evident from the 
comparison of the correlation webs of the different systems, where residues with 
dynamic correlations higher than 0.3 are connected by a line (Figure 3.13A, B). The wt-
hPAH web (Figure 3.13A) shows a dense network of connections between the two 
helices on one side and the β sheet on the other, indicating that the two parts of the 
protein move concertedly in the main collective motions. All the mutant webs show a 
more disconnected pattern (see I65S in Figure 3.13B for an example), with a reduced 
number of links connecting helices with β-sheets (Figure 3.13C). 
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Figure 3.11: Average distances between selected residues of the hydrophobic core in the 
mutants. Distance matrices calculated on selected residues (Leu37, Phe39, Leu41, Val51, 
Phe55, Ile65, Phe79, Leu91, Ile94, Leu98) of the hydrophobic core in the wt-hPAH and in the 
mutants. Distances between pairs of residues are calculated as the minimum over all possible 
pairs of non-hydrogen atoms of the side chain. Average values calculated over the 50-ns 
simulation are reported. 
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Figure 3.12: Time evolution of SASA of selected residues. (A) Time evolution of Phe55 
(black) and Val60 (green) SASA in the F39C mutant. (B) Time evolution of the SASA of the 
residue in position 65 in the I65S (yellow), I65T (violet) and I65V (cyan) mutants. 
 
 
 
 
Figure 3.13: Correlation webs and number of links between helix and β-sheet residues. 
Correlation webs of wt-hPAH (A) and I65S (B) generated with Dynatraj. C
α
 atom pairs with 
dynamic correlation higher than 0.3 are connected with a line. (C) Total number of links 
connecting helix to β-strand residues in the correlation webs. Values from both replicas in each 
simulated system are reported.  
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3.4 Discussion 
MD simulations were performed on the isolated ACT regulatory domain of both human 
and rat wild-type PAH and of six human disease-causing mutants. The analysis of the 
trajectories was shown to provide dynamical and structural insight on the isolated RD 
and on the effects of the mutations.  
We have simulated the structured regions of the RD (residues 33-111), as the N-
terminal part is partially unstructured (residues 1-32). The structured regions of the RD 
coincide with the structural motif known as ACT domain, consisting of a four-stranded 
antiparallel β-sheet, two short α-helices and four connecting loops. 
Examination of the 50-ns-long MD trajectories highlights a specific dynamic behaviour 
of the wild-type enzymes and the mutants. The simulated systems, while preserving 
their overall secondary structure, showed significant rearrangements of the loop-
containing regions. 
In 10 out of 16 simulations, the L2 region, which in the rat crystallographic structure 
(and in the generated models) has a turn/bend conformation, undergoes a 
conformational change to a β-strand conformation that elongates the strand β2. The β2 
elongation is associated with the formation of a typical H-bond pattern with the adjacent 
β3, leading to the stabilisation of the β-sheet. This suggests that the β-strand 
conformation of the L2 region is an accessible and intrinsically stable conformation of 
the RD. This finding is supported by the similarity with the known structure of the other 
ACT domain-containing proteins and by the stability of the L2 β-strand conformation 
during the 50-ns-long MD simulations of a model of the rat PAH, obtained using as 
template the ACT domain from 3PGDH with an elongated β2 strand. 
The conformational change of the L2 region leads to the stabilization of the β2 strand 
formed by residues 65-69. These residues constitute the conserved motif IESRP 
involved in the putative Phe binding at the isolated PAH RD. In addition, the residues 
60-63 in the L2 region, show a high degree of evolutionary conservation (Gjetting et al., 
2001b). A large portion of mutations leading to hyperphenylalaninemia cluster within or 
around the β2 strand (Gjetting et al., 2001b), suggesting that these residues are relevant 
for the activity of the enzyme. 
The principal motion in most of the studied systems involves a correlated 
conformational change in both the L2 and L4 regions. The movement of L2 towards L4 
and the unwinding of the N-terminal part of the α2 helix promote the formation of H-
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bonds between L2 and L4. Collectively, all these movements result in a transition from 
an initial open to a final more closed structure of the domain.  
Our findings are in agreement with the hypothesis formulated by Li and co-workers on 
the basis of hydrogen/deuterium exchange experiments on the PAH (Li et al., 2010). 
These authors concluded that upon Phe-binding (i) the interactions between the two 
peptides 39-59 and 82-91 are partly disrupted, leading to a more open RD, and (ii) the 
interaction between the RD and the catalytic domain is altered. Interestingly, the 39-59 
and 82-91 peptides partially and completely coincide with the dynamic L2 and L4 
regions, respectively. 
In addition, from the analysis of our trajectories we could identify a hydrophobic patch 
in the region between the helix α1 and the strand β2, corresponding to the ligand 
binding-site of the ACT protein family. This could be a possible site of interaction for 
the benzyl side chain of the Phe ligand. We found that the solvent accessibility of the 
hydrophobic surface is correlated to the global intrinsic motions of the protein and, 
particularly for the wild-type enzyme, to the motions of L2 and L4 regions, suggesting a 
relationship between the Phe-binding and the overall dynamic behaviour of the enzyme. 
The transition from an open to a closed form of the domain leads to the decrease of the 
solvent exposure of the hydrophobic surface where the Phe ligand could bind to the 
domain. This suggests that the closed form of the enzyme, with a smaller hydrophobic 
surface, is unbound, while the open form is able to bind Phe. This is in agreement with 
the regulatory model in which PAH switches from an inactive to an active form upon 
Phe binding (Thorolfsson et al., 2003; Thorolfsson et al., 2002).  
The difference between the rat and human PAH RD dynamics might be related to the 
difference in the activity of the two enzymes. For the rat enzyme, pre-treatment with 
phenylalanine is reported to produce a 10- to 30-fold increment of the activity, while for 
the human enzyme this increment is only ~3 to 6-fold (Miranda et al., 2002; 
Thorolfsson et al., 2003). This is due to the higher levels of activity of the inactive 
human enzyme, which probably undergoes different conformational changes from the 
rat enzyme in the activation process.  
To better compare the binding site of the ACT domain-containing proteins and the 
corresponding region in hPAH, we generated an in silico model of hPAH tetramer (see 
Materials and Methods) and superposed such model to Phe-bound PDT (PDB code 
2QMX). The superposition reveals that a Phe-binding site of PDT is located at the 
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interface between the RD and the catalytic domain of the adjacent subunit in PAH. In 
particular, an α-helix (Cα4) from the catalytic domain in PAH is located in a similar 
position to the Phe-binding site region of the second ACT domain in PDT (Figure 3.14). 
Thus, some residues of Cα4 helix could participate in the Phe-binding in PAH, 
presumably through conformational changes in the catalytic domain and a reorientation 
of the two interacting domains upon Phe-binding.  
To get insight into the structural role of HPA disease-causing mutations in the RD 
hydrophobic core, we selected F39C, F39L, I65T, I65S and I65V mutants. The residues 
39 and 65 are the most frequently mutated positions and their resulting phenotypes can 
range from mild to severe PKU. In addition, we selected the G46S mutant, which is 
associated with a severe form of PKU (Eiken et al., 1996). The Gly46 residue, located 
between the β1 strand and the α1 helix, is a good candidate for Phe binding, since it 
belongs to the ligand binding site in other ACT domain-containing proteins.  
In all mutants, the extent of correlation of motion between the helix and β-sheet residues 
is smaller than in the human wild-type enzyme. In G46S, F39L, I65T and I65V mutants, 
also the correlation between the variation of the hydrophobic surface and the 
movements of the L2 and L4 regions is smaller than in the wild-type enzyme. Together, 
these data suggest that changes in the interactions within the hydrophobic core of the 
RD may significantly affect its stability and hence its regulatory role. Indeed, changes in 
the RD stability could interfere with the cross-talks with the other domains and affect 
the conformational changes that are involved in cooperativity. 
We hypothesise a mechanism for which alterations in the hydrophobic interactions of 
the RD may hamper the functionality of the whole enzyme. 
The RD mutations can influence the correct binding of Phe to the domain, resulting in a 
poor Phe activation that ultimately reduces the enzyme activity. This is in line with 
experimental data on the mutants, that have been characterized in vitro, showing a 
reduced Phe activation and a reduced activity (Erlandsen et al., 2004; Gjetting et al., 
2001a; Gjetting et al., 2001b; Pey et al., 2007). 
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Figure 3.14: Superimposition of the Phe-bound prephenate dehydratase (PDT) from 
Chlorobium tepidum TLS (cyan) (PDB code 2QMX) and the tetrameric model of the human 
PAH (RD in green, catalytic domain in violet). The bound Phe ligand is shown in yellow as 
stick. 
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CHAPTER 4. In silico identification of the allosteric Phe-
binding site in the hPAH 
 
4.1 Introduction  
The proposal that mammalian PAH has an allosteric binding site for Phe, in addition to 
the catalytic site, has been a controversial issue for many years.  
Phe plays an important role in the regulation of the catalytic activity of tetrameric PAH 
which is activated several-fold by preincubation with the substrate (Shiman and Gray, 
1980). Phe allosterically modulates the activity of PAH by positive cooperativity 
(Kappock and Caradonna, 1996; Kaufman, 1993; Knappskog et al., 1996a), but the 
mechanism is still unclear. The cooperativity reflects a transition from a low-activity 
and low-affinity ‘‘T’’ to a high-activity and high-affinity ‘‘R’’ state, accompanied by 
large conformational changes (Kappock et al., 1995; Shiman et al., 1979; Stokka and 
Flatmark, 2003; Thorolfsson et al., 2003). An in vitro binding of Phe to recombinant 
wild-type and some mutant forms of the isolated RD was demonstrated (Gjetting et al., 
2001b). Recently, NMR spectroscopy of the isolated RD revealed chemical shift 
perturbations in the presence of Phe, that are consistent with its binding at a specific site 
(Li et al., 2011). However, isothermal titration calorimetry measurements, 
demonstrating that Phe binds to full-length hPAH tetramer with a stoichiometry of 
Phe:subunit = 1.2 : 1, do not support an effector binding site in addition to the active site 
(Thorolfsson et al., 2002).  
By contrast, though low sequence identity occurs between the regulatory ACT domain 
of hPAH and its distant homolog prephenate dehydratase (PDT) (i.e. 20% over 80 
residues) (Liberles and Martinez, 2009), it is noteworthy that both enzymes contain the 
sequence motifs GA(S)L/IESRP within the ACT domain. These motifs are involved in 
the binding of Phe to the isolated regulatory domain of hPAH (Gjetting et al., 2001b) 
and their role in Phe binding has been crystallographically proven for PDT (Tan et al., 
2008). 
However, in most cases ACT domains interact with other ACT domains, but this is not 
the case for the ACT domain in PAH. In PAH, the motifs are located at the interface 
between the interacting regulatory and catalytic domains. A structure of PDT from 
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Chlorobium tepidum TLS shows Phe bound to its regulatory ACT domain (PDB code: 
2QMX) (Tan et al., 2008). Phe is coordinated by Asn206 (Asp in hPAH), Leu211, 
Tyr240, and Phe242, plus Asp224 (Asn in hPAH) and Leu225 from the adjacent ACT 
domain. A superimposition of hPAH and PDT reveals that an α-helix (Cα4, residues 
204-216) from the catalytic domain in the adjacent chain in hPAH is located in a 
position similar to that in the second ACT domain in PDT. 
In my previous MD studies on the isolated RD (manuscript in preparation), I found a 
correlation between the variation of the SASA of a hydrophobic region, corresponding 
to the ligand binding-site of the ACT proteins family, and the global intrinsic motions of 
the protein, suggesting a relationship between the Phe-binding and the dynamics of the 
enzyme (see sections 3.3.3 and 3.4). 
In this context, I aimed to shed light on the open questions on the regulation role of the 
enzyme through the in silico identification of the putative allosteric Phe-binding site. 
According to our previous studies and by analogy with the other ACT-domain 
containing proteins, we proposed a putative hydrophobic region for Phe-binding at the 
dimeric interface between the RD and the CD (lined by the ACT-domain motifs GAL-
ESRP) of two distinct subunits. Thus, I extended the structural and dynamical study to 
the hPAH, rPAH and G46S dimers. Furthermore, through docking simulations, I 
generated a model for the Phe-PAH interactions and elucidated the structural effects of 
the disease-causing G46S mutant (on the Phe-binding).  
To address this complex study I considered, in explicit water solution, a total of 9 
systems (3 unbound and 6 Phe-bound dimeric PAH forms), each consisting of about 
20500 atoms. To run simulations of complex bio-systems of such dimensions (784 
residues per dimer) long computation time was required. All the simulations on the 
unbound and Phe-bound forms were extremely demanding and computationally 
intensive, and they were beyond the capabilities of the resources available at my 
institution. For these reasons, I attended the “HPC-Europa2 Transnational Access 
programme” to accede to the modern fast supercomputer at EPCC (Edinburgh Parallel 
Computing Centre) in Edinburgh. Moreover, during the HPC-Europa2 project, I 
continued collaborating with the Dr. Fraternali’s group at King’s College in London. 
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4.2 Experimental methods 
4.2.1 Building of dimeric models 
Models of the dimer (residues 33-424 of two chains A and B within the dimer) of the 
wt-hPAH enzyme and G46S mutant were generated in silico with the program 
MODELLER 9v8 (Sali and Blundell, 1993) using as template the composite dimeric 
model built by superimposing the secondary structure elements of the respective 
catalytic domains of the dimeric rPAH (PDB code 1PHZ), the dimeric hPAH (PDB 
codes 1PAH) structures. The template was built using the dimeric rPAH structure for 
the N-terminal RD (residues 33-116), the dimeric hPAH structure for the catalytic 
domain, the dimerization motif (residues 117-424) and the position of Fe(III) ion and 
the three water molecules coordinated to Fe in the active site. The template and the 
target sequences were aligned using BODIL (Lehtonen et al., 2004). Subsequently, the 
alignment files were used as input in MODELLER and 200 models of each studied 
forms were generated. For the mutants, the mutated residues were replaced in the 
alignment file. The model that presented the best MODELLER DOPE score was 
selected for the MD simulations.  
 
4.2.2 MD simulations of the studied dimers 
MD simulations were performed with the GROMACS (Van Der Spoel et al., 2005) 
package using the GROMOS 43a1 force field (van Gunsteren et al., 1996) on the 
unbound and some selected Phe-bound systems. The initial dimeric models (each 
consisting of 784 residues) generated in silico and the dimeric wt-rPAH structure were 
solvated in dodecahedral boxes containing simple point charge (SPC) water molecules 
(Berendsen et al., 1981). To neutralize the system, some Na
+
 ions were randomly placed 
far away from the surface of the enzymes. Van der Waals parameters and the charge for 
Fe(III) were fixed at zero. His285 and His290 coordinating the Fe(III) ion were assigned 
δ-hydrogen atoms. Constraints on the bond distances of the Fe with its coordinated 
residues were used. Simulations were carried out with periodic boundary conditions and 
a 2-fs time step. All the bonds in the protein were frozen with the LINCS method (Hess 
et al., 1997), while SETTLE (Miyamoto and Kollman, 1992) was used for water 
molecules. The Berendsen algorithm (Berendsen et al., 1984) was applied for 
temperature and pressure coupling. The particle mesh Ewald method (Essmann et al., 
1995) was used for the calculation of the electrostatic contribution to non-bonded 
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interactions with a direct sums cut-off of 14 Å. A 14 Å cut-off was used for van der 
Waals interactions. The systems were energy minimized with 2000 steps of the steepest 
descent method and subsequently with 2000 steps of conjugate gradient method. After 
the minimization, harmonic positional restraints (with an initial force constant of 4.8 
kcal/mol/Å
2
) were imposed onto the protein heavy atoms and gradually turned off in 
360 ps, while the temperature was increased from 200 to 300 K at constant volume. The 
system was then equilibrated for 2 ns without restraints in NPT conditions (T=300 K, 
p=1 bar). Finally, NPT MD simulations were performed for 40 ns for the unbound wt-
hPAH, for 30ns for the unbound rat and mutant PAH, and from 5ns to 15ns for the 
complexes. Two replicas were run for each system, because we have noted, in our 
preliminary study, that replicas significantly improve the statistical description of the 
dynamics of the studied system on the nanosecond scale. We studied a total of 2x9 
systems (3 unbound and 6 Phe-bound enzymes) in explicit water solution, each 
comprised of about 20500 atoms.  
Long simulations are needed to investigate motions having functional implications and 
to reveal conformational changes as a function of time. To run long simulations of 
complex bio-systems, long computation time is required. The use of a modern fast 
supercomputer was essential to the success of this computationally intensive project. 
The work has been performed under the HPC-EUROPA2 project (project number: 
228398) with the support of the European Commission - Capacities Area - Research 
Infrastructures. MD simulations were run on 128 processors of the HECToR (High End 
Computing Terascale Resources) supercomputer at EPCC in Edinburgh.  
MD trajectories were analysed using GROMACS analysis tools. 
 
4.2.3 Molecular docking  
Molecular docking is a computer simulation procedure to predict the conformation of 
protein-protein and protein-ligand complexes. The docking simulation, investigating 
the conformational space, searches for the best fit between two or more molecules 
considering several parameters as: geometrical receptor-ligand complementarity, 
regarding atomic VDW radius and charge; receptor or ligand structure flexibility; 
interatomic interactions, such as hydrogen bonds and hydrophobic contacts. As result, 
the predicted orientations (poses) of a ligand in the target’s binding site are generated.  
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The interactions receptor-ligand depend both on the specific interactions in the binding 
site as well as on the non-specific forces outside the binding pocket. The complexity of 
interactions between proteins and flexible target molecules, including other proteins, 
nucleic acids and small molecules, is often determined by the considerable flexibility of 
the protein binding sites and by the structural rearrangements that occur upon binding of 
the associated molecule. Protein flexibility and the dynamics of inter molecular 
interfaces can regulate binding affinity and specificity in molecular recognition. 
Docking applications, considering the flexibility of the ligand and/or the receptor 
docking algorithms can be classified in two large groups: rigid-body and flexible 
docking. Rigid-body docking method does not take into account the flexibility of 
neither ligand nor receptor, limiting the specificity and accuracy of results, considering 
essentially geometrical complementarities between two molecules. This approach 
considers the protein-ligand system as a lock and key mechanism, with the ligand being 
the key that, upon correct positioning, opens the lock of the interaction. Flexible 
docking methods consider several possible conformations of ligand or receptor, as well 
as for both molecules at the same time, in order to accommodate upon the binding of the 
partner. In this second method, the docking is an induced fit, or hand-and-glove 
approach. However, the conformational flexibility results in very large degrees of 
freedom, which implies either that searching such a space would be very slow or very 
incomplete or both. The ways to reduce the degrees of freedom of the docking problem 
are: (i) to define local regions of space as interaction zones, and to look only at 
conformations in this region while keeping the rest of the system rigid; (ii) or  
alternatively, to keep the protein rigid and to allow only the generally much smaller 
ligand to sample conformation space. 
  
The main issues of a docking approach therefore are: choosing whether the system 
would be considered absolutely rigid, semiflexible (e.g. flexible ligand and rigid 
protein) or flexible, deciding how the contribution of the solvent is included, the choice 
of the searching algorithm, the scoring function, and the evaluation of the results. The 
contemporary docking software programs have several methods for addressing the 
aforementioned issues and reaching the goals of wide input range, fast and reliable 
docking. There is a number of docking packages being used nowadays, ones more or 
less suited for specific types of interactions, mutually differing at the basis of approach 
to the docking problem. These docking software programs include for example GOLD 
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(Verdonk et al., 2003), GLIDE (Halgren, 2000), FlexX (Kramer et al., 1999), 
HADDOCK (Dominguez et al., 2003), ICM (Abagyan et al., 1994), DOCK (Lang et al., 
2007) or AutoDock (Morris et al., 1998). 
Usually docking algorithms predict several orientations (poses) for the ligand inside the 
binding site. Scoring functions, that are able to evaluate intermolecular binding affinity 
or binding free energy, are employed in order to optimize and rank results, obtaining the 
best orientation after the docking procedure. There are several scoring functions 
available. Scoring functions are mathematical approximating methods for estimating 
binding affinity, in order to lead optimization of virtual screening results, finding the 
highest affinity ligand against a target. Using as input the atomic coordinates of a binary 
complex, scoring functions are able to estimate free energy of binding or binding 
constant. Scoring functions can be classified in 3 different types: force-field based, 
knowledge based and empirical based scoring functions. Force-field based scoring 
functions use non-bonded terms of classical mechanics force fields. Knowledge-based 
scoring functions are based on statistical observations of intermolecular contacts 
identified from structure databases. Empirical scoring functions make use of several 
intermolecular interaction terms that are calibrated through a linear regression 
procedure, where theoretical values are fitted to be closest as possible to experimental 
data. 
 
4.2.4 MOE (Molecular Operating Environment) software 
Phe docking into the dimeric PAH enzymes has been performed with the MOE 
(Molecular Operating Environment) software (Chemical Computing Group Inc., 2012). 
MOE's Dock application searches for favorable binding configurations between small- 
to medium-sized ligands and a not-too-flexible macromolecular target. For each ligand, 
a number of configurations called poses are generated and scored. The score can be 
calculated as either a free energy of binding, which takes into account solvation and 
entropy, or the enthalpic term of the free energy of binding. The final top-scoring poses, 
along with their scores and conformation energies, are written to a database where they 
are ready for further analysis. 
The Dock application was designed for flexibility and customizability. The algorithm is 
arranged as a series of self-contained stages. At most stages, there is a choice from 
among multiple different methods.  
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The Dock workflow is divided into five sequential stages (Figure 4.1): receptor and 
ligand preparation,  placement, rescoring (1), refinement, rescoring (2).  
 
 
 
Figure 4.1: Dock workflow of the MOE’s dock application (Chemical Computing Group Inc., 
2012). 
 
The purpose of the first step is to correct structures and to prepare macromolecular data 
for further computational analysis. X-ray crystal structures with missing or poorly 
resolved atomic data need to be modeled and fixed before subsequent computational 
analyses. The bond orders, charges and protonation states of ligands and cofactors 
should be inspected and corrected. Once the backbone and side chains are complete and 
any errors in the ligand and cofactor structures have been corrected, a typical structure 
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preparation workflow includes addition of hydrogens and calculation of partial charges 
followed by tethered energy minimization (molecular mechanics refinement) to relieve 
bad crystallographic contacts or other bad geometries. A sophisticated algorithm for 
calculating protonation state and hydrogen placement, designed especially for 
macromolecular systems, is provided by PROTONATE3D that optimizes the hydrogen 
orientations to maximize H-bond networks and minimize the overall self-energy.  
SITE FINDER is used to calculate possible active sites in the receptor from the 3D 
atomic coordinates. The SITE FINDER methodology is based upon Alpha Shapes 
which are a generalization of convex hulls developed in (Edelsbrunner et al., 1995).  
The Placement phase generates a collection of poses from the pool of ligand 
conformations using one of the placement methods. To each of the generated poses a 
score is assigned by the placement method. Triangle Matcher method was used to 
generate 30 poses for each docking simulation. This placement method  generates poses 
by aligning ligand triplets of atoms on triplets of alpha spheres in a very systematic 
way.  
Poses generated by the placement methodology can be rescored using one of the 
available methods. In the procedure I used, the London dG scoring function has been 
chosen for the first step of rescoring, it estimates the free energy of binding of the ligand 
from a given pose. For the second step of rescoring the GBVI/WSA dG scoring has 
been used; it is a forcefield-based scoring function which estimates the free energy of 
binding of the ligand from a given pose. For both scoring functions, lower scores 
indicate more favorable poses. 
Poses resulting from the placement stage can be refined using either the explicit 
molecular mechanics forcefield method or the grid-based energetics method. In the used 
Forcefield Refinement, energy minimization of the system is carried out using the 
conventional molecular mechanics setup. 
 
4.2.5 Phe docking into putative allosteric site on the dimeric PAH forms   
Phe docking has been performed into one putative allosteric site (between the RD of 
chain A and the CD of chain B) on different conformations of the unbound dimeric 
enzymes. As template for the position of the Phe and for the identification of the Phe-
binding site, the Phe bound structure of the protein prephenate dehydratase (PDT) has 
been used. Complexes were generated with MOE software using different 
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conformations of the unbound dimeric enzymes: (i) the initial models at 0 ns, (ii) the 
minimum energy structures extracted from the previous MD simulations on the 
unbound form, (iii) the representative structures of the first most-populated cluster of 
protein configurations sampled by the simulations of the unbound form. In addition, (iv) 
complexes were generated superimposing the initial dimeric models and the Phe in the 
PDT structure. Furthermore, to verify the presence of a site in the putative region that 
we identified for the Phe-binding, MOE’s SITE FINDER (Chemical Computing Group 
Inc., 2012) was used and some complexes were generated using the site found by such 
program. The latter complexes resulted very similar to the complexes generated using as 
template the PDT binding site and hence they were not subjected to MD simulations.  
 
4.2.6 Analysis Tools 
Cluster analysis was performed using the GROMOS method (Daura et al., 1999). 
Structures of the enzymes were taken from the MD trajectory at 100 ps intervals. The 
protein configurations sampled by the simulations are assigned to classes defined by 
similarity. The criterion of similarity for two structures was the backbone atom 
positional RMSD ≤ 0.12 nm. For each cluster a structure represents the class of 
structurally similar configurations.  
To obtain the minimum energy structure of the unbound PAH forms for docking 
simulations, potential energy of all structures, produced during MD simulations of the 
three PAH forms, was calculated using g_energy program in GROMACS. This program 
extract the energy components from the energy files. Subsequently, the minimum 
energy structure was extracted from the files obtained from g_energy using a home-
made script. 
The electrostatic potential surfaces of the monomeric and dimeric forms of hPAH and 
PDT were calculated with PyMOL (Schrödinger, 2009). PyMOL can call upon the 
Adaptive Poisson-Boltzmann Solver (APBS) under a Unix environment to perform 
quantitative electrostatic calculations. As a first step, the PDB2PQR server (Dolinsky et 
al., 2004) was used to generate a PQR file. PDB2PQR is a software package that 
automates many of the common tasks of preparing structures for, by among others, 
electrostatics calculations, providing a utility for converting protein files in PDB format 
to PQR format. The PQR file contain the same information as the PDB file and, in 
addition, the hydrogen atoms, information about titration states (protonation), and 
Chapter 4 
 
78 
 
charges and radius parameters for each atom. PyMOL provides both the execution of 
APBS and the visualization of the resulting electrostatic potentials. 
The calculation of the evolutionary conservation in the structure of hPAH and PDT was 
made with the ConSurf server (Ashkenazy et al., 2010; Glaser et al., 2003; Landau et 
al., 2005). The ConSurf server is a bioinformatics tool for estimating the evolutionary 
conservation of amino/nucleic acid positions in a protein/DNA/RNA molecule based on 
the phylogenetic relations between homologous sequences. Given the amino or nucleic 
acid sequence (can be extracted from the 3D structure), ConSurf carries out a search for 
close homologous sequences using BLAST (or PSI-BLAST) (Altschul et al., 1990; 
Altschul et al., 1997). A multiple sequence alignment (MSA) of the homologous 
sequences is constructed using T-COFFEE (Notredame et al., 2000). The MSA is then 
used to build a phylogenetic tree using the neighbor-joining algorithm as implemented 
in the Rate4Site program (Pupko et al., 2002). Position-specific conservation scores are 
computed using the empirical Bayesian or ML algorithms (Mayrose et al., 2004; Pupko 
et al., 2002). The continuous conservation scores are divided into a discrete scale of 
nine grades for visualization, from the most variable positions (grade 1) colored 
turquoise, through intermediately conserved positions (grade 5) colored white, to the 
most conserved positions (grade 9) colored maroon. The conservation scores are 
projected onto the protein/nucleotide sequence, on the structure and on the MSA. 
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4.3 Results 
In silico models were generated for the dimer (residues 33-424 of chain A and chain B) 
of wt-hPAH enzyme and of the G46S hPAH mutant, using as template the dimeric wt-
rPAH structure. In Figure 4.2 the wiring diagram of the generated dimeric hPAH 
models is shown. Two replicas of MD simulations were performed onto the generated 
models and the dimeric wt-rPAH template. Overall, during the simulations, the systems 
showed no large deviations from the initial structures and at the end of the simulations 
all trajectories reached a plateau (hPAH in 40 ns, rPAH and G46S in 30 ns) within 4-5 
Å in the RMSD from the initial structures calculated over C
α
 atoms. 
 
4.3.1 Mobility of the unbound dimeric PAH forms 
The dynamics of wt-hPAH is mostly characterized by the large motions of the RD, the 
hinge region Arg111-Thr117 and the segments 135-151 (L5), 336-339 (L6), 360-
371(L7), 376-384 (L8) in the CD (Figures 4.3, 4.4, 4.5).   
During all simulations, in at least one chain of the dimers, a high RD mobility was 
observed, confirming the high flexibility found in our previous MD simulations on the 
isolated RD (Figures 4.4, 4.5A). Particularly, in the chain A of wt-hPAH, the two α-
helices and the loop-containing regions (from L1 to L4) show higher mobility with 
respect to the β-sheet (Figures 4.4, 4.5A).  
A large rearrangement is also observed for the loop Arg111-Thr117 (Figures 4.4, 4.5B), 
connecting the RD to the CD (Figure 4.3). The loop represent the center of hinge-
bending motions of the two domains.  
Moreover, in the CD dynamics, the segments L5, L6, L7, L8 showed large motions 
(Figures 4.4, 4.5C). The segment L5 is a long loop located at the surface and connecting 
two α-helices (Cα1 and Cα2) of the CD (Figure 4.3). The segment L6 consists of a β-
hairpin (between Cβ3 and Cβ4) located at the surface of the protein (Figure 4.3). The 
segment L7 contains both loop and secondary structure elements in a surface region 
(Figure 4.3). The L7 and L8 segments are divided by a short helix (Cα11) on the protein 
surface that results quite flexible as well. The L8 segment is a surface loop (Figure 4.3) 
that closes over the active site cavity when both BH4 and the substrate are bound.  
As shown by Essential Dynamics (ED) analyses, the movements of RD, of the hinge 
111-117 segment and of the abovementioned CD loops are represented by the first PC 
of the motion in the human wild-type enzyme (Figures 4.5A-C). 
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Figure 4.2: Primary and secondary structure of a subunit belonging to the in silico generated 
hPAH dimer model. Letters R, C and D associated to the secondary structure nomenclature refer 
to Regulatory domain, Catalytic domain and Dimerization motif. Flexible loop-containing 
regions (L1 to L4 in the RD, hinge 111-117, L5 to L8 in CD) are highlighted in red boxes. 
Figure from PDBsum server (Laskowski et al., 1997). 
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Figure 4.3: Starting model of a subunit of wt-hPAH dimer. The iron is shown as an orange 
sphere. Mobile loop-containing regions L1 to L4 in RD, the hinge region between RD and CD, 
regions L5 to L8 are drawn in different colours. 
 
 
 
Figure 4.4: Root Mean Square Fluctuation (RMSF) of the C
α
 atoms during the simulations of 
the unbound PAH forms. Color code: wt-hPAH in black, wt-rPAH in red, G46S in green. 
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Figure 4.5: Porcupine plot illustrating the motions represented by the first PC from the 
simulation of the wt-hPAH. Each Cα atom has a cone attached pointing in the direction of 
motion described by the eigenvector corresponding to that atom. Chain A is drawn in green, 
chain B in magenta. Three different orientations show the movements of (A) the RD, where red 
arrows highlight its motion, of (B) the hinge region 111-117 highlighted in a red circle, and of 
(C) the surface loop-containing regions L5 to L8 in the CD drawn in yellow.  
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The principal movement of the RD and the hinge region results in the RD shift with 
respect to the CD of the adjacent subunit within the dimer (Figure 4.5A), with changes 
in the distances between residues at the dimeric interface (Figure 4.6A). The contacts 
formed by selected residues in the putative Phe-binding site of wt-hPAH (Glu43 (A), 
Gly 46 (A), Leu48 (A), Ala49 (A), Leu52 (A), Tyr77 (A), His208 (B), Pro211 (B), 
Leu212 (B), Lys215 (B)) were calculated on the first 5ns and on the last 5ns of the 
simulations by the minimum distance matrices (Figure 4.6B). The distances of residues 
Leu48 (A), Ala49 (A), Leu52 (A), Tyr77 (A) from His208 (B) and the distances of 
Leu52 (A) from Pro211 (B) and Lys215 (B) decrease (Figure 4.6B). Thus, regions 
involved in the RD/CD interface and close to the putative Phe-binding site show 
relevant differences from the initial structures. 
The conformational stability of residues within 6 Å from the catalytic iron was assessed 
measuring during simulations the RMSD of C
α
 atoms from their initial coordinates. 
These residues can be functionally important as they can play an important role in 
biological activity of the molecule. All these residues were found to be very stable in all 
systems.   
Similar features were also observed for the rat dimer and the G46S mutant (Figure 4.4). 
During each simulation, the diverse rearrangement of the hinge 111-117, exploring the 
conformational space, drives the orientation of the RD respect to the CD within the 
dimer in all MD runs. However, compared to the wt enzymes, the mutant shows lower 
flexibility of the RD (Figure 4.4), where the mutated residue is located. 
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Figure 4.6: (A) Superimposition of the ribbon structure at 0 (green) and 50 (cyan) ns of wt-
hPAH with selected residues in the putative Phe-binding site as stick. Some residues are 
labeled. (B) Distance matrices calculated on selected residues in the putative Phe-binding site of 
wt-hPAH (Glu43 (A), Gly 46 (A), Leu48 (A), Ala49 (A), Leu52 (A), Tyr77 (A), His208 (B), 
Pro211 (B), Leu212 (B), Lys215 (B)). Average distances calculated over (rigth) the first (0-5ns) 
and  (left) the last (45-50ns) 5 ns of simulation are reported. Distances between pairs of residues 
are calculated as the minimum over all possible pairs of non-hydrogen atoms of the side chain.  
 
 
 
Chapter 4 
 
85 
 
4.3.2 Docking poses of the Phe-bound dimeric PAH forms 
Taking into account (i) the experimental information about the residues in the RD that 
are most affected by the Phe-binding (Gjetting et al., 2001b), (ii) the data obtained by 
our previous MD simulations (Chapter 3) and (iii) the information about the position of 
the allosteric Phe-binding site in the ACT-containing PDT protein (Tan et al., 2008), we 
generated models of the PAH/Phe complex by molecular docking.  
The docking procedure was driven with the MOE software (Chemical Computing 
Group Inc., 2012) using diverse conformations of the unbound hPAH, rPAH and G46S 
mutant dimers (see section 4.2.5). A detailed scheme summarizing all the generated 
complexes is shown in Table 4.1. Althougth the Phe-bound structure of the PDT has 
been used as template for the position of the Phe in the dimers, in all the docking 
simulations Phe has been placed in a region slightly different from that of the template, 
i.e. a region more external of the protein. However, the binding site of all the generated 
poses is located in proximity of the L1 loop and β2 strand in the RD at the interface 
with the Cα4 helix formed by residues 204-216. 
Because of the great number of all the generated complexes and the similarity of some 
poses, only some selected poses were subsequently subjected to MD simulations. These 
poses were chosen on the basis of three criteria: (i) the good agreement between the 
position of the Phe docked and the position of the Phe in the template structure;  (ii) the 
analysis of the protein-ligand interactions in order to compare the poses; (iii) the choice, 
for each performed docking simulation, of the pose with the lowest MOE’s score. The 
poses that satisfied the three criteria for each PAH forms resulted in: (i) the complex 
formed by the initial conformation of the unbound forms (complex1), (ii) the complex 
formed by the minimum energy conformation extracted from the MD simulations on the 
unbound forms (complex2). 
In figure 4.7 the Phe-PAH interactions in the binding site of the selected complexes are 
shown. 
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Table 4.1: Scheme summarizing all the generated complexes. 
Complex generated 
by MOE 
PAH structure used in docking simulations Ligand 
   
Complex1 Structure of PAH dimeric forms at 0 ns Phe 
Complex2 Structure at minimum energy extracted from the MD simulations 
of the unbound PAH dimeric forms 
Phe 
Complex3 Representative structure of the first most-populated cluster 
sampled by the simulations of the unbound forms 
Phe 
   
Complex generated 
by superposition 
Structures used Ligand 
   
Complex4 Structure of PAH dimeric forms at 0 ns + structure of PDT Phe 
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Figure 4.7: Phe-PAH interactions diagrams of the selected docked complexes. Interactions in: 
(A) hPAH complex1, (B) hPAH complex2, (C) rPAH complex1, (D) rPAH complex2, (E) 
G46S complex1, (F) G46S complex2. Figure from the MOE’s ligand interaction tool (Chemical 
Computing Group Inc., 2012). 
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4.3.3 Analysis of the Phe-binding site in hPAH and PDT 
To investigate the diversity of the Phe position in the hPAH complexes from the 
template, the electrostatic surface and the evolutionary conservation of residue positions 
of the binding site in hPAH and PDT has been calculated.  
The electrostatic potential surfaces of the monomers and dimers were calculated with 
PyMOL (Schrödinger, 2009). The resulting electrostatic potential is mapped onto the 
molecular surface in Figure 4.8, where the proteins are shown as an electrostatic surface 
colored blue in the positive regions and red in the negative regions. The analysis 
showed that the Phe-binding site in both enzymes is positively charged. However, in the 
PDT the positive charge is more localized and buried in the site (Figure 4.8A), whereas 
in the hPAH the positive charge is also extended on the surface (Figure 4.8B).  
The calculation of the evolutionary conservation in the structure of hPAH and PDT was 
made by the ConSurf server (Ashkenazy et al., 2010; Glaser et al., 2003; Landau et al., 
2005). The ConSurf’s conservation score at a site corresponds to the site's evolutionary 
rate: positions that evolve slowly are commonly referred as "conserved", whereas 
positions that evolve rapidly are referred as "variable". Usually, conserved patches 
suggest functions as in enzymatic activity or in ligand binding or, alternatively, in 
protein-protein interactions. In Figure 4.9, where the nine-color conservation scores are 
projected onto the 3D structures, we can see the conservation pattern of the monomer of 
the enzymes, which shows that ConSurf clearly detects the conservation among the 
amino acids facing the Phe-binding region. In fact, the analysis revealed, as expected, 
that the binding regions of these proteins are highly conserved. In particular, the 
glycines in the loop between the first β-strand and the first α-helix were assigned the 
highest conservation scores (Figure 4.9). However, in the PDT the conservation is 
higher only for the residues interacting with Phe (Figure 4.9), whereas in the hPAH a 
higher number of residues in the same region has a good conservation score (Figure 
4.9). Thus, the PDT seems to have a more centered conserved Phe-binding site than 
hPAH.  
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Figure 4.8: The calculated electrostatic potential is mapped onto the molecular surface of (A) 
the dimeric (left) and monomeric (right) PDT, and (B) the dimeric (left) and monomeric (right) 
hPAH. The Phe-binding sites are indicated by green arrows. Figures from Pymol. 
 
 
Figure 4.9: Conservation pattern of the PDT and hPAH monomers. The Phe-binding sites are 
indicated by green arrows and the residues of the sites are drawn in green boxes according to the 
nine-color conservation scores. Figures from the Consurf server. 
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4.3.4 MD simulations of the complexes 
The selected complexes were refined by performing 10ns-long MD simulations. This 
helped in incorporating protein as well as ligand flexibility and also to check the 
stability of the complexes obtained by docking studies. Furthermore, it was interesting 
to investigate whether the binding pocket residues, identified by docking, persisted and 
if new contacts were formed throughout the MD simulations.  
For all three PAH forms, the trajectories of the complexes2 were more stable over the 
simulations than the trajectories of complexes1 and reached a plateau after 2-3ns 
(Figure 4.10), indicating their higher stability and reliability.  
In both wt-hPAH complexes, the RD of the chain A, which binds Phe, has less mobility 
than in the unbound enzyme (Figure 4.11), indicating that Phe-binding reduces the 
movements of this domain. Instead, in both complexes of the wt-rPAH and of the G46S 
mutant, the mobility of RD in the chain A is similar to that of the unbound forms. 
During the simulations, in the wt-hPAH complex1 Phe explored diverse conformations 
and moved deeper into the ACT-domain core (Figure 4.12A); while in the complex2 the 
Phe position does not substantially change (Figure 4.12B). In Figure 4.13A and 4.13B 
superpositions of the structures of wt-hPAH complex1 and complex2 are shown at 0ns 
and 10ns respectively. These superpositions show that the positions and the orientations 
of Phe in the two complexes are quite different. In the wt-hPAH complex1 at the end of 
the simulation, the amino group forms H-bonds with the residues Glu44, Tyr77 from 
chain A and His208 from chain B (Figure 4.14A). Whereas, in the wt-hPAH complex2, 
the carboxylic group forms H-bonds with residues Ala47, Leu48, Lys49, Lys74, Tyr 77 
from chain A (Figure 4.14B). 
For the wt-rPAH, during the dynamics, the Phe in both complexes slightly shifted 
towards the N-terminal part of the Cα4 helix and its aromatic ring was pointing inwards 
of the enzyme (Figures 4.15A, B). Also for the rat form, the superpositions of the two 
complexes (Figures 4.16A, B) show that the positions and the orientations of Phe in the 
two complexes are quite different, with the polar moiety pointing in diverse directions 
(towards the enzyme in complex1 and towards the surface in complex2). In the wt-
rPAH complex1 at the end of the simulation, the amino group forms a H-bond with the 
residue Glu43 from chain A and the carboxylic group forms H-bonds with residues 
Glu44, Gly46, Ala47, Leu48 from chain A (Figure 4.17A). Whereas, in the wt-rPAH 
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Figure 4.10: Root Mean Square Deviation (RMSD) of the C
α
 atoms during the simulations of 
all analysed complexes. Color code: hPAH complex1 in black, hPAH complex2 in red, rPAH 
complex1 in green, rPAH complex2 in blue, G46S complex1 in yellow. 
 
 
Figure 4.11: Root Mean Square Fluctuation (RMSF) of the C
α
 atoms during the simulations of 
the unbound hPAH in black, the hPAH complex1 in red and the hPAH complex2 in blue. 
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Figure 4.12: (A) Superimposition of the structure at 0 (green) and 10 (yellow) ns of hPAH 
complex1. (B) Superimposition of the structure at 0 (cyan) and 10 (magenta) ns of hPAH 
complex2. Phe is shown as stick. 
 
 
Figure 4.13: (A) Superimposition of the structure of hPAH complex1 (green) and complex2 
(cyan) at 0 ns. (B) Superimposition of the structure of hPAH complex1 (yellow) and complex2 
(magenta) at 10 ns. Phe is shown as stick. 
 
 
Figure 4.14: (A) H-bonds of Phe, shown as orange stick, in hPAH complex1 at 10 ns. (B) H-
bonds of Phe, shown as blue stick, in hPAH complex2 at 10 ns (see text for details). 
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complex2, the amino group forms a H-bond with the residue Lys199 from chain B and 
the carboxylic group forms a H-bond with residues Asn207 from chain B (Figure 
4.17B). 
For the G46S mutant, the dynamics of Phe are very different from that of the other 
systems. In fact, only in 1 out of 4 simulations (two replicas per each complex) the Phe 
remained in the putative allosteric site. In the other simulations, Phe explored regions of 
the space far away from the mutant after 1-5 ns. At the end of one simulation of the 
complex1, the Phe was located closer to the CD than before MD (Figure 4.18A), 
forming H-bonds between the amino group and the residues Glu43 (from chain A), 
His208 (from chain B) and between the carboxyl group and the mutate residue Ser46 
(Figure 4.18B). 
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Figure 4.15: (A) Superimposition of the structure at 0 (green) and 10 (yellow) ns of rPAH 
complex1. (B) Superimposition of the structure at 0 (cyan) and 10 (magenta) ns of rPAH 
complex2. Phe is shown as stick. 
 
 
Figure 4.16: (A) Superimposition of the structure of rPAH complex1 (green) and complex2 
(cyan) at 0 ns. (B) Superimposition of the structure of rPAH complex1 (yellow) and complex2 
(magenta) at 10 ns. Phe is shown as stick. 
 
 
Figure 4.17: (A) H-bonds of Phe, shown as orange stick, in rPAH complex1 at 10 ns. (B) H-
bonds of Phe, shown as blue stick, in rPAH complex2 at 10 ns (see text for details). 
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Figure 4.18: (A) Superimposition of the structure at 0 (green) and 10 (yellow) ns of G46S 
complex1. Phe is shown as stick. (B) H-bonds of Phe, shown as orange stick, in G46S complex1 
at 10 ns (see text for details). 
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4.4 Discussion 
As an identification of the proposed allosteric Phe-binding site has been lacking by 
now, I used computational methods, i.e. homology modelling, molecular docking and 
MD simulations, to achieve this goal.  
MD simulations were performed on the in silico generated unbound and Phe-bound 
dimers of human and rat wild-type PAH and of human disease-causing G46S mutant. 
The analysis of the trajectories provided dynamical and structural insight on the 
unbound dimeric forms, on the complexes and on the effects of the G46S mutation. 
The dynamics of the unbound dimeric PAH forms are mostly characterized by the large 
motions of the RD, the hinge region Arg111-Thr117 and the surface segments L5, L6, 
L7, L8 in the CD.   
Once again, MD simulations of the unbound PAH dimeric forms highlighted the 
flexibility of the RD and, in particular, the high mobility of the loop containing regions 
from L1 to L4 in line with our previous MD simulations on the isolated ACT domain. In 
the dimer, L1 and L3 loops showed a large rearrangement although they form 
interactions with the CD of the other subunit.  
As expected, very high flexibility was also detected for the hinge region Arg111-Thr117 
connecting the RD to the CD from the same subunit. My results indicate that the 
dynamics of the enzyme is characterized by conformational changes including the 
domain movements around this hinge.  
Furthermore, in the CD the simulated systems showed significant rearrangements of the 
loop-containing surface regions L5, L6, L7 and L8. These findings from MD 
simulations, linking dynamics of the loop-containing regions in the CD, are in good 
agreement with experimental data on allosteric regulation of PAH (Li et al., 2010).  
Li and co-workers showed, by an increase in exchange kinetics of hydrogen/deuterium 
exchange, that these regions are highly flexible, solvent-accessible and, in addition, they 
are influenced by the presence of Phe.  
The L5 region contains the 136-143 segment that is usually not seen in crystal structures 
of the AAAHs in the absence of the substrate, consistent with its flexibility. The L5 
loop is in close proximity to the active site and was found to be highly flexible also in 
the MD simulations performed by Fuchs and co-workers (Fuchs et al., 2012). These 
authors observed a loop movement towards the active site in the oxidized state of PAH 
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(containing an artificial disulfide bond between two vicinal Cys residues), thereby 
partially blocking access for the substrate (Fuchs et al., 2012). Moreover, with respect to 
the binary cofactor complex crystal structure (ΔN102/ΔC24-hPAH-Fe(II)·BH4), in the 
ternary complex, hinge-bending motions, upon Phe-binding, result in a displacement of 
L5 flexible surface loop (Andersen et al., 2002; Andersen et al., 2003) and a relocation 
of the side chain of Tyr138 from a surface position to a partially buried position within 
a hydrophobic core at the active site. A similar movement of the side chain of Tyr138 
was also observed in my MD simulations; it leads to a decrease in the accessibility of 
the catalytic site.  
Also the L8 dynamic loop closes over the Phe when both BH4 and Phe are bound to the 
catalytic site in the crystal structure (Li et al., 2010).  
Thus, this dynamic behavior of the surface loop-containing regions (L5 to L8) from my 
MD simulations agrees with data from literature and confirms the role of the 
movements of L5 and L8 loops in the catalytic mechanism.  
MD simulations of the Phe-bound PAH dimeric forms were performed on selected 
complexes generated with MOE, starting from different conformations of the unbound 
enzymes (see sections 4.2.5 and 4.3.2). In all the docking simulations, Phe has been 
placed in a region slightly different from that of the Phe-binding site of PDT used as 
template, i.e. a region more external of the protein. To better compare the binding site of 
the ACT domain-containing protein PDT and the corresponding region in hPAH, the 
electrostatic surfaces and the residues conservation of the binding site were evaluated. 
Evaluation of the electrostatic properties of biomolecules has become an important tool, 
as many molecules are charged and electrostatic forces are relatively long range, the 
electrostatic properties have the potential to accelerate association of molecules, and are 
thus an important contributor to molecular recognition, protein-ligand, protein-
membrane, and protein-protein binding. Another important tool is the calculation of the 
evolutionary conservation of residues positions. Usually, conserved patches suggest 
functions as in enzymatic activity or in ligand binding or, alternatively, in protein-
protein interactions. These analysis reveled a more centered positive charge and residue 
conservation in the binding site of PDT than hPAH, indicating a higher specificity for 
the PDT Phe-binding site. 
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However, during MD simulations, the trajectories of the selected Phe-bound hPAH and 
rPAH reached a plateau, indicating their stability and reliability. Although the Phe 
position slightly differs in the different analysed systems, the binding site over the 
simulations remained localized at the dimeric RD/CD interface and some residues from 
L1, α1 (which includes the GAL sequence motif) and Cα4 were involved in the binding.  
These results confirm my starting hypothesis on the Phe-binding site.  
For the hPAH, I also found a decrease in the mobility of the RD where the Phe is bound 
in the complexes. This interesting finding indicates that Phe-binding reduces the 
movements and probably enhances the stability of this domain. 
Moreover, during the simulations, the complexes2 resulted more stable than the 
complexes1, and Phe in complex2 moved much less than in complex1. This suggests 
that starting from a more stabile protein structure, as that used in complex2, improves 
the reliability of the docking simulation predictions.  
For the G46S mutant, during the MD simulations, the dissociation of most of the 
complexes occurred. Furthermore, in the only stable complex, Phe formed a H-bond 
with the side chain of the mutated residue, i.e. Ser46. These results suggest that the 
mutation affects the correct binding of Phe, as we predicted in a previous study (see 
section 3.4). The substitution of the Gly in the conserved GAL sequence motif with Ser, 
having a polar side chain that obstructs the allosteric site, leads to an unproductive Phe 
binding. The G46S mutant has a reduced stability both in vitro and in vivo that results in 
misfolded protein and in a severe form of PKU (Goodwill et al., 1997). Phe binding to 
the wt-hPAH showed a stabilizing effect, and a loss of this ability in the G46S mutant 
may contribute to explain its low stability and hence its disease-causing nature. 
In conclusion, this work paves the way for more detailed theoretical investigation aimed 
at validating my models and sets the basis for site-directed mutagenesis experimental 
work on the proposed Phe binding-site and on the interface of the PAH dimeric 
structure.  
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CHAPTER 5. Conclusions 
 
Phenylketonuria (PKU) is an autosomal recessive disease that leads to severe mental 
retardation in humans if left untreated. In this classical inborn error of metabolism,  the 
gene primarily affected is the PAH gene, which results in a protein with reduced 
enzyme activity that is not sufficient to hydroxylate phenylalanine to tyrosine. PKU is 
considered a protein misfolding disease with loss of function. In fact, a large number of 
mutations result in a reduced folding efficiency and a reduced thermal/chemical stability 
of the enzyme. 
Understanding the background of diseases is crucial to medical research, with 
implications in diagnosis, treatment and drug development. As molecular approaches to 
this challenge are costly and time consuming, computational approaches offer an 
efficient alternative. Thus, in my thesis, to get insight into the structural basis of the 
PAH defects underlying the disease, I used computational methods.  
Here, my current results contribute to elucidate specific aspects of PAH and PKU 
related to: (i) the conformational stability of disease-causing PAH mutants (Chapter 2), 
(ii) the structural and dynamical features of the isolated ACT domain of the wild-type 
enzyme and of six mutants (Chapter 3), (iii) the structural basis for the regulation of 
PAH, through the identification in silico of the putative allosteric Phe-binding site 
(Chapter 4). 
The studies described in the Chapter 2, showing a decrease in the PAH conformational 
stability of the PKU-causing mutations, revealed the relevance of conformational 
flexibility for PAH activity (Paper I). The decreased conformational stability of the 
studied hPAH mutants can be associated to possible defects in the folding and a reduced 
activity of the enzyme, leading to the disease. 
MD studies on the isolated ACT regulatory domain (Chapter 3) highlighted a specific 
dynamic behaviour of the wild-type enzymes and of the six mutants. Collectively, all 
the movements result in a transition from an initial open to a final more closed structure, 
leading to the decrease of the solvent exposure of the hydrophobic surface, where the 
Phe ligand can bind to the domain. Moreover, the correlation, found between the 
solvent accessibility of the hydrophobic surface and the global intrinsic motions of the 
protein, suggested a relationship between the Phe-binding and the overall dynamic 
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behaviour of the enzyme. In the mutants, the simulations revealed changes in the 
interactions within the hydrophobic core of the RD that may significantly affect its 
stability and hence its regulatory role.  
Molecular docking studies combined with MD simulations on the dimeric PAH 
(Chapter 4) generated models for the Phe-PAH interactions. The allosteric Phe-binding 
site was localized at the dimeric RD/CD interface where some residues from L1, α1 
(which includes the GAL sequence motif) and Cα4 are involved in the binding. For the 
hPAH, the Phe-binding showed also to reduce the mobility of RD domain. The analysis 
of these models elucidated the structural effects of the disease-causing G46S mutant 
which showed to affect the correct binding of Phe. 
In conclusion, this thesis adds further evidences toward a deeper understanding of the 
regulatory mechanisms of the enzyme and of the relationship between the mutations and 
the disease.  
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Appendix I. Structural analysis of selected glucokinase (GCK) mutants 
causing MODY2 
 
Mutations in human genes can change the sequence and structure of a protein, impair its 
function, and lead to a disease. The function of most genes is determined by the 3D 
structure of their protein product. Interpreting the effects of mutations in a protein 
structure provides more detailed information about the environment and role of a 
mutated residue and can explain the impaired function and thus the disease.  
Genetic diseases due to loss-of-function mutations, as the PKU, are very common. An 
additional example, among this diseases, is the type 2 Maturity Onset Diabetes of the 
Young (MODY2). 
MODY2 is a monogenic autosomal disease characterized by a primary defect in insulin 
secretion and hyperglycemia. It results from glucokinase (GCK) gene mutations that 
impair enzyme activity. GCK catalyzes the ATP-dependent phosphorylation of glucose 
in the first, rate-limiting step of glycolysis in pancreatic β-cells. The 3D structure 
consists of two domains, namely small and large domain, separated by the catalytic site. 
The GCK switches from a super-open inactive conformation to a closed active 
conformation upon ligand binding. A huge conformational transition occurs through a 
large rotation of the small domain. 
GCK function and its involvement in the MODY2 disease is one of the main field 
studied by the group of Prof. Sacchetti and her co-workers at the research institute 
CEINGE. During my thesis work, in collaboration with the afore-mentioned group, I 
carried out a structural study, by homology modelling, on the effects of some disease-
causing GCK mutations (Paper II). 
In the attempt to understand how detected mutations could contribute to MODY2 
insurgence, we searched for structure/function correlations of the disease-causing GCK 
mutants. To this aim, I evaluated the impact of studied mutations (p.E40D, p.E70D, 
p.F150Y, p.V154L, p.A188T, p.G223S, p.A259T, p.G261R, p.D278E, p.Y289C, 
p.R303W, p.E395_R397del, p.K420E, p.A449T) on the enzyme 3D-structure.  
All the mutations considered are buried in the enzyme, except for p.E70D which is 
located on the surface of the protein, and all mutations are far from the active and ATP 
binding sites. Apart from p.V154L and p.F150Y that undergo large movements during 
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the conformational transition from the super-open to the closed active form, all the 
mutant structures exhibit local structural alterations that well correlate to kinetic 
parameters and thermal inactivation data (see Paper II). In all cases, the amino acid 
replacement either provokes the loss of stabilizing interactions or generates unfavorable 
interactions that can destabilize the whole structure of the enzyme.  
In conclusion, this our study, carried out by integrating DHPLC, sequencing, 
bioinformatics and functional analysis, provides new information about the structure-
function relationship of human GCK mutations and MODY2. 
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Hyperphenylalaninemias are genetic diseases prevalently caused by mutations in the phenylalanine
hydroxylase (PAH) gene. The wild-type PAH enzyme is a homotetramer regulated by its substrate, cofactor
and phosphorylation. We reproduced a full-length wild-type protein and seven natural full-length PAH
variants, p.I65M, p.N223Y, p.R297L, p.F382L, p.K398N, p.A403V, and p.Q419R, and analyzed their biochemical
and biophysical behavior. All mutants exhibited reduced enzymatic activity, namely from 38% to 69% of wild-
type activity. Biophysical characterization was performed by size-exclusion chromatography, light scattering
and circular dichroism. In the puriﬁed wild-type PAH, we identiﬁed the monomer in equilibrium with the
dimer and tetramer. In most mutants, the equilibrium shifted toward the dimer and most tended to form
aggregates. All PAH variants displayed different biophysical behaviors due to loss of secondary structure and
thermal destabilization. Speciﬁcally, p.F382L was highly unstable at physiological temperature. Moreover,
using confocal microscopy with the number and brightness technique, we studied the effect of BH4 addition
directly in living human cells expressing wild-type PAH or p.A403V, a mild mutant associated with BH4
responsiveness in vivo. Our results demonstrate that BH4 addition promotes re-establishment of the
oligomerization equilibrium, thus indicating that the dimer-to-tetramer shift in pA403V plays a key role in
BH4 responsiveness. In conclusion, we show that the oligomerization process and conformational stability are
altered by mutations that could affect the physiological behavior of the enzyme. This endorses the hypothesis
that oligomerization and folding defects of PAH variants are the most common causes of HPAs, particularly as
regards mild human phenotypes.
© 2011 Elsevier B.V. All rights reserved.
1. Introduction
Phenylketonuria (PKU, Online Mendelian Inheritance in Man
database: 261600) and its hyperphenylalaninemia (HPA) variants
represent the most common inherited disorder of amino acid metab-
olism transmitted by an autosomal recessive mode [1]. The primary
cause of HPA is a dysfunction of phenylalanine hydroxylase (PAH: EC
1.14.16.1). In the liver, this enzymemetabolizes L-Phenylalanine (L-Phe)
to L-Tyrosine (L-Tyr) using (6R)-L-erythro-5,6,7,8-tetrahydrobiopterin
(BH4) as coenzyme. More rarely, forms of HPAs can also be caused by a
lack of the BH4 cofactor due to defective cofactor biosynthesis and
regeneration [2]. Untreated PKU patients present an abnormal pheno-
type, with growth failure, microcephaly, seizures and permanent
neurologic damage because their body ﬂuids contain elevated levels of
L-Phe and its neurotoxic metabolites (phenylpyruvate, phenylacetate
and phenylactate) [1,3].
The major manifestations of the disease, which start at birth, are
prevented by severe dietary restriction of L-Phe [4] and, in selected
cases, by BH4 supplementation, which reduces L-Phe levels and
increases L-Phe tolerance in HPA patients [5]. Several new therapeutic
strategies based on the biochemistry and pathogenetic features of
PKU are currently being investigated [6,7].
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The human PAH gene, mapped on 12q23.2, consists of 13 exons
encompassing 171 kb. The full-length PAH cDNA encodes a protein of
about 52 kDa (452 amino acids) that in the mature form is assembled
as a homotetramer. Each subunit consists of three functional domains:
a ﬂexible N-terminal regulatory domain (residues 1–142); a catalytic
domain (residues 143–410) that includes binding sites for iron,
substrate and cofactor; and a C-terminal oligomerization domain
(residues 411–452) with dimerization (residues 411–426) and
tetramerization motifs (residues 427–452) [8] (Fig. 1). The crystal
structure of PAH has revealed that the tetrameric oligomers are
dimers of dimers in which the interaction between the two dimers is
mediated by the C-terminal ‘arm’ [8].
The tetrameric and dimeric forms of PAH are in equilibrium [9,10]
and have different catalytic properties because the tetramer, but not
the dimer, demonstrates a positive kinetic cooperativity with respect
to L-Phe [11]. In particular, substrate activation results in conforma-
tional changes involving the tertiary as well as the quaternary
structure [12] and drives the tetramer–dimer equilibrium toward
the tetrameric form [13]. Further regulation mechanisms require
binding of BH4 [12] and phosphorylation [14].
The clinical and metabolic features associated to HPA are complex
[15] and various genotype–phenotype correlation studies have been
performed [16–18]. In addition, at molecular level, about 600
mutations have been identiﬁed, most of which are point mutations
scattered throughout the whole PAH gene (http://www.pahdb.mcgill.
ca), although frequencies differ among populations and geographic
areas [16–18].
Recombinant variant proteins containing prevalently missense
mutations have been analyzed and characterized in vitro; each
mutation exerts a distinct effect on the behavior of the PAH protein,
which in many cases allows the prediction of the biochemical
phenotype [19–21]. The effects of a speciﬁc mutation on protein
functions have been studied with different approaches, i.e., enzyme
assay, in vivo isotopic studies and in vitro expression. Moreover, the
crystal structures of human and rat PAH [8,22] provided the structural
basis of HPA [23]. It is now established that, inmost HPA cases, the loss
of PAH function is due to decreased stability [21,24], increased
susceptibility toward aggregation and degradation of PAH mutant
proteins [19,24,25], thermodynamic instability [26] and/or folding
efﬁciency [27]. About 75% of PAH mutations, characterized by high
residual activity, have been found to be associated with BH4
responsiveness, both in vitro [28–30] and in vivo [4,5]. It has recently
been speculated that pharmacological doses of BH4 may augment the
conformational stability and the amount of functional PAH [31].
We previously carried out a molecular analysis of the PAH gene in
HPA patients from Southern Italy, and identiﬁed and characterized
several novel mutations [32–34]. In the present study, we analyzed
the wild-type PAH protein and some PAH natural mutants to obtain
further information about the molecular basis of HPAs and the
mechanism of BH4 responsiveness. To this purpose, we reproduced,
by in vitro mutagenesis, the wild-type and seven natural variants of
PAH: p.I65M, p.N223Y, p.R297L, p.F382L, p.K398N, p.A403V, and
p.Q419R, and characterized the biophysical–biochemical properties of
the above-mentioned puriﬁed full-length proteins in order to
understand the impact of each mutation on the activity, oligomeric
structure and stability of PAH. In addition, we investigated the
mechanism underlying BH4 responsiveness using p.A403V, which is
one of the most frequent mutations in our geographic area [32], and is
associated with a BH4-responsive mild phenotype [35].
2. Material and methods
2.1. Construction of PAH expression plasmid and site-directed
mutagenesis
PAHwild-type andmutant constructs were obtained by modifying
the pMAL Xa PAH plasmid, kindly provided by Drs CR. Scriver and P.
Waters (McGill University-Montreal Children's Hospital Research
Institute, Montreal, Canada), to digest the fusion protein MBP-PAH
with enterokinase (Ek) [9]. The Ek site was inserted downstream the
sequence encoding the factor Xa site, by site-directed mutagenesis
using the primers 5′gatgacgatgacaagtctactgcggtcctgg3′ and 5′
gccctaactcccttccctactgctactgttc3′ and the Quick Site-directed muta-
genesis kit (Stratagene, CA, USA). GFP was ampliﬁed by PCR from
pEGFP-N1 (Clonetech, CA, USA) using the primers: 5′acattaggtac-
cagccatggtgagcaagggcgag3′ and 3′ gtagatgaattctccaccacccttgtacagctcg
5′ and cloned into pcDNA3 (Invitrogen, Carlsbad, CA) using Kpn1
and EcoR1 sites. PAH cDNA was ampliﬁed from pMAL Xa Ek PAH
by using the primers: 5′catcattgaattctccactgcggtcctgg3′ and 3′
cgtaatgcggccgcttactttattttctggag 5′ and cloned downstream GFP,
using EcoR1 and Not1 sites. Sequence analysis conﬁrmed the correct
frame.
Mutations were introduced into pMAL Xa Ek PAH and pCDNA3-
GFP-PAH using mutagenic primers and the Quick Site-directed
mutagenesis kit (Table 1). The modiﬁed plasmid and the mutant
clones were sequenced to verify the introduction of each single
mutation. Commercial MBP was obtained from New England Biolabs
(Ipswich, MA, USA).
2.2. Expression, puriﬁcation and N-terminal sequencing of the
PAH protein
pMAL Xa Ek PAH expression plasmids were transformed into
Escherichia coli BL21 cells and the colonies were selected using Luria-
Broth plates with ampicillin (0.1 mgmL−1). Bacteria were grown to
2×108 cells/mL (A600nm~0.5) and overexpression of wild-type and
variant MBP-PAH fusion proteins was induced with 1 mM isopropylthio-
β-D-galactoside (IPTG) for 16 h at 37 °C. Cells were harvested by
centrifugation and treated according to the instruction manual of the
pMAL protein fusion and puriﬁcation system (New England Biolabs). The
fusion proteinwas digested overnight at room temperaturewith Ek (New
England Biolabs) to obtain wild-type and mutant forms of PAH without
the MBP tag, using 0.5 ng of enzyme for each 50 μg fusion protein. The
mixturewas then applied to ahydroxyapatite column (1 cm×10 cm, Bio-
Rad Laboratories, CA, USA) and subjected to several washes with 20 mM
sodiumphosphate, 200 mMNaCl (pH7.2). Proteinswere thenelutedwith
0.5 MNa phosphate, pH 7.2 and subsequentlyMBPwas isolated from the
Fig. 1. Full-length composite model of the PAH monomer structure and distribution of
the HPA-related missense mutations studied in this paper. The N-terminal regulatory
domain is shown in blue, the catalytic domain in red and the tetramerization domain in
green. The Fe ion is shown as a cyan sphere at the center of the catalytic domain; the
mutation sites are marked as yellow balls.
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cleavagemixture by re-binding to amylose resin. PAHwas ﬁnally puriﬁed
by size-exclusion chromatography with a HiLoad 16/60 Superdex 200
column (GE Healthcare, UK). Protein concentrations were determined
spectrophotometricallywith the use of the absorption coefﬁcient A280 or
the dye-binding Bradford assay (Bio-Rad Laboratories). The N-terminal
aminoacid sequenceofPAHwasdeterminedbyEdmandegradationonan
automated Procise H49 sequencer (Applied Biosystems, MA, USA).
It has been reported [36] that, during the various steps of
recombinant protein production, some labile Asn residues are
deamidated: however, any possible deamidation of these residues,
which would in the activity assay produce substrate inhibition, would
most likely be the same in the presence of wild-type and of the variant
forms of PAH we have employed.
2.3. Concentration and storage of proteins
The concentration of proteins was determined both by the micro
BCA protein assay and spectrophotometrically. The ﬁnal protein
concentration was measured based on optical density at 280 nm
using, for the extinction coefﬁcient, a value of 49,780, 66,350 and
115,630 M−1 cm−1 for PAH, MBP and the fused wild-type MBP-PAH
respectively, deduced from the amino acid composition of the protein.
We used a SpeedVac concentrator (Thermo Scientiﬁc, Rockford, IL,
USA) to concentrate the protein solutions because ultra-ﬁltration led
to considerable sample loss. All protein samples, if not utilized within
few days, were stored at −20 °C in their elution buffer (see below).
2.4. PAH activity and thermal inactivation assay
Enzymatic activity analysis was carried out on a whole equilibrium
mixture of oligomeric species of puriﬁed full-length wild-type and
mutant PAH (see Supplementary Table S1). The activity was assayed
in the presence of 0.25 μCi L-[14C] Phe (Amersham, Buckinghamshire,
UK; 460 μCi/mmol); 0.25 mM cold L-Phe, 1.3 units of beef liver
catalase; 0.8 mM BH4; 250 mM Tris HCl pH 7.8, 1 μg of protein;
ﬁnal volume: 100 μL. The reaction was conducted at 25 °C with
an incubation time of 1 h [32–34]. After centrifugation at room
temperature andmaximum speed, an aliquot of each supernatant was
applied on a thin-layer chromatography system and the amount of
[14C] radio-labeled L-Phe converted to [14C] radio-labeled L-Tyr was
measured. The mean PAH activities were calculated from three sets of
experiments. The residual activities of mutant PAH enzymes were
expressed as a percentage of wild-type enzyme activity. The same
assay was used for the thermal inactivation analysis of the wild-type
protein and of the p.F382L mutant. Thermal inactivation of both
proteins was determined by measuring the decay of tyrosine
production as a function of temperature in the 32–58 °C range.
2.5. Electrophoresis and immunoblotting
SDS/PAGE was performed at 100 V (2 h) in a 10% (w/v)
polyacrylamide gel. The puriﬁcation of all proteins was veriﬁed after
staining with Colloidal Coomassie. The absence of MBP contamination
in all preparations was determined by western blot analyses.
Immunoblotting was performed using afﬁnity-puriﬁed rabbit anti-
hPAH [32–34] and mouse anti-MBP (New England Biolabs) as primary
antibodies. The enhanced chemiluminescence system from Amersham
(GE Healthcare) was used for immunodetection.
2.6. Size-exclusion chromatography with multiangle light scattering
Size-exclusion chromatography (SEC) was performed using Akta
FPLC chromatography equipment (GE Healthcare) on a Superdex 200
10/300 GL column. The column was previously calibrated for
molecular mass using a Gel Filtration High Molecular Weight
calibration kit (GE Healthcare) constituted by ovalbumin (44 kDa),
conalbumin (75 kDa) and aldolase (158 kDa). Before each run, the
column was equilibrated with at least two column volumes of elution
buffer and each run was performed at both 4 °C and room
temperature (20–23 °C). The elution buffer was Tris–HCl 20 mM pH
7.4, NaCl 100 mM (buffer A) and, in a few cases, Na-phosphate 20 mM
pH 7.0, KF 150 mM (buffer B).
The eluent ﬂow was 0.5 mL min−1. Only freshly prepared or
recently defrosted proteins were loaded on the column because
storage at 4 °C for more than one week led to sample aging. A total of
0.1÷0.2 mg of proteins were loaded. At room temperature, the
elution proﬁle was monitored at three UV absorption wavelengths
(280 nm, 215 nm and 258 nm). At 4 °C, UV absorption was measured
only at 280 nm. The chromatograms were deconvoluted by Unicorn
software, supplied with the FPLC device, to calculate the percentage of
single species. All chromatograms were normalized in the (0.0÷1.2)
range.
At roomtemperature, size-exclusionchromatographywithmultiangle
light scattering (MALS) experiments was carried out with the AKTA
systemcoupled toa three-angle (45°, 90° and135°)WyattMinidownEOS
light scattering instrument linked to a Wyatt Optilab refractometer
(Wyatt Technology Corp., Santa Barbara, CA). These experiments served
to determine the sizes of oligomers of wild-type and mutant PAH.
Molecular masses, polydispersity and root mean square radius
calculations were made by ASTRA software, which is supplied with
the light scattering device, using a dn/dc value of 0.185 mL g−1.
2.7. Circular dichroism
Circulardichroism(CD) analysiswasperformedoncommercialMBP,
on the fused wild-type MBP-PAH tetrameric sample and on the most
abundant species of cleaved PAH proteins after SEC puriﬁcation. In the
case of the cleaved wild-type PAH, CD experiments were performed
with both the tetrameric form and the whole equilibrium mixture. A
2-day dialysis at 4 °C against Tris–HCl 20 mM pH 7.4 (buffer C) was
conducted to eliminate NaCl before CDexperiments. All CD spectrawere
recorded with a Jasco J-810 spectropolarimeter equipped with a Peltier
temperature control system(model PTC-423-S). The spectropolarimeter
was calibrated with an aqueous solution of D-10-(+)-camphorsulfonic
acid at 290 nm. The molar ellipticity per mean residue, [θ] in deg cm2
dmol−1, was calculated from the equation [θ]=[θ]obs mrw (10 l C)−1,
where [θ]obs is the ellipticity measured in degrees, mrw is the mean
residue molecular weight (111.5 Da), C is the protein concentration in
Table 1
The seven mutant forms of PAH reproduced in vitro as recombinant products and analyzed. The primer pairs used to produce the pMAL Xa Ek PAH plasmid.
Mutant forms of PAH Mutagenic primers (forward) Mutagenic primers (reverse)
Ek site 5′GATGACGATGACAAGTCTACTGCGGTCCTGG3′ 5′GCCCTAACTCCCTTCCCTACTGCTACTGTTC3′
p.I65M 5′ACCTGACCCACATGGAATCTAGACCTTCTC3′ 5′GAGAAGGTCTAGATTCCATGTGGGTCAGGT3′
p.N223Y 5′CATGAAGATTACATTCCCCAGCTGGAAGAC3′ 5′GTCTTCCAGCTGGGGAATGTAATCTTCATG3′
p.R297L 5′TGTTTTCAGATCTCAGCTTTGCCCAGTTTT3′ 5′AAAACTGGGCAAAGCTGAGATCTGAAAACA3′
p.F382L 5′ACTGTCACGGAGTTGCAGCCCCTGTATTAC3′ 5′GTAATACAGGGGCTGCAACTCCGTGACAGT3′
p.K398N 5′GCCAAGGAGAACGTAAGGAACTTTGCTGCC3′ 5′GGCAGCAAAGTTCCTTACGTTCTCCTTGGC3′
p.A403V 5′GAAAGTAAGGAACTTTGTTGCCACAA3′ 5′CCGAGGTATTGTGGCAACAAAGTTCC3′
p.Q419R 5′ATACACCCGAAGGATTGAGG3′ 5′CCTCAATCCTTCGGGTGTAT3′
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g mL−1, and l is the optical path length of the cell in cm. Far-UV
(ultraviolet) measurements (190–260 nm) were carried out at 20 °C
using a 0.2 cmoptical path length cell and a protein concentration in the
range 0.10–0.15 mg mL−1. CD spectra, recordedwith a time constant of
4 s, a 1-nm bandwidth, and a scan rate of 20 nmmin−1, were signal
averaged over at least three scans. The baseline was corrected by
subtracting the buffer spectrum. Thermal denaturation curves were
recorded over the 20–80 °C temperature range and by monitoring the
CD signal at 222 nm.After preliminary trialswithin the scan rate interval
of 0.5÷2.0 °C min−1, all curves were recorded using a 0.2-cm path
length cell and a scan rate of 1.0 °C min−1. Irreversibility of the
denaturation was veriﬁed by recording, after cooling to 20 °C, the
spectra of samples subjected toaﬁrst temperature scan.All denaturation
curves were normalized in an interval of 0.0÷1.0. The Tm values were
determined from the ﬁrst derivatives of the denaturation curves after
noise reduction by using the standard analysis program provided with
the instrument.
2.8. Cell culture
HeLa cellswere grown inD-MEMhigh glucosemedium (Invitrogen)
containing 10% heat inactivated fetal bovine serum (Invitrogen), 1%
penicillin/streptomycin, at 37 °C in 5% CO2. Transfections of both wild-
typePAHand thep.A403Vmutantwere carriedout using theProFection
Mammalian Transfection System (Promega, WI, USA) in accordance
with the manufacturer's protocol. Cells were plated on 35-mm glass
bottom dishes (MatTek, MA) for imaging.
2.9. Confocal microscopy and number and brightness analysis
Constructs containing GFP-PAH fusion proteins were transfected
in HeLa cells and experiments were started 18 h after transfection. To
evaluate BH4 responsiveness, transfected cells were treated with
60 μM BH4 in aqueous solution. Analyses were performed 6 h later.
Number and brightness (N&B) analysis was performed according to
Gratton and colleagues [37,38] using a Zeiss LSM 510 META confocal
microscope. Cells grown for 4 days on bottom glass dishes were
imaged in vivo in CO2-independent medium (150 mM NaCl, 5 mM
KCl, 1 mM CaCl2, 1 mMMgCl2, and 20 mM Hepes, pH 7.4). Fifty frame
time series were acquired with a LSM 510META equipped with a plan
apo 63× oil-immersion (NA 1.4) objective lens using the following
settings: 488 nm Argon laser, 25% of output power, 1.5% transmission,
505–550 nm emission, gain equal to 850, offset 0.1, and digital gain 1.
Scanning parameters were: 512×512 frame window, 25.61 μs/pixel
dwell time, no average, zoom 6×, ROI (x,y) 256×64, and pinhole
corresponding to 1 μmoptical slice. Data from each cell were analyzed
with the simFCS software (Globals Software, East Villa Grove, IL
61956, USA). Brieﬂy, data analysis was performed pixel-by-pixel over
time to calculate variance and average intensity. Correction was
applied to take into account the analog detection of ﬂuorescence by
the photomultiplier tubes of the confocal microscope. Brieﬂy, the
correction parameters S, offset and sigma0 were determined, for each
experiment, by plotting the measured average intensity (bIN) vs
average variance (bVarN) of 50 frame time series acquired using same
settings as above, but setting 4 different values of laser transmission
percentages. Moreover, ﬁlters and beam splitters were conﬁgured to
obtain reﬂection images to detect the deﬁned amount of light
originating directly from the laser. The obtained plots were linearly
interpolated and the equation of straight line (R≥0.99) was used to
extract the parameters S and offset based on the following equation:
bVarN=S∗b IN+offset∗S. The parameter sigma0 was estimated from
time-series acquired with laser off, as the half maximum width of the
histogram peak of the “dark”-counts. Its value was constantly lower
than 0.1, and consequently was approximated to zero in all the
calculations. Brightness (B) was calculated pixel by pixel from the
following equation B=V(x,y)/(S∗ Ix,y), where I = Im-offset (Im:
measured average ﬂuorescence).
The number of molecule subunits constituting each oligomer was
calculated with the following calibration procedure: the brightness of
monomeric GFP and of GFP-based molecules made by two or three GFP
moieties fused in tandeminexpressionvectorpcDNA3.1andexpressed in
HeLa cellsweremeasuredwith the same experimental settings described
above. The measured B values for monomeric, dimeric and trimeric GFP
and the corresponding number of subunits were linearly interpolated to
obtain the experimental equation describing the dependence of
brightness on thenumberofGFP subunits: B=k×nsub+c. This equation
was used to calculate the unknown number of GFP subunits correspond-
ing to the measured brightness. The following formula B=sum (Bi2 ni)/
sum(Bi ni) provides the brightness ofmultiple species (Bi)whose number
is ni in a single pixel, is combined in the measured brightness (B). This
formula is used to interpret non integer subunit values obtained by the
above procedure.
2.10. Structural analysis
The effect of themutations on the 3D structure was investigated by
analyzing the structural environment of each substituted residue in
the PAH crystal structures deposited in the Protein Data Bank (PDB).
Since no crystal structure of any full-length enzyme is available,
various models were used: tetrameric human PAH lacking residues
1–117 (pdbcode 2pah); dimeric truncated human PAH lacking
residues 1–117 and 425–452 (PDB code 1kw0); and the dimeric rat
PAH, from residue 19 to 427 (pdbcode 1phz), which encompasses the
regulatory domain. A composite monomeric model that included the
three domains was built by superimposing the secondary structure
elements of the respective catalytic domains of the rat (1phz) and
human structures (2pah and 1kw0). The structural superposition was
performed using the program O [39].
3. Results
3.1. Enzymatic activity analysis of wild-type and mutant forms of PAH
Wemeasured the enzymatic activity of the equilibriummixture of
the wild-type and mutant forms of PAH to investigate the effect of the
mutations on catalytic activity. As shown in Fig. 2, the residual
activities of the mutant PAH enzymes, expressed as a percentage
of wild-type enzyme activity, were: 38±3% (p.I65M), 48±14%
(p.N223Y), 60±12% (p.R297L), 69±11% (p.F382L), 58±9%
(p.K398N), 43±4% (p.A403V) and 63±5% (p.Q419R). In our
conditions, we found in multiple experiments that isolated oligomeric
species are not stable and evolve toward the equilibriummixture (see
Fig. 2. Enzymatic activity of the PAHmutants expressed as percentage of wild-type PAH
activity. The activity was measured by the amount of [14C] Tyr produced by [14C] Phe as
analyzed by thin layer chromatography. Mean values and the standard deviation
derived from three sets of independent experiments for each construct are shown
expressed as percentage of wild-type PAH activity. The experimental assay conditions
are reported in Section 2.4.
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also below under Section 3.2); hence the activity of the isolated
tetramers and dimers was not possible to be measured with accuracy.
3.2. Oligomerization equilibrium of wild-type and mutant forms of PAH
The oligomerization equilibrium for the fused MBP-PAH protein,
the puriﬁed cleaved wild-type protein, and the missense mutants was
analyzed by SEC (Fig. 3a,b). SEC runs were carried out at both 4 °C and
room temperature. The elution proﬁle was essentially the same at
both temperatures, therefore only the data at room temperature are
reported. Unless speciﬁed otherwise, SEC measurements were carried
at a constant pH of 7.4 (buffer A). The SEC proﬁles revealed that wild-
type and most of the mutant forms of PAH elute as tetramers and
dimers although monomers and aggregates are also present,
depending on the mutation of the protein. Fig. 3a shows the SEC
proﬁles of proteins in which the tetramer is the most abundant
species, i.e., the fused protein, the cleaved wild-type PAH and mutant
p.R297L. Fig. 3b shows the proﬁles of the wild-type PAH (as reference)
and of mutants p.I65M, p.N223Y, p.F382L, p.K398N, p.A403V and
p.Q419R in which dimer is the dominant species. The peaks
corresponding to tetramer, dimer and monomer species elute at
11.5 mL, 13.1 mL and 14.7 mL respectively (Fig. 3a,b).
The presence of the PAH protein was conﬁrmed in each of the
fractions obtained by SEC (Fig. 3a) after separation by SDS/PAGE and
Western blot analysis using anti-PAH serum (Fig. 3c). This result
demonstrates the existence of a monomeric form of the PAH enzyme.
This formwas probably underestimated in previous studies because it
was masked by MBP. Western blot analysis also showed that samples
did not contain MBP after cleavage (Fig. 3c).
The percentage of PAH oligomeric species is reported in Fig. 4 (see
also Supplementary Table S1). The tetramer and dimer species of the
wild-type PAH were separately collected and stored for less than one
week at 4 °C. Subsequently, SEC analysis of tetramers and dimers
showed that the tetramer shifts back toward the dimer and the
monomer, while the dimer is fairly stable, since about 90% of the
protein applied was recovered in the dimeric form (data not shown),
according to literature data [21].
All chromatographic runs were done in conjunction with MALS.
The masses resulting from MALS measurements in wild-type PAH
mutants were 203 kDa (within 1%) and 102 kDa (within 3%) for
tetramer species and dimer species, respectively. Because of the small
quantities of monomer, we were not able to calculate its molecular
mass. A representative proﬁle of wild-type PAH obtained from MALS
is shown in Fig. 5.
Fig. 3. Chromatographic proﬁles of the PAH natural variants and immunoblotting of wild-type PAH. a) Size exclusion chromatographic (SEC) runs carried out in buffer A (see text)
and normalized in the 0.0÷1.2 interval. All curves are shifted along the ordinate axis by 0.05n, n integer (1≤n≤5), with respect to the wild-type PAH curve. b) SEC runs of wild-type
and other mutant recombinant PAH proteins. All curves are shifted along the ordinate axis by 0.05n, n integer (1≤n≤5), with respect to the wild-type PAH curve, to better visualize
the single curves. c)Western blot analysis using the anti-PAH antibody of each of the fractions in panel a obtained fromwild-type (depicted as a black curve in a); peak A) aggregated
forms, possibly multimeric; peak T) tetramer; peak D) dimer; peak M) monomer. Western blot analysis of the wild-type PAH monomer (peak M of panel a) with anti-PAH or anti-
MBP antibodies.
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3.3. Thermal stability and inactivation
The dominant oligomeric species of wild-type PAH and mutants,
collected after gel ﬁltration and dialyzed against buffer C, were
analyzed by CD. The CD spectra of all samples were recorded in the
far-UV region (190–250 nm), in buffer C, pH 7.4, at 20 °C. Fig. 6a
shows the normalized spectra for wild-type PAH and selected
mutants, together with the spectrum for the fused wild-type MBP-
PAH. In the spectra of Fig. 6a, the maximum centered at 195 nm and
the two broad minima centered at 208 and 222 nm are indicative of
the presence of both α and β secondary structure elements. The
spectra proﬁles do not differ signiﬁcantly from each other, but the
molar ellipticity of all the mutants is much lower than that of wild-
type enzyme. Therefore, these spectra provide evidence for local
unfolding of the mutants.
We also recorded the thermal denaturation curves in the
20÷80 °C temperature range by monitoring the molar ellipticity at
222 nm (Fig. 6b) of the most abundant oligomeric species of cleaved
PAH proteins (Figs. 3a,b; 4, Supplementary Table S1). The far-UV CD
spectra of denatured species of all samples at 80 °C are typical of
random coil (data not shown). The spectrum of cooled samples after
denaturation is virtually identical to that of the denatured protein at
80 °C (data not shown), thereby conﬁrming the irreversibility of the
unfolding process, as previously reported [24,40]. In the case of the
wild-type PAH, the denaturation curve of the equilibriummixturewas
also recorded; for comparison purposes, this curve and that of the
tetramer are shown in Fig. 6c. It is clear that the denaturation process
depends on the oligomeric species.
The sigmoidal denaturation curve obtained with the fused wild-
type MBP-PAH protein shows two inﬂection points, with a plateau,
corresponding to the two melting temperatures of the two proteins.
Visual inspection of the denaturation curves (Fig. 6b) of the cleaved
PAH proteins shows a sigmoidal shape with a single inﬂection point.
Differently, a detailed analysis of the curves through the ﬁrst
derivatives, revealed two midpoints corresponding to two transitions
(data not shown), according to literature data [40]. As shown in
Table 2, the melting temperatures of the PAH proteins range from 33
to 57 °C. The thermal denaturation curve of mutant p.F382L is
signiﬁcantly shifted to lower temperatures with respect to the wild-
type PAH (Fig. 6b). Therefore, we carried out the thermal inactivation
assay of the wild-type PAH and the p.F382L mutant at temperatures
between 32 and 58 °C (Fig. 6d). Consistently, the p.F382L mutant was
much more temperature sensitive than the wild-type enzyme. In fact,
under these conditions a lower amount of Tyr was produced (Fig. 6d),
and the half-inactivation temperature was close to 44 °C, which well
agrees with the value of Tm2=43.6 °C obtained by CD. These ﬁndings
show that the stability of speciﬁc mutants, such as p.F382L, can
markedly diverge from that of the wild-type protein.
3.4. N&B analysis
Confocal microscopy observation of cells expressing GFP-wild-
type PAH and GFP-A403V fusion proteins revealed a cytoplasmic
localization of PAH and its mutant p.A403V, as expected (Fig. 7a,b). No
ﬂuorescence was detected in the cell nuclei. To estimate the number
of subunits constituting wild-type PAH and the p.A403V mutant at
steady state in live cells, the recently developed N&B technique was
performed on cells expressing the fusion proteins treated and not
with BH4 for 6 h. The “brightness” of the GFP-wild-type PAH fusion
protein was 1.091 and 1.099 upon BH4 treatment, which, at the t-test,
was not signiﬁcantly different from values obtained without BH4
treatment. On the contrary, in cells expressing the GFP-A403V fusion
protein there was a statistically signiﬁcant (pb0.001) shift of
brightness from 1.047 without BH4 to 1.094 upon its addition.
Fig. 4. Percentage of the molecular species of the recombinant wild-type PAH protein and its mutants. The histograms indicate a) the percentage of tetramers and dimers, and b) the
percentage of aggregate and monomers of recombinant wild-type PAH, MBP-PAH, p.I65M, p.N223Y, p.R297L, p.F382L, p.K398N, p.A403V and p.Q419R. All data with standard
deviations were calculated on at least triplicate runs carried out at 20 °C.
Fig. 5. SEC-MALS analysis of wild-type PAH. Representative proﬁle of wild-type PAH
obtained from light scattering and refractive index detectors. The molecular mass is
shown. The experimental data are represented by squares and the ﬁtting of
experimental data is shown by a red line.
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These brightness values were used to calculate the number of
subunits that constitute each PAH oligomer at steady state, namely
wild-type and p.A403V before and after BH4 administration (see
Material andmethods for details). Brieﬂy, a calibration curve (number
of subunits vs brightness) was constructed using reference GFP-based
molecules constituted by 1, 2 or 3 GFPmonomers andmeasuring their
brightness in the same experimental conditions used above. The
reference curve obtained (which was perfectly linear) was used to
extrapolate the unknown number of subunits from the brightness of
GFP-PAHs. The wild-type PAH conserved an average number of
subunits (see Material andmethods for deﬁnition of “average number
of subunits”) equal to approximately 3.1, which reﬂects the presence
of tetramers and dimers in equilibrium. The addition of BH4 did not
affect this number. Differently, exposure of the A403V-PAH mutant
form to BH4 caused the subunit number to increase from 2.4 to 3.1,
this latter being the same as that of the wild-type enzyme (Fig. 7c).
4. Discussion
4.1. The oligomerization equilibrium is shifted toward the dimeric form
in PAH mutants
To characterize the oligomeric state of PAH in solution, we
performed SEC with on-line detection of LS and refractive index
signals. This approach allowed us to measure the molecular mass of
Fig. 6. CDmeasurements. a) Far-UV spectra recorded in buffer C (see text) at 20 °C. b) CD-monitored thermal unfolding curves in the 25–80 °C temperature range. The change of the
molar ellipticity at 222 nm was monitored versus the temperature. The most abundant oligomeric form was considered for each PAH protein. c) Thermal denaturation of the
tetrameric form and of the equilibrium mixture of cleaved wild-type PAH. d) Thermal inactivation assay of wild-type and F382L PAH. Proteins were incubated at increasing
temperatures and the amount of produced tyrosine was determined.
Table 2
Melting temperatures inferred by ﬁrst derivative of unfolding curves.a
Forms of PAH Tm1±1.0 (°C) Tm2±1.0 (°C)
Wild-type PAH 52.2 57.6
MBP-PAH 52.0 57.5
p. I65M 53.0 59.2
p.N223Y 54.2 57.6
p.R297L 50.8 59.0
p.F382L 32.6 43.6
p.K398N 46.4 53.6
p.A403V 46.0 55.6
p.Q419R 50.1 57.3
All experiments were conducted in buffer C (see Material and methods).
a See also Fig. 6b.
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the eluted peaks independently of their shape and/or amino acid
composition and elution volume. The operative conditions used in the
SEC experiments were the same for all samples. No substrate, cofactor
or any other compound was added and only a buffer at physiological
pH (buffer A; pH 7.4) was used because a lower pH and the addition of
L-Phe can affect the oligomeric equilibrium [10].
In line with previous data [10,21,24], the SEC proﬁle of the fused
wild-type MBP-PAH protein revealed that tetramer was the dominant
species (88.4%), whereas the dimeric form was less abundant and the
monomeric form was absent. Differently, all three species were
obtained in the cleaved full-length wild-type enzyme (see Fig. 4 and
Supplementary Table S1 for the relative percentages). The observation
of three distinct peaks demonstrates that self-association of mono-
mers or dimers is slow on the time scale of separation. Previous
studies showed that both fused and truncated/cleaved forms of wild-
type and mutant enzymes consist of an equilibrium mixture of
dimeric and tetrameric species in a ratio that depends on the protein
nature and on the experimental conditions used [10,24].
Only in a few cases in which proteins were expressed in a coupled
in vitro transcription–translation eukaryotic system [41,42] was the
monomeric form also detected. Here, we report evidence that a
monomer species occurs in the equilibriummixture of PAH albeit in a
low amount. The presence of a monomer species may have been
underestimated in previous studies for several reasons: i) because of
its low abundance, ii) because the fused protein was analyzed [24] or
iii) because the cleaved wild-type PAH was analyzed in the presence
of MBP which co-elutes with the PAH monomer [10]. Western blot
analysis (Fig. 3c) and re-chromatography of the isolated tetramer of
wild-type PAH, which regenerate the dimer and the monomer peak
(data not shown), indicate that the monomer contributes to the
equilibriummixture. The equilibriummixture of the PAH enzyme can
be described as follows: 4M⇆2D⇆T.
The oligomerization process of the mutants is clearly disturbed by
the mutation, except in the case of mutant p.R297L that has a SEC
proﬁle similar to that of the wild-type enzyme although it lacks a
monomer (Fig. 3a). For all the other mutants (p.I65M, p.N223Y,
p.F382L, p.K398N, p.A403V and p.Q419R), the equilibriumwas shifted
toward the dimeric enzyme (Fig. 3b). In any event, all mutants present
a reduced activity of the enzyme because of the diverse composition
of the equilibriummixture. This conﬁrms that oligomerization defects
of PAH variants are one of the most common causes of HPAs.
4.2. Thermal stability and defect at the secondary structure level of
PAH mutants
The CD spectrum of wild-type PAH is characterized by typical
ﬁngerprints of α/β proteins (Fig. 6a), in line with the known 3D
structure [43]. Despite the similarity of CD spectra proﬁles in thewild-
type and mutant forms of PAH, the latter present a partial loss of
secondary structure with respect the wild-type folded structure, their
molar ellipticity being signiﬁcantly decreased (Fig. 6a). This loss
occurs for all the mutants except for mutant p.R297L in which the loss
is less pronounced. Therefore, the CD spectra have provided evidence
for a folding defect at secondary structure level. To characterize
further all the PAHmutants, we estimated the α-helical content using
the equation of Richardson and Makhatadze [44]. The calculations
showed a progressive decrease of the α-helical content of the PAH
mutants (see Supplementary Table S2).
Thermal denaturation of all the PAH proteins proved to be an
irreversible process as previously reported [40]. Therefore, the
thermodynamic features of the enzyme cannot be further character-
ized. As expected for the wild-type MBP-PAH fused protein, the two
steps in the sigmoidal curve correspond to two independent
unfolding processes for the two proteins. Indeed, the two melting
Fig. 7. N&B analysis. a) Confocal microscopy images of cells expressing GFP-wild-type PAH protein and b) GFP-p.A403V mutant protein. c) Histograms showing the oligomeric state
of both GFP-wild-type PAH and GFP-p.A403V mutant in untreated (blue bars) and BH4-treated (red bars) cells. Asterisks above the bars indicate statistical signiﬁcance for the
p.A403V mutant protein.
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temperatures (Table 2) correspond to the independent structural
collapse of PAH (52.0 °C) and MBP (57.5 °C), respectively (see also
Supplementary data for details).
Earlier differential scanning calorimetry, ﬂuorescence and CD
experiments indicated that, upon heating, two partially overlapping
transitions occur with an apparent melting temperature Tm1 of about
46 °C and a Tm2 of about 54 °C, respectively [14,40]. Apart from rare
exceptions, two transitions were identiﬁed also in the mutants. Their
melting temperatures diverged from that of wild-type PAH within a
range from −6 to +2 °C [24,45]. On the other hand, unfolding
experiments conducted on the truncated PAH (aa 112–452) revealed
only one cooperative transition centered at about 54 °C [40].
Therefore, the ﬁrst transition was interpreted as a denaturation of the
N-terminal regulatory domain and the second, partially overlapping
transition as a denaturation of the catalytic-tetramerization domain
[40].
Unfolding experiments were carried out for wild-type PAH and
mutants in buffer C and the ellipticity at 222 nm was monitored as a
function of temperature. Two overlapping transitions occurred for the
wild-type PAH and all the mutants. For the wild-type PAH, the Tm1
and Tm2 were 52.2 °C and 57.6 °C, slightly different from previous
reports [24,40,45]. This discrepancy is due to the species studied. If the
denaturation process is followed using only the PAH tetramer, as in
our case, the melting temperatures are Tm1=52.2 °C and
Tm2=57.6 °C. On the other hand, if all the species present in the
oligomerization equilibrium are considered, the Tm1 well agrees with
that reported previously (Tm1=46.1 °C) (Fig. 6c) [24,40,45]. To verify
that the unfolding process depends only on the oligomerization
equilibrium, we carried out unfolding experiments in the same buffer
and scan-rate conditions used in previous studies (buffer B, scan-rate
0.7 °C/min) [40,45], and obtained a Tm1 and Tm2 of 52.0 °C and 54.8 °C,
respectively. Indeed, a small destabilization has been reported for
most of the previously described mutants, as shown by a decrease in
ΔTm of about a couple of degrees. There are only a few instances
where ΔTm decreases down to ~6 °C [45]. For example, Tm1 and Tm2
decreased by as much as 42.6 °C and 52.0 °C and 40.7 °C and 50.2 °C,
respectively in the non-natural mutants p.N223D and p.T427P with
respect to wild-type enzyme Tm1 and Tm2 [45].
Themelting temperatures of mutants p.I65M and p.N223Y indicate
a very marginal stability gain, being only a couple of degrees higher
with respect to the wild-type enzyme (Table 2). Furthermore, the
denaturation curves of p.R297L and p.Q419R are similar, and the
denaturation slopes differ only slightly from that of the wild-type
enzyme, which indicates that the thermal stability is hardly affected.
Formutants p.K398N and p.A403V, however, the Tm1 is about 6° lower
and the Tm2 about 2–3° lower with respect to the wild-type, thereby
indicating a loss of stability. Interestingly, the Tm1 (33.0 °C) and Tm2
(43.6 °C) of mutant p.F382L are about 20 °C and 14 °C lower with
respect to those of the wild-type enzyme, which indicates that this
enzyme variant has a high thermal structural instability.
The results of thermal denaturation experiments of the p.F382L
mutant suggest that the replacement of L-Phe by L-Leu at position 382
leads to temperature-dependent functional alterations. These results
were conﬁrmed by the thermal inactivation assay performed on the
p.F382L mutant and, for comparison, on the wild-type PAH. Indeed,
the half-inactivation temperature obtained for this mutant (~44 °C)
well agrees with the Tm2 of 43.6 °C obtained by CD (Fig. 6b and d,
Table 2).
4.3. Mapping the mutations to search for structural alterations
For the present study, we built a composite model of the full-
length human enzyme and used it as a template for structural analysis
of the wild-type and mutant proteins. Mutations p.I65M and p.Q419R
fall in the regulatory and tetramerization domain, respectively;
mutations p.N223Y, p.R297L, p.F382L, p.K398N and p.A403V fall in
the large catalytic domain. All mutations are far from the active and
cofactor binding sites. All, except mutations at positions 65 and 403,
are located on the surface of the molecule in hydrated regions. In
Fig. 1, the position of the seven mutations is drawn on the monomer
structure. There are four previously identiﬁed variants at codon 65
(p.I65T, p.I65V, p.I65N, and p.I65S). The PAH database contains in
vitro expression data only for p.I65T, namely, increased proteolytic
degradation in pulse-chase experiments, increased aggregation and
decreased solubility. The residual activity of the I65T/V mutants,
tested in different in vitro systems, was about 21–29% (http://www.
pahdb.mcgill.ca).
Ile65 is located in a hydrophobic environment of the regulatory
domain. In the mutant enzyme p.I65M, the Ile change to a somewhat
larger but differently shaped Met may distort the hydrophobic
packing of the region [30]. In addition, Ile 65 makes a favorable
interaction with the catalytic domain of another subunit within the
dimer (the Ile65 oxygen atom is hydrogen-bonded to the hydroxyl
group of Tyr 216). As a result, both the tertiary structure and the
quaternary structure are perturbed. These data are in line with the
dimer abundance (Fig. 4 and Supplementary Table S1).
Asn223 is located in a solvent exposed loop [46]. In mutant
p.N223Y the structural perturbation is mainly due to tyrosine solvent
exposure that may affect the function. It has been proposed that this
residue is embodied in an intra-domain hinge bending region [45]
that is involved in the conformational transition induced by substrate
binding. Overall, its properties are similar to those of the wild-type
enzyme, except that the dimeric form is favored over the tetramer.
Mutant p.R297L exhibits properties very similar to those of the wild-
type enzyme. Interestingly, two other mutants reported in the
database, i.e., p.R297C and p.R297H, which are also associated with
a mild phenotype, indicate that mutations at this site are not critical
[32].
Mutant p.F382L is the one that differs most from the wild-type
enzyme. It occurs prevalently as a dimer (88.3%). Moreover, the
mutation falls in a region rich in aromatic residues. L-Phe forms
various stacking aromatic interactions with the aromatic residues
Tyr356 and Tyr277 in the wild-type enzyme [33]. The replacement by
Leu, despite the hydrophobic nature of this residue, breaks the
aromatic network and results in marked destabilization. This is in line
with larger ΔTm1 (19.6 °C) and ΔTm2 (14.0 °C) and with a lower
inactivation temperature compared to the wild-type protein (Fig. 6d).
This is the largest difference observed so far for a PAH mutant. This
highlights that L-Phe in position 382 is crucial for the stability of this
aromatic amino acid-rich region.
Lys398 is located at the tetramer interface, although it is not
directly engaged in intersubunit interactions. The positively charged
Lys is embedded in a negatively charged environment because of the
presence of Asp394 and Glu390 [43]. The high dimer/tetramer ratio
observed for mutant pK398N (75.0/17.2, Fig. 4 and Supplementary
Table S1) is in line with tetramer destabilization. Also the structural
stability was decreased. In fact, Tm1 and Tm2 were lower than that of
the wild-type enzyme being 5.6 and 4.0 °C, respectively (Table 2).
Q419 lies in a hydrated region at the dimer/tetramer interface. The
substitution of Gln by an Arg generates unfavorable ionic interactions
with a nearby Arg241 that destabilize the tetramer. The thermal
stability of p.Q419R is not signiﬁcantly affected by the mutation.
4.4. BH4 effect and the dimer–tetramer p.A403V equilibrium
In this study, we investigated the effect of BH4 on p.A403V that, in
our geographic area, is the most frequent mutant in mild, BH4-
responsive patients [32,33]. To this aim, we used the N&B technique
that has been successfully employed to discern minor changes in
molecular composition [37,38]. We monitored the ﬂuorescent
molecular forms of GFP-wild-type PAH and the GFP-A403V mutant
after transient transfection of HeLa cells. The addition of BH4 to the
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wild-type enzyme did not cause any change. Differently, BH4 addition
to cells expressing the p.A403Vmutant promoted a shift from dimeric
to tetrameric molecular forms.
The BH4 responsiveness in HPA has been the subject of numerous
studies. Various mechanisms have been proposed to explain BH4-
responsiveness, namely: increased enzyme activity [1,30,47,48],
correction or compensation of the BH4 decreased afﬁnity, protection
toward catalytic inactivation and chaperone-like activity that, by
stabilizing the protein, protects it from proteolytic degradation
[1,15,30]. In addition, BH4 supplementation may restore the optimal
concentration of BH4 cofactor in hepatocytes [28,46]. In our study, the
N&B technique revealed that the addition of BH4 to HeLa living cells
inﬂuences the oligomerization equilibrium of the p.A403V mutant by
shifting it toward a tetrameric quaternary structure.
4.5. Concluding remarks
About 600 mutations associated with the PKU/HPA phenotype
have been identiﬁed in the PAH gene. The resulting phenotypes range
frommild to severe HPA. This study demonstrates that our seven gene
variants reduce the enzymatic activity to 38–69% of that of wild-type
activity and affect the oligomerization state, thermal stability and
folding of PAH protein. Perturbation of these biophysical and
biochemical features may, therefore, be considered major disease-
causing alterations, also in mild phenotypic forms of HPAs. In addition
to the well recognized effect of BH4 on the stability of PAH mutants
[30], we provide the ﬁrst evidence, obtained with the N&B technique,
that in cellulo exposure to BH4 inﬂuences the oligomerization
equilibrium of the p.A403V mutant. Therefore, we surmise that, in
this case, a shift from dimer to tetramer plays a major role in BH4
responsiveness.
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Abstract
Type 2 Maturity Onset Diabetes of the Young (MODY2) is a monogenic autosomal disease characterized by a primary defect
in insulin secretion and hyperglycemia. It results from GCK gene mutations that impair enzyme activity. Between 2006 and
2010, we investigated GCK mutations in 66 diabetic children from southern Italy with suspected MODY2. Denaturing High
Performance Liquid Chromatography (DHPLC) and sequence analysis revealed 19 GCK mutations in 28 children, six of which
were novel: p.Glu40Asp, p.Val154Leu, p.Arg447Glyfs, p.Lys458_Cys461del, p.Glu395_Arg397del and c.580-2A.T. We
evaluated the effect of these 19 mutations using bioinformatic tools such as Polymorphism Phenotyping (Polyphen), Sorting
Intolerant From Tolerant (SIFT) and in silico modelling. We also conducted a functional study to evaluate the pathogenic
significance of seven mutations that are among the most severe mutations found in our population, and have never been
characterized: p.Glu70Asp, p.His137Asp, p.Phe150Tyr, p.Val154Leu, p.Gly162Asp, p.Arg303Trp and p.Arg392Ser. These seven
mutations, by altering one or more kinetic parameters, reduced enzyme catalytic activity by .40%. All mutations except
p.Glu70Asp displayed thermal-instability, indeed .50% of enzyme activity was lost at 50uC/30 min. Thus, these seven
mutations play a pathogenic role in MODY2 insurgence. In conclusion, this report revealed six novel GCK mutations and
sheds some light on the structure-function relationship of human GCK mutations and MODY2.
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Introduction
Maturity Onset Diabetes of the Young (MODY), a monogenic
diabetes inherited in an autosomal dominant mode, accounts for
1–2% of all diabetes forms in Europe [1,2]. It is a clinically
heterogeneous group of diseases caused by at least eight gene
defects in the pancreatic b-cell that impair insulin secretion [3].
MODY is characterized by onset before 25 years of age; patients
usually lack auto-antibodies, and clinical manifestations go from
slight non-ketotic hyperglycemia to severe complicated hypergly-
cemia [4]. Heterozygous mutations in the glucokinase (GCK) gene
produce two distinct diseases, MODY type 2 (MODY2)
(MIM:125851) and persistent hyperinsulinemia of infancy
(MIM:601820) [5,6]. Persistent hyperinsulinemia of infancy is
associated with hyperactive GCK variants, while MODY2 is
associated with GCK mutations that impair its activity [7]. GCK
(hexokinase IV) catalyzes the ATP-dependent phosphorylation of
glucose in the first, rate-limiting step of glycolysis in pancreatic b-
cells [1]. The crystal structure determination of the enzyme by
Kamata et al. [8] revealed that the enzyme exists in at least two
distinct forms, the super-open ligand-free form and the closed
active form that is bound to glucose and ATP. The molecule
consists of two domains, namely a small and large domain
separated by the glucose site. In detail, amino acid residues 1–64
and 206–439 belong to the large domain, amino acid residues 72–
201 and 445–465 to the small domain, and amino acid residues
65–71, 202–205 and 440–444 to the three loops connecting the
domains [8]. The GCK protein switches from an inactive
conformation to a close active conformation upon ligand binding.
A huge conformational transition occurs through a large rotation
of the small domain [8].
The heterozygous loss-of-function GCK mutations causative of
MODY2 diabetes include missense, nonsense, splicing, small
deletions/insertions/duplications variants, and result in stable
fasting hyperglycemia from birth (.5.5 mol/L) and rare micro-
vascular complications [1]. Over 644 GCK mutations have been
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described, and a study of the mutational mechanisms for a number
of these has shed light on GCK regulation [9].
The molecular diagnosis of MODY2 is important: to classify the
type of diabetes correctly, to predict prognosis, and to initiate
screening of family members [1]. It is particularly important to
identify MODY2 in diabetic pregnant patients in order to start
‘‘ad hoc’’ treatment [10]. However, the identification of GCK
mutations by molecular analysis will not always reveal whether a
variant is really pathogenic or how serious the diabetic phenotype
could be. Therefore, in this five-year study, we applied an
integrated approach to investigate the effect of GCK mutations in
the diabetic phenotype in children from southern Italy. First, we
used DHPLC and mutation sequencing to identify variants, then a
computational approach to predict the effect of the variants
identified, and finally a functional study to determine the effect of
seven candidate variants on enzyme activity and on enzyme
thermo-stability.
Results
Among the 66 enrolled patients with suspected MODY2, 28/66
were diagnosed as MODY2 based on mutations in the GCK gene
(MODY2+) and 38/66 were MODY2-negative (MODY22). All
mutated patients were unrelated, except two pairs of siblings
(patient identification: MD19/20: two sisters and MD69/70:
brother/sister). The mean age at diagnosis (6 Standard Deviation:
SD) was lower, albeit not significantly, in MODY2+ than in
MODY22 patients (105645 months vs 113645 months). Mean
triglyceride levels did not differ between the two groups (0.660.2
and 0.760.3 mmol/L, respectively). Mean Fasting Plasma Glu-
cose (FPG) and glycosylated hemoglobin (HbA1c) concentrations
were significantly higher (p,0.003 and p,0.001, respectively) in
MODY2+ than in MODY22 patients (6.760.8 mmol/L and
6.260.3% vs 6.160.7 mmol/L and 5.560.5%, respectively). The
Body Mass Index zeta-score (BMIz-score) of enrolled children at
first admission was always in the reference range for the children’s
age (reference range: 21.5/+1.5), except in one patient (BMIz-
score: 2.5). Two/28 MODY2+ patients were positive for only one
type-1 diabetes auto antibody (glutamate decarboxylase: 8 and
18 U/mL). The patients were untreated until diagnosis.
Identification of GCK Mutations
We identified 19 different GCK mutations in 28/66 patients
(Table 1). Six of them were novel: two missense mutations
(p.Val154Leu and p.Glu40Asp), one splice site variant (c.580-
2A.T) and three deletions (p.Lys458_Cys461del, p.Arg447Glyfs,
and p.Glu395_Arg397del). We also found 13 previously reported
mutations: 11 missense mutations (p.Arg303Trp, p.Gly261Arg,
p.Phe150Tyr, p.Ala259Thr, p.Glu70Asp, p.Lys420Glu,
p.Ala188Thr, p.Tyr289Cys, p.Asp278Glu, p.Gly223Ser, and
p.Ala449Thr) and two splice site variants (c.864-1G.A and
c.1019+5G.A). All the detected mutations were always present in
the children’s mother or father and were absent from 200
chromosomes of our euglycemic controls. Seven mutations were
each present in two unrelated families: p.Arg303Trp, p.Lys458_-
Cys461del, p.Arg447Glyfs, p.Gly261Arg, p.Phe150Tyr, p.Lys420-
Glu and p.Ala259Thr, the latter was also identified in two siblings.
The splice variant c.580-2A.T was present in two siblings.
Table 1 shows, for each mutation (except the three splice variants
c.864-1G.A, c.580-2A.T and c.1019+5G.A, the frameshift
mutation p.Arg447Glyfs and the p.Lys458_Cys461del), the
nucleotide position, the amino acid change (if present), the effect
on the protein predicted by bioinformatics.
Bioinformatics Study of the GCK Variants
All substitutions, except p.Val154Leu and p.Glu40Asp, were
predicted to be deleterious mutations by online prediction tools
(Table 1, column 4). Overall, the theoretical structural models of
the mutants we obtained in silico (Table 1, column 5), preserve the
overall protein fold. In detail, however, all mutations produced
local conformational alterations 2 in some cases, such as
p.Gly162Asp, dramatic perturbations – that well account for the
functional alterations we found (Table 2). p.Arg303Trp-Arg303
is a highly conserved residue located in the a8 helix within the
large domain. Mutation p.Arg303Trp disrupts two salt-bridges
between the side chain of Arg303 and the side chain of Glu300,
located in the same helix. These salt-bridges may be essential for
the stability of the helix and their loss could destabilize the helix
structure. p.Val154Leu-The p.Val154Leu mutation (Figure 1)
does not cause any significant change in the local structure.
Indeed, Val154 is located in the b-sheet that encompasses the
small domain hydrophobic core. Its substitution with a leucine
residue does not affect the hydrophobic interactions. Nevertheless,
Val154 is involved in the large conformational variation from the
super-open to close form upon glucose binding (Figure 1A).
p.Gly261Arg-Gly261 is located in the loop connecting the b-
sheet and the a6 helix in the large domain. p.Gly261Arg is a
dramatic mutation because the small, flexible hydrophobic Gly
residue is replaced by a very large Arg residue that bears a positive
net charge. This substitution causes a local re-arrangement that
involves the nearby residues such as Leu266 and Leu270. This
process results in destabilization of the local structure.
p.Phe150Tyr-Phe150 is a highly conserved residue located in
the b-sheet that encompasses the small domain hydrophobic core.
The p.Phe150Tyr mutation (Figure 1B, C) introduces a polar
residue inside the hydrophobic core in a region rich in
phenylalanine. This replacement can influence the stability of
the b-sheet thereby altering the structure of the domain.
p.Ala259Thr-Ala259 residue is located in the large domain near
the glucose-binding cleft. Introduction of a larger and polar side
chain of threonine in the p.Ala259Thr mutant could influence the
hydrogen bond network in that area. In fact, Thr259 can compete
with other residues in the formation of hydrogen bonds with two
water molecules. See our previous study for a description of the
p.Glu70Asp variant [11]. p.Lys420Glu-Mutation p.Lys420Glu
involves an inversion from a positively charged lysine to a
negatively charged glutamic acid. The substitution affects the
interaction of Lys420 with surrounding residues. Indeed, Lys420 is
located in the a12 helix (Figure S1) in the large domain and forms
a salt bridge with Glu440 located in a connecting loop between the
two domains. The loss of this bond, caused by the mutation, could
destabilize the region. p.Ala188Thr-The p.Ala188Thr mutation
alters a highly conserved amino acid. Ala188 is located in the a4
helix within the small domain. The mutation leads to the
substitution of a hydrophobic residue, alanine, with a polar
residue, tyrosine, on the hydrophobic side of an amphipathic helix.
Thr188 can form hydrogen bonds through the hydroxyl group
with the side chains of the Ser127 and Asp124 residues on the a3
helix that is on the surface of the enzyme. The introduction of the
threonine can cause a different arrangement of such side chain.
p.Tyr289Cys-Tyr289 is located in the a7 helix in the large
domain. The substitution of the bulk tyrosine in position 289 with
the smaller cysteine side chain leads to the formation of a cavity.
The mutant disrupts a favorable interaction between Tyr289 and
Met381 of the a11 helix that may be important to keep helices
together. It is noteworthy that, in our model, Cys289 is not bound
to the nearby Cys230 because the distance (4.1 A˚) between the two
sulfur atoms too long for a disulfide bond formation. p.As-
Characterization of GCK Mutations
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p278Glu-The p.Asp278Glu mutation affects a highly conserved
amino acid. Asp278 is located on the polar side of the a6 helix in
the large domain. The replacement of Asp with a Glu residue in
the mutant does not seem to cause significant changes in the
enzyme structure. p.Gly223Ser-Gly223 is a highly conserved
residue located in the b-sheet of the large domain hydrophobic
core. The substitution with a serine involves the serine side-chain
hydrogen bonding to Cys 233, close to Gly223 in the structure of
GCK and could perturb the b-strand. p.Glu40Asp-The
pGlu40Asp mutation substitutes a conserved glutamate residue
with aspartate. Glu40 is located on the polar side of the a2 helix in
the large domain. These amino acids are acidic residues but the
side chain of the aspartate is shorter than the side chain of the
glutamate. Nevertheless, the mutation does not seem to cause
significant changes in the structure of the enzyme. p.Ala449Thr-
Ala449 is a highly conserved residue located on the C-terminal
a13 helix. This helix is part of the small domain in the closed form,
but it lies between the two domains in the super-open form. In the
closed form, the small domain has a three-layer architecture and
the a13 helix is in the inner layer. At the domain interface, the a13
helix makes favorable interactions with the a5 helix of the large
domain. Because the conformational features of this region are
essential for the super-open (inactive form)/closed (active form)
conversion, the introduction of a larger and polar side chain of the
threonine in the p.Ala449Thr mutant could influence the
enzymatic activity and/or stability. p.Glu395_Arg397del–The
p.Glu395_Arg397 deletion causes the elimination of the last
residue, Glu395, of the a11 helix in the large domain and two
residues of the following loop, Ser396 and Arg397. In the wild-
type enzyme, Glu395 is involved, through the backbone N atom,
in the formation of a hydrogen bond of the a11 helix. Its deletion
in the mutant causes the lack of this bond and could destabilize the
C-terminal region of the helix. Moreover, also the backbone N
atom of Arg397 interacts with an oxygen atom of Arg394 thereby
Table 1. GCK mutations detected in MODY2 children from South Italy.
Patient
code
GCK
Exona
cDNA
mutationb
Polyphen/SIFT
predictionc
Aminoacid changed/Domain
localization/Secondary structure Effect on protein 3D-structure Reference
MD01/92 8 c.907C.T 1/deleterious p.Arg303Trp/Large domain/a8 helix Disruption of two salt-bridges [25]
MD05/71 10 c.1373_1385del p.Lys458_Cys461del/Small domain/
a13 helix
NOVEL
MD10 4 c.460G.T 2/tolerated p.Val154Leu/Small domain/b-strand 6 Severe perturbation during the
transition from the super-open to
closed form. Mild local structural
alteration
NOVEL
MD12/89 10 c.1339delC p.Arg447Glyfs/Small domain/a13 helix NOVEL
MD16/75 7 c.781G.T 1/deleterious p.Gly261Arg/Large domain/loop Replacement of a small and flexible
hydrophobic residue with a large
positive residue
[26]
MD18/94 4 c.449T.A 1/deleterious p.Phe150Tyr/Small domain/b-strand 5 Introduction of a polar residue in the
hydrophobic core. Perturbation of
the b-sheet
[27]
MD19e/20e/79 7 c.775G.A 3/deleterious p.Ala259Thr/Large domain/loop Influence on the hydrogen bond
network near the glucose-binding
cleft
[28]
MD25 2 c.210A.C 1/deleterious p.Glu70Asp/Connection/Loop
spatially near a13 helix
Weakness of salt bridge interaction
with K458 (a13 helix)
[11]
MD26/65 10 c.1258A.G 2/deleterious p.Lys420Glu/Large domain/a12 helix Loss of a salt bridge between K420
and E440
[29]
MD38 Intron 7 c.864-1G.A IVS7-1G.A [9]
MD57 5 c.562G.A 1/deleterious p.Ala188Thr/Small domain/a4 helix Substitution of a hydrophobic
residue with a polar residue
[30]
MD59 8 c.866A.G 1/deleterious p.Tyr289Cys/Large domain/a7 helix Disruption of a favorable interaction
between Y289 and M381
[9]
MD68 7 c.834G.A 1/deleterious p.Asp278Glu/Large domain/a6 helix Mild structural alteration [9]
MD69e/70 e Intron 5 c.580-2A.T IVS5-2A.T NOVEL
MD80 6 c.667G.A 3/deleterious p.Gly223Ser/Large domain/b-strand 9 Perturbation of the b-strand [31]
MD86 Intron 8 c.1019+5G.A IVS8+5G.A [27]
MD90 2 c.120G.C 2/tolerated p.Glu40Asp/Large domain/a2 helix Mild structural alteration NOVEL
MD91 10 c.1345G.C 3/deleterious p.Ala449Thr/Small domain in the
closed form/a13 helix
Introduction of a larger and polar
side chain
[9]
MD95 9 c.1182_1191del p.Glu395_Arg397del/Large domain/
last residue of a11 helix and following
loop
Destabilization of the C-terminal
region of the helix and shortening
of loop
NOVEL
aGenBank: accession number (AH005826). bThe reference cDNA sequence was obtained from GenBank (NM_000162) and +1 corresponds to the A of the ATG translation
initiation codon. cPolyphen prediction: probably damaging (1), benign (2), possibly damaging (3). SIFT score: ,0.05 deleterious variant, $0.05 tolerated variant.
dSwissprot accession number: P35557. eSibling pairs (MD19/20: two sisters; MD69/70: brother/sister).
doi:10.1371/journal.pone.0038906.t001
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stabilizing the helix. In the mutant, the loop becomes shorter and
the side chain of Arg394, which in the wild-type enzyme is
directed towards the loop, changes the orientation because of
steric interactions. This change disrupts interactions between the
side chain of Arg394 and some residues of the loop. Although the
interaction between the side chains of Arg394 and Ser433 in the
loop following the a12 helix is conserved, the binding appears to
be weakened compared with the wild-type enzyme.
Kinetic Analysis and Thermo-stability of Recombinant
GCK Mutants
To select representative mutations for a functional study to
evaluate their pathogenic significance, we considered all the
mutations found in our population in the last decade (11 and
present work) in terms of severity and location. All the selected
mutations were mapped in the whole GCK structure: p.Hi-
s137Asp, pPhe150Tyr, p.Val154Leu, p.Gly162Asp, in the small
domain, Arg303Trp and p.Arg392Ser, in the large domain and
p.Glu70Asp in a loop connecting the two domains. Three among
these mutations, (p.Gly162Asp, p.His137Asp and p.Arg392Ser)
were the most severe and none have been produced or
characterized. Figure 2 shows the position of selected mutated
residues in the structure model of the GCK enzyme. All variants
displayed reduced enzyme activity versus the wild-type GST-
GCK, as shown by the Ia index. The kinetic characteristics of
GST-GCK-wt and GST-GCK-mutants, determined in vitro
enzymatic assays, are shown in Table 2. Mutations p.Gly162Asp,
p.Phe150Tyr and p.Val154Leu, localized in the core of the
molecule, not far from the substrate binding site, produced the
strongest effect. The p.Gly162Asp change is very deleterious since
no enzymatic activity was detected in the mutant protein, and
mutations p.Phe150Tyr and p.Val154Leu reduced enzyme
activity to below 10% of the wild-type enzyme. In contrast,
mutations p.Glu70Asp, p.His137Asp, p.Arg303Trp and p.Arg392-
Ser, localized in more peripheral positions, retained at least 25%
of wild-type activity. We also evaluated the protein stability of
wild-type and of mutant GST-GCK and the time-course of
thermal inactivation at different temperatures (Figure 3A and B
respectively). Wild-type GCK activity remained practically con-
stant under temperatures up to 50uC, but fell abruptly at 55uC. In
contrast, the enzyme activity of all mutants, except GST-GCK
(p.Glu70Asp), rapidly decreased by more than 50% at 50uC
(Figure 3A). The time-course analysis of GCK thermal inactiva-
tion indicated that the mutants rendered the enzyme thermo-
unstable (more than 50% of GCK activity was lost within 30 min
at 50uC), whereas 50% of wild-type GCK activity was present
after 30 min of incubation at the critical temperature (Figure 3B).
Discussion
A correct diagnostic approach to the MODY2 patient is
important to avoid useless, expensive analyses and misclassification
of the diabetes. In this study, we characterized the GCK gene by
DHPLC followed by sequence analysis in 66 patients with
suspected MODY2 enrolled between 2006 and 2010. We
identified 19 GCK mutations in 28 children accounting for
42.4% of suspected MODY2 children. Our data are similar to
those we obtained between 2001 and 2005 [11] and are also in
agreement with the high prevalence of MODY2 (up to 61% of
MODY forms) found in Italy and in southern Europe [12,13].
Among the 19 GCK variants described herein, six are new
(p.Lys458_Cys461del, p.Val154Leu, p.Arg447Glyfs, IVS5-2A.T,
p.Glu40Asp and p.Glu395_Arg397del) and 13 previously report-
ed. Glucokinase missense mutations are the most frequent causes
of MODY2 [9]. In our study, the missense mutations (13/19: two
new and 11 known), and deletions (n = 3) were distributed
throughout the protein: six/16 (38%) in the small domain, nine/
16 (56%) in the large domain and one/16 (6%) in the connecting
region of the protein. These findings are in agreement with a study
in which no hot spot mutations were reported [9].
In the attempt to understand how the detected mutations could
contribute to MODY2 insurgence, we searched for structure/
function correlations of the disease-causing mutated proteins. First,
we evaluated the impact of each mutation (except splice variants
and deletions) on the enzyme 3D-structure and then, for seven
selected mutations, we carried out functional studies. All the
mutations considered here are buried in the enzyme, except for
p.Glu70Asp that is located on the surface of the protein, and all
mutations are far from the active and ATP binding sites (Table 1).
Apart from p.Val154Leu and p.Phe150Tyr that undergo large
movements during the conformational transition from the super-
open to the closed active form, all the mutant structures exhibit
local structural alterations (Table 1) that well correlate to kinetic
parameters and thermal inactivation data (Table 2, Figure 3). In
all cases, the amino-acid replacement either provokes the loss of
stabilizing interactions or generates unfavorable interactions that
may destabilize the enzyme.
Table 2. Kinetic constants of human recombinant wild type-GCK and mutant b-cell GST-GCK fusion proteins.
Preparation
Protein yield
(mg/L of culture) Kcat (s21)
S0.5 for glucose
(mmol/L) nH
Km for ATP
(mmol/L) Ia
Wild-type GST-GCK 3.1260.91 44.1067.50 7.2060.40 1.4060.08 0.4060.00 1.060.07
GST-GCK(Glu70Asp] 2.3560.55 27.4064.80* 20.1063.20{ 1.2060.07 0.2560.05 0.2560.06**
GST-GCK(His137Asp] 2.8260.47 17.2061.20** 18.1063.10* 1.1060.03** 0.2360.03* 0.2660.09**
GST-GCK(Phe150Tyr] 3.0760.55 9.9262.38* 101.4066.20** 1.0660.05* 3.1160.48* 0.01460.003*
GST-GCK(Val154Leu] 2.7760.48 46.6064.40 26.0063.40* 1.5460.01 1.6260.16* 0.09960.036**
GST-GCK(Gly162Asp] 2.7860.58 Undetectable activity
GST-GCK(Arg303Trp] 1.5860.26 14.6061.38** 4.6260.10** 1.5260.02 0.2960.01* 0.5960.09*
GST-GCK(Arg392Ser] 2.4460.74 41.30611.30 11.9061.70* 1.3060.03 0.6360.03* 0.6060.25
Data represent means 6 SEM of 3 separate enzyme expressions each tested in duplicate. Note that the Hill coefficient (nH) and the relative activity index (Ia) are unit
less. Kcat: GCK catalytic constant; S0.5: affinity constant for glucose; nH: Hill coefficient; Km for ATP: affinity constant for ATP; Ia: GCK activity index. (*)p,0.05, t test;
(**)p,0.005, t test.
doi:10.1371/journal.pone.0038906.t002
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We evaluated the effects on GCK kinetics and thermo-stability
of seven GCK variants distributed in different functional
domains of the enzyme: three variants described in the present
study (p.Phe150Tyr, p.Val154Leu, p.Arg303Trp) and four
(p.Glu70Asp, p.His137Asp, p.Gly162Asp and p.Arg392Ser)
previously reported [11]. The GST-GCK (p.Glu70Asp) mutant
showed a GCK activity index significantly lower than the wild
type (mean Ia = 0.25). This effect is due to discrete defects in the
kinetic constants, in particular, glucose affinity was significantly
reduced (S0.5 for glucose: 20.163.2 vs 7.260.4 mM). Variant
p.Glu70Lys displayed a similarly decreased activity index (mean
Ia = 0.31) without significant thermo-instability [14,15]. The
substitution of histidine with aspartic acid (p.His137Asp) affected
GCK function (mean Ia = 0.26). As shown by molecular
modelling, this mutation introduces a negative charge in the
region that may affect the charge distribution of the protein [11].
The previously reported mutation p.His137Arg, in which His is
replaced by the positively charged arginine, did not affect
enzyme activity (mean Ia = 0.92) [15]. This finding shows that a
negatively charged amino acid is not tolerated at this site.
p.Phe150Tyr and the novel p.Val154Leu mutations dramatically
reduced GCK activity (mean Ia = 0.014 and 0.099, respectively)
Figure 1. View of the mutations p.Phe150Tyr and p.Val154Leu in the whole structures and in their local environment. A: The
structures of GCK in the super-open inactive form (PDB code code: 1v4t) and in the closed active form (PDB code code: 1v4s) are shown on the left
and on the right, respectively. In the closed form (right) the sugar is shown as a yellow stick. In both panels, the large domain is in the same
orientation and is circled. It is clear that the small domain undergoes a large conformational variation from the super-open to the closed form.
Specifically the region embodying the residues Phe150 (blue sphere) and Val154 (red sphere) dramatically changes its orientation. B: Close-up view of
the wild-type closed structure showing the hydrophobic core rich in aromatic/hydrophobic amino acids. Leu79, Phe123, Phe148, Phe150, Val154,
Leu164, Trp167 and Phe171 form an intricate network of stabilizing hydrophobic interactions. C: Structure of GCK closed structure containing the
both the Tyr150 and Leu154 mutated residues. Introduction of the oxydryl group (red) of Tyr150 within the hydrophobic core disrupts the
interactions present in the wt-enzyme. The replacement of Val154 by leucine produces only small changes in the closed form.
doi:10.1371/journal.pone.0038906.g001
Characterization of GCK Mutations
PLoS ONE | www.plosone.org 5 June 2012 | Volume 7 | Issue 6 | e38906
and thermo-stability (,40% at 50uC/30 min than in wild-type).
Both mutations displayed high S0.5 and ATP Km values, which
indicate a greatly reduced affinity for glucose and ATP. In
particular, the cooperativity of p.Phe150Tyr was significantly
reduced (nH = 1.06 vs 1.40, t test, p = 0.038). It is noteworthy
that Val154 is one of residues that undergo large movements
during the transition from the super-open to the closed form.
Even though the replacement of Val by Leu provokes only small
local perturbations, the latter may be relevant during the
conformational transition induced by ATP and glucose binding.
The substitution of glycine 162 by aspartic acid (p.Gly162Asp)
affected the hydrophobic core of the enzyme and, as predicted
by molecular modelling [11], markedly alters the structure and
dynamics of the domain. This is one of the most dramatic
mutations we identified as it introduces a net negative charge
into a hydrophobic environment [11]. In fact, the enzyme
activity of this mutant was undetectable. Although any reduction
in the Ia below 30% of the wild type would have little further
effect on the fasting plasma glucose [15], it is noteworthy that
fasting glycemia was higher in the child with this mutation
(10.0 mmol/L) [11] than in other MODY2 children (mean
6.760.8 mmol/L). Arg 303 is located in the a8 helix and
molecular modelling indicates that the Arg-to-Trp change at this
position would destabilize the helix structure. Mutation
p.Arg303Trp caused a reduction of the activity index (mean Ia
= 0.59), mainly due to a decrease in the catalytic constant, being
Figure 2. Distribution of the selected GCK mutations. The structure of GCK in the active closed form is shown (PDB code: 1v4s); the small and
large domains are drawn in cyan and red, respectively; glucose appears as a yellow stick. Mutation sites are shown as green or blue spheres.
doi:10.1371/journal.pone.0038906.g002
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both glucose and ATP affinities modified. Our results concord
with the finding that other mutations in the same helix
(p.Leu309Pro and p.Arg308Trp) increased thermal inactivation
and/or modified glucose affinity [16,17]. Taken together, these
results suggest that the a8 helix plays a role in the regulation of
substrate affinity and protein stability. Mutation p.Arg392Ser is
located in the protein periphery and, like the neighboring
mutation p.Arg397Leu [17], it only slightly affected GCK
activity. Thus, our mutants reduced the enzyme’s catalytic
activity by altering one or more kinetic parameters. Moreover, all
mutants, except GCK-Glu70Asp, displayed thermal-instability,
which has been implicated in hyperglycemia in MODY2 patients
[17,18]. Nevertheless, additional defects caused by these muta-
tions on other mechanisms of GCK control, such as post-
translational regulation, interaction with other protein partners
or organelles, cannot be excluded. Globally our evaluation of
enzyme activity indicates that all seven mutants play a
pathogenic role in MODY2 insurgence. In addition although
altered glucose and ATP binding, and thermal stability appear to
be the major causes of the disease, in a few cases mutations
affected cooperativity and molecular motions, and hence
impaired enzyme activity.
Although the in vitro functional evaluation of a GCK-mutant is
a useful method with which to predict the effect exerted by a DNA
change on enzyme activity, it is not a practical approach to the
diagnosis of MODY. In our experience, taking into account all the
experimental data concerning the seven mutants expressed, we
found that the mutations induced structural alterations predicted
by modeling that were in good agreement with kinetics/
thermostability analyses. Therefore, this approach could be a
reliable surrogate to predict the pathogenic role of a GCK variant.
In conclusion, in this five-year update of GCK mutations in
MODY2 children from southern Italy, we have identified six new
GCK variants thereby expanding the MODY2 mutation panel.
Furthermore, our study, carried out by integrating DHPLC,
sequencing, bioinformatics and functional analysis, provides new
information about the structure-function relationship of human
glucokinase mutations and MODY2.
Figure 3. Effect of temperature on the stability of GST-GCK mutants. Stock enzyme solutions were diluted to 250 mg/ml in storage buffer
containing 30% glycerol, 50 mM glucose, 10 mM glutathione, 5 mM DTT, 200 mM KCl and 50 mMTris/HCl, pH 8.0. Panel A: The enzyme solutions
were incubated for 30 min at temperatures ranging from 30 to 55uC and then assayed at 30uC as described in the Methods section. Panel B: The
enzyme solutions were incubated for periods of time from 5 to 60 min at 50uC. Results are means and SEM of three independent enzyme
preparations for each mutant except for GST-GCK (Phe150Tyr) which corresponds to two independent enzyme preparations. (*) p#0.03, ({) p,0.008.
doi:10.1371/journal.pone.0038906.g003
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Materials and Methods
Ethics Approval
The study was conducted according to the Helsinki II
declaration and it was approved by the Ethics Committee of the
School of Medicine Federico II, Naples, Italy.
Written informed consent to the study was obtained from each
adult subject and from both parents of children.
Subjects
Between 2006 and 2010, 720 hyperglycemic children were
monitored at the Departments of Pediatrics of the University of
Naples ‘‘Federico II’’ and of the Second University of Naples,
Italy. Sixty-six patients (mean age 109 months, 53% girls) who had
fasting hyperglycemia (.5.5 mmol/L), HbA1c ,7.0% and a
family history of diabetes for at least two consecutive generations
were enrolled in the study as suspected MODY2 individuals. The
autoimmune markers of type-1 diabetes (glutamate decarboxylase,
protein tyrosine phosphatase-like protein and insulin antibodies)
were evaluated; the presence of more than one antibody was
considered an exclusion criterion. One hundred unrelated
euglycemic controls (mean age 363 months, 69% girls) were
recruited at CEINGE (Advanced Biotechnologies, s.c.a.r.l. Naples)
also between 2006–2010.
Patients, their mother and father, and controls provided 2 blood
samples for biochemical testing and for DNA extraction. BMIz-
score (Center for Disease Control normative, http://www.cdc.
gov), family history of diabetes and/or other diseases, birth weight
and age at admission were recorded for each patient. FPG,
triglycerides (evaluated with routine methods) and HbA1c
measure with HPLC (HLC-723 G7 TOSOH Bioscience Tokyo,
Japan) were evaluated in each suspected MODY2 child. Genomic
DNA from patients, their mother and father, and controls was
extracted with the Nucleon BACC 2 kit (Amersham Biosciences
Europe, Milan, Italy).
GCK Gene Analysis
The 10 exons, including their flanking intronic regions, of the
GCK gene were amplified using primers and PCR conditions
described elsewhere [11]. The amplified fragments were dena-
tured at 95uC for 10 min and then renatured for 10 min to
generate heteroduplices. Each fragment was run on the DHPLC
WAVE DNA fragment analysis system (Transgenomic, Inc.
Omaha, NE) using DHPLC conditions reported in Table S1.
Any additional or abnormal peak shape observed in the
chromatogram was further sequenced (ABI PRISM 3730;
Biosystems Foster City, CA, USA). All sequences were analysed
in comparison with the wild-type reference sequence
(NM_000162, http://www.ncbi.nlm.nih.gov/nuccore/
NM_000162) by the ABI Seqscape software v.2.5 (Applied
Biosystems). The mutations and variants were then numbered
according to the Human Genome Variation Society (http://www.
hgvs.org/).
Analysis of GCK Mutations
We first evaluated each detected GCK mutation by bioinfor-
matics (Polyphen and SIFT algorithms and Modeller programs).
We also examined the enzyme function of seven mutations among
the most severe found in our population in the last decade and
never characterized. The mutations for the latter study mapped in
the whole enzyme structure (small, large and loops connecting
domains).
Bioinformatic Analysis
Two free online prediction programs, Polyphen (http://
genetics.bwh.harvard.edu/pph/) and SIFT (http://sift.jcvi.org/
www/SIFT_seq_submit2.html), [1] were used to predict the effect
of GCK mutations on the protein. The Polyphen program [19] is
a tool for the prediction of the impact of an amino acid
substitution on the structure of a human protein using straight
forward physical and comparative considerations. The SIFT
program [20] tests a query sequence and uses multiple alignment
information to predict tolerated and deleterious substitutions for
every position of the query sequence. SIFT is a multistep
procedure that searches for similar sequences, chooses closely
related sequences that may share a function similar to that of the
query sequence, obtains the alignment of these chosen sequences,
and calculates normalized probabilities for all possible substitu-
tions from the alignment. Models of all mutants of GCK were
generated in silico with the Modeller 9v8 program using the active
form of the GCK crystal structure as template [2.3 A˚, Brookhaven
Protein Database code (PDB code) 1v4s]. The inactive super-open
form (3.4 A˚, PDB code 1v4t) was also considered for comparison.
After alignment with using BODIL [21], the query and
template sequences were used as input in the Modeller program
[22] and 20 models were generated. The most abundant
conformers of the replaced residue were selected and a simulated
annealing procedure was carried out to optimize side chain
conformations. The model that presented the best Modeller
Discrete Optimized Protein Energy (DOPE) score was selected to
be used in subsequent analyses. The initial models of selected
mutants were energy minimized with the GROningen MAchine
for Chemical Simulations (GROMACS) package using the
GROningen MOlecular Simulation (GROMOS) 43a1 force field,
to regularize the protein structure geometry. The molecules were
solvated in boxes containing simple point charge water molecules.
The energy minimization was obtained by 1000 steps of the
steepest descent method and subsequently by 1000 steps of the
conjugate gradient method. The notation used for secondary
structure was taken from Kamata et al. [8].
Production of Recombinant Wild-type and Mutant
Glutathionyl-S-transferase-glucokinase (GST-GCK)
Recombinant human wild-type beta cell GCK fused to GST
(GST-GCK) was prepared as described previously [23]. Mutations
were introduced into the GST-GCK construct by PCR using the
QuikChangeH II Site Directed Mutagenesis Kit (Stratagene, La
Jolla, CA, USA); the oligonucleotides are reported in Table S2.
Mutant constructs were checked by sequencing and digestion with
specific restriction enzymes (Table S2). Fusion proteins from E. coli
were expressed and purified as described previously [24]. Fusion
proteins were stored at a concentration of about 1 mg/ml at –
80uC in 30% glycerol, 50 mM glucose, 10 mM glutathione, 5 mM
DTT, 200 mM KCl and 50 mM Tris/HCl, pH = 8.0. Protein
concentrations were determined with the Bio-Rad Protein Assay
(Bio-Rad Laboratories, GmbH Mu¨nchen Germany), and bovine
serum albumin as standard. GST-GCK purification was verified
by Coomassie-stained SDS-PAGE as a single band of 75 kDa.
Enzymatic Assay
GCK activity was measured spectrophotometrically on a
UVIKONxl spectrophotometer (Secoman, France), using a
NADP+-coupled assay with glucose-6-phosphate dehydrogenase.
Determination of kinetic parameters and thermal inactivation
were performed as previously described [23]. The Km for ATP
was measured at a glucose concentration near the relative S0.5
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values (7, 15, 8.5, 100, 20, 5 and 11 mM respectively for wild type,
p.Glu70Asp, p.His137Asp, p.Phe150Tyr, p.Val154Leu,
p.Gly162Asp, p.Arg303Trp and p.Arg392Ser). Thermal inactiva-
tion experiments were assayed at a glucose concentration of
100 mM. Results are reported as means 6 standard error of the
mean (SEM) of three independent enzyme preparations assayed at
least in duplicate.
Statistical Analysis
Variables are reported as mean6SD (continuous variables) or
mean 6SEM (categorical variables). We used the Student t test to
compare variables; significance was set at p,0.05. The SPSS
statistical software was used.
Supporting Information
Figure S1 Close-up view of the p.Lys420Glu mutation at
the inter-domain interface. The small and large domains are
drawn in cyan and red, respectively. Helix 13 is shown in orange.
Lys420 (red stick) forms a salt-bridge with Glu440 (yellow stick)
which is located in a loop connecting the two domains.
(DOCX)
Table S1 DHPLC conditions to detect GCK variants.
(DOCX)
Table S2 Primers used for site-directed mutagenesis in
GCK cDNA.
(DOCX)
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